

**CURRICULUM VITAE
DON S DIZON, MD**

Business address: Lifespan Cancer Institute
Rhode Island Hospital
593 Eddy Street
Providence, RI 02903

Business Phone: 401-444-5392

Business Fax: 401-444-4184

Business Email: don_dizon@brown.edu

Social Media: Twitter: @drdonsdizon (7500+ Followers; 69K Impressions/month)
Instagram: drdonsdizon (600+ Followers)
Blog: bit.ly/DizonACblog
Facebook: <https://www.facebook.com/people/Don-S-Dizon/100012638015136>

EDUCATION

Undergraduate: University of Portland, 1987-1988 (No degree)
University of Rochester, Biology (Minor in Religious Studies), BA (Cum Laude), 1991

Medical School: University of Rochester School of Medicine and Dentistry, MD, 1995

POSTGRADUATE TRAINING

Residency: Yale University School of Medicine
330 Cedar Street, New Haven, CT 06510
Internal Medicine, 1995-1998

Fellowship: Memorial Sloan-Kettering Cancer Center
1275 York Street, New York, NY 10065
Medical Oncology, 1999-2001

Other: Planned Parenthood League of Massachusetts
Certified Sex Educator, 2005

Brown University Medicine Leadership Academy
Bryant University, 2018

POSTGRADUATE HONORS AND AWARDS

Fellow, American College of Physicians, 2005
Dean's Teaching Award, Warren Alpert Medical School of Brown University, 2008, 2010, 2012
Hospital-Based Faculty Teaching Award, Warren Alpert Medical School of Brown University, 2011
Out of the Blue Award, Program in Women's Oncology at Women & Infants' Hospital, 2012
APEX Grand Award for Best Blog Series, Communications Concepts, 2013
APEX Award for Best Single Blog Entry, Communications Concepts, 2014
Top Doctor in Cancer, Castle Connolly, 2015-
Top Doctor in Cancer, Boston Magazine, 2017
Fellow, American Society of Clinical Oncology, 2017
NCI Director's Service Award, Cervical Cancer Task Force Co-Chair, May 2018
NCI Director's Service Award, Co-Chair Cervical Cancer Clinical Trials Planning Committee, October 2018

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

Medical License, State of Rhode Island, #11323, 2003
 American Board of Internal Medicine, Diplomat in Internal Medicine, 1998, Recertified in 2008, 2018
 American Board of Internal Medicine, Diplomat in Medical Oncology, 2002, Recertified in 2012
 Medical License, State of Massachusetts, #222651, 2004 (*Not active*)
 Medical License, State of Connecticut, #037016, 1998 (*Not active*)
 Medical License, State of New York, #213867, 1999 (*Not active*)

ACADEMIC APPOINTMENTS

Clinician-Educator, Primary Care Internal Medicine Program, Yale University School of Medicine, 1998-
 Instructor, Department of Medicine, Weill Medical College of Cornell University, 2001-2003
 Assistant Professor, Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown
 University, 2003-2010 (Secondary appointment to Department of Medicine, 2004-2010)
 Associate Professor (Research Scholar), Departments of Obstetrics and Gynecology and Medicine, Warren
 Alpert Medical School of Brown University, 2010-2012
 Lecturer in Medicine, Harvard Medical School, 2012-2017
 Associate Professor (Research Scholar), Department of Medicine, Warren Alpert Medical School, Brown
 University, 2017-2018
 Professor of Medicine, Warren Alpert Medical School, Brown University, 2019-

HOSPITAL APPOINTMENTS

Attending Physician, Department of Internal Medicine, St. Mary's Hospital, Waterbury, CT, 1998-1999
 Clinical Assistant Physician, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 2001-2003
 Director of Medical Oncology, Program in Women's Oncology, Women & Infants' Hospital, 2003-2012
 Co-Director, Center for Sexuality and Intimacy, Program in Women's Oncology, Women & Infants'
 Hospital, 2005-2012
 Founder and Director, The Oncology Sexual Health Clinic, Massachusetts General Hospital Cancer Center, 2012-
 2017
 Clinical Co-Director, Gynecologic Oncology, Massachusetts General Hospital Cancer Center, 2015-2017
 Director, Women's Cancers, Lifespan Cancer Institute, 2017-
 Director, Medical Oncology, Rhode Island Hospital, 2017-

OTHER APPOINTMENTS

Advisory Committee for Breast Cancer in Young Women, Centers for Disease Control
 Member, 2015-
 Co-Chair, Survivorship panel, 2015-2016
American College of Physicians
 Executive Committee, RI Chapter, 2009-2011
American Reproductive Health Professionals
 Member, Expert Panel on Sexual Health Fundamentals, 2009
American Society of Clinical Oncology
 Cancer Education Committee, Gynecologic Oncology, 2011-2013 (Track Leader, 2012)
 Integrated Media and Technology Committee, 2010-2014 (Chair, 2011-2012)
 Cancer Communications Committee, 2013-2016 (Chair, 2015-2016)
 Chair, Social Media Working Group, 2015-2018
 Clinical Practice Guidelines Committee on Neoadjuvant chemotherapy for Ovarian Cancer, 2015
 Publications Editors Committee, 2015-
 Communication Clinical Practice Guideline Committee, 2016-2017
 Leadership Group, Annual Meeting, 2018, 2019
 Ethics Committee, 2019-2022

American College of Surgeons

Member, American Joint Commission on Cancer (AJCC) \

Gynecologic Oncology Expert Panel

Chair, Uterine Sarcoma, 2015

Breast Cancer Symposium

Program Committee, 2008

Steering Committee, 2009

Cancer and Leukemia Group B

Local Responsible Investigator, 2004-2008

Cancer Care Manitoba, Program in Evidence-Based Care

Member, Expert Panel for Clinical Practice Guidelines on Interventions to Improve Sexual Function and Sexuality for People with Cancer, (ASCO Representative), 2015

Gynecologic Cancer Steering Committee, National Institutes of Health

Member, Cervical Cancer Task Force, 2009-2018 (Co-Chairman, 2012-2018)

Co-Chair, Cervical Cancer Clinical Trials Planning Meeting, 2018

GOG Foundation

Data Safety and Monitoring Board, 2017-

International Gynecologic Cancer Society

Member, Education Committee, 2008

Member, Speakers' Bureau, 2008

Member, Program Committee, Annual Meeting, 2012

Steering Committee Member, Education Committee, 2018-

Metastatic Cancer Task Force, Department of Defense

Advisory Committee, 2016-2017

National Comprehensive Cancer Center Network

Survivorship Panel, 2014-2015

Cervical and Uterine Cancer Panel, 2015-2017

National Consortium of Breast Centers

Program Chair, Annual Meeting, 2008, 2009, 2018, 2019

Vice President, 2007-2009

President, 2009-2011

Trustee Emeritus, 2013-

Program Committee, 2018, 2019, 2020

Co-Chair, Fundamentals in Sexual Health, 2017

Co-Chair, Oncology Sexual Health First Responders Course, 2018-

NRG Oncology (formerly Gynecologic Oncology Group).

Member, Developmental Therapeutics (DT) Committee, 2005-2015

Member, Phase I Working Group, 2007-2015

Disease Site Lead-Cervical Cancer for the DT Committee, 2010-2015.

Publications Subcommittee, 2011-2013

Rhode Island Comprehensive Cancer Control Plan

Treatment Workgroup, 2007-2009

Sexual Medicine Society of North America

Female Sexual Function Committee, 2015-

Program Committee, Cancer Survivorship, 2018

Society of Gynecologic Oncologists

Breast Cancer Task Force, 2007-2013

Member, Program Committee, Annual Meeting, 2012

Steering Committee, Annual Meeting, 2017

Diversity Committee, 2017-

SWOG Cancer Research Network

Chair, Digital Engagement Committee, 2016-

Chair, Search Committee for Melanoma Research Committee Chair, 2019

The Hope Foundation

Grant Review Panel, 2017

Member, Board of Directors, 2017-

Chair, Career Engagement Awards Sub-committee, 2019

Young Survival Coalition

Centers for Disease Control Cooperative Grant Steering Committee, 2014-2017

Member, Board of Trustees, 2016-

Co-Chair, Council of Advisors, 2017-

Editorial Boards

Editor in Chief, American Society of Clinical Oncology Annual Meeting Educational Book, 2012-

Section Editor, The Oncologist, 2014- (Narratives in Oncology)

Section Editor, Gynecologic Oncology, UpToDate, 2015-

Editor in Chief, The Breast Cancer Bulletin, National Consortium of Breast Centers, 2015-

Associate Editor (Medical Oncology), American Journal of Clinical Oncology, 2008-present

Editorial Board: Journal of Clinical Oncology, 2015-2018

Reviewer:

New England Journal of Medicine, 2018-

Lancet, 2018-

Journal of Clinical Oncology, 2015-

Gynecologic Oncology, 2012-

Clinical Medicine: Oncology, 2007

Oncology & Biotech News, 2009-

Contemporary Oncology, 2009-

Frontiers in Oncology, 2012-

Journal of Gynecology and Obstetrics, 2012-2013

Cancer Therapy Advisor, 2013-

Scientific Reports, 2014-2015

Frontiers in Oncology, 2014

HOSPITAL COMMITTEES

Executive Alumni Committee, Memorial Sloan-Kettering Cancer Center, 2002-2003

Cancer Committee, Women & Infants' Hospital, 2003-2010; Cancer Liaison Physician to Commission on Cancer, 2007-2008

Institutional Review Board, Women & Infants' Hospital, 2004-2011

Clinical Advisory Committee, Care New England Health Systems, 2005-2011

Web Oversight Committee, Care New England Health Systems, 2005-2007

Institutional Review Board, Dana-Farber/Harvard Comprehensive Cancer Center, 2012-2017

Executive Committee, Lifespan Cancer Institute, 2017-

Cancer Clinical and Research Council, Lifespan Cancer Institute, 2017-

Breast Cancer Steering Committee, Lifespan Cancer Institute, 2017-

Institutional Review Board, Rhode Island Hospital, 2017-

Physicians Informatics Council, Lifespan Health Systems, 2017-

Schwartz Center Rounds, Rhode Island Hospital (Physician Lead), 2019-

Research Study Review Committee, Brown Medicine, 2019-

UNIVERSITY COMMITTEES

Brown University Oncology Group

Member, Breast Cancer Committee, 2007-2011

Member, Data Safety Monitoring Committee, 2007-2011

Co-Chair, Women's Cancers Committee, 2017-

Warren Alpert Medical School of Brown University

Admissions Committee, 2005-2011
 Medical Committee on Academic Standing, 2006-2011
 Search Committee. Pediatric Hematology-Oncology, Hasbro Children's Hospital, 2017-
 Search Committee, Cancer Biology, Brown University, 2018-
Brown University
 Admissions Committee, Program in Liberal Medical Education, 2007-2009

MEMBERSHIP IN SOCIETIES

American Society of Clinical Oncology, 2001-
 American College of Physicians, 2003-
 National Consortium of Breast Centers, 2003-
 Society of Gynecologic Oncologists, 2004-2015, 2017-
 International Gynecologic Cancer Society, 2008-2016, 2018-
 Sexual Medicine Society of North America, 2015-

PUBLICATION LIST

h-index 31 (*Web of Science, 2/2/2019*)

ORIGINAL PUBLICATIONS IN PEER REVIEWED JOURNALS

1. **Dizon DS**, Hensley ML, Sabatini P, et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. *J Clin Onc.* 2002; 20:1238-1247.
2. **Dizon DS**, Sabatini PJ, Aghajanian C, et al. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma re-treated with cisplatin after the development of a carboplatin allergy. *Gyn Onc.* 2002; 84:378-382.
3. Aghajanian C, Soignet S, **Dizon DS**, et al. A Phase I Trial of the Novel Proteasome Inhibitor PS341 in Advanced Solid Tumor Malignancies. *Clin Cancer Res* 2002; 8:2505-2511.
4. Abu-Rustum NR, Sonoda Y, Chi DS, Teoman H, Brown C, Poynor E, Gemignani M, **Dizon DS**, et al. The effects of CO2 pneumoperitoneum on the survival of women with metastatic ovarian cancer. *Gyn Onc* 2003; 90:431-434.
5. Leitao MM, Hummer A, **Dizon DS**, et al. Platinum re-treatment of platinum-resistant ovarian cancer after nonplatinum therapy. *Gynecol Oncol.* 2003; 91:123-9.
6. **Dizon DS**, Dupont J, Anderson S, et al. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center Experience. *Gynecol Oncol.* 2003; 91:584-90.
7. Leitao MM, Boyd J, Hummer A, Olvera N, Arroyo CD, Venkatraman E, Baergen R, **Dizon D**, et al. Clinicopathological analysis of early stage sporadic epithelial ovarian carcinoma treated at a single institution. *Am J Surg Path* 2003; 28:147-59.
8. Sabatini PS, Aghajanian CA, Leitao MM, Venkatraman E, Anderson S, Dupont J, **Dizon D**, et al. Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II trial. *Clin Ca Res* 2004; 10:2962-2967.
9. Krychman ML, Carter J, Aghajanian CA, **Dizon DS**, Castiel M. Chemotherapy-induced dyspareunia: a case study of vaginal mucositis and pegylated liposomal doxorubicin injection in advanced stage ovarian carcinoma. *Gynecol Oncol.* 2004 May;93(2):561-3.
10. Sabatini P, Aghajanian C, **Dizon D**, et al. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. *J Clin Onc* 2004; 15:4523-4531.
11. Gordinier ME and **Dizon DS**. Dyspnea during thalidomide treatment for advanced ovarian cancer. *Ann Pharmacother.* 2005; 39:962-5.
12. Aghajanian C, **Dizon DS**, Sabatini P, et al. A Phase I Trial of Bortezomib and Carboplatin in Recurrent Ovarian or Primary Peritoneal Cancer. *J Clin Onc* 2005; 23:5943-5949.
13. **Dizon DS**, Schwartz J, Rojan A, et al. Cross-Sensitivity Between Paclitaxel and Docetaxel in a Women's Cancers' Program. *Gynecol Oncol.* 2006; 100:149-151.

14. **Dizon DS**, Rojan A, Schwartz J, et al. Two for Good Measure: Six versus Eight Cycles of Carboplatin and Paclitaxel as Adjuvant Treatment for Epithelial Ovarian Cancer. *Gynecol Oncol* 2006; 100:417-421.
15. Gordinier ME, **Dizon DS**, Fleming EL, et al. Short Communication: Palmar-plantar erythrodysesthesia is not related to body mass index in patients receiving pegylated liposomal doxorubicin. *Gynecol Oncol* 2006; 103:72-4.
16. Satyan KS, Swamy NS, **Dizon DS**, et al. Phenethyl isothiocyanate (PEITC) inhibits growth of ovarian cancer cells by inducing apoptosis: Role of caspase and MAPK activation. *Gynecol Oncol* 2006; 103:261-270.
17. Somasundar P, Gass J, Steinhoff M, Koelliker S, **Dizon DS**, et al. Role of ultrasound-guided axillary fine-needle aspiration in the management of invasive breast cancer. *American Journal of Surgery* 2006; 192:458-61.
18. Kalkunte S, Swamy N, **Dizon DS**, Brard L. Benzylisothiocyanate (BITC) induces apoptosis in ovarian cancer cells in vitro. *J Exp Ther Oncol*. 2006; 5:287-300.
19. **Dizon DS**, Tejada-Berges T, Koelliker S, Steinhoff M, Granai CO. Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient. *J Gynecol and Obstet Invest* 2006; 62:226-228
20. Gordinier ME, **Dizon DS**, Weitzen S, et al. Oral thalidomide as palliative chemotherapy in women with advanced ovarian cancer. *J Palliat Med* 2007;10:61-6.
21. Schwartz J, Bradley AM, Bandera C, Brard L, DiSilvestro P, Legare R, Moore R, Tejada-Berges T, Granai CO, **Dizon DS**. Does the platinum-free interval predict severity or incidence of hypersensitivity reactions to Carboplatin? The experience from Women & Infants' Hospital. *Gynecol Oncol* 2007; 105:81-83.
22. **Dizon DS**, Gass J, Bandera C, et al. Does one person provide it all? Primary Support and Advanced Care Planning for women with cancer. *J Clin Oncol* 2007; 10:1412-1416.
23. Hensley ML, **Dizon DS**, Derosa F, et al. A phase I trial of BMS-247550 (NSC#710428) and gemcitabine in patients with advanced solid tumors. *Invest New Drugs*, 2007; 25:335-41.
24. Bandhari T, **Dizon DS**, Taneja C, et al. Clinical characteristics of women presenting with skin-only recurrences. *Am J of Surgery*, 2007; 194:494-6.
25. Gass J, **Dizon DS**, Weitzen S, et al. Defining Social Support Systems for Women with Breast Cancer. *Am J of Surgery*, 2007; 194:501-3.
26. Wiggins DL, Wood R, Granai CO, **Dizon DS**. Sex, Intimacy, and the Gynecologic Oncologist: Survey results of the New England Association of Gynecologic Oncologists (NEAGO). *J Psychosocial Oncology*, 2007; 25:61-70.
27. **Dizon DS**, McCourt CK, Martin-Hanley T, et al. Adjuvant therapy for endometrial cancer: "sandwich therapy" of carboplatin and paclitaxel with radiation therapy. The Women & Infants' Hospital experience and review of the literature. *Cancer Therapy*, 2007; 5:395-400. Available on-line at: www.cancer-therapy.org/articles5B.html.
28. **Dizon DS**, Beheshti J, McDonough K, Gass J. The differential diagnosis of dyspnea in a woman with metastatic breast cancer: Consideration beyond pulmonary embolism. *The Breast Journal*, 2008; 14:90-1.
29. **Dizon DS**, Restivo A, Lomme M, et al. For Women Receiving Chemotherapy for Clinically Apparent Early Ovarian Cancer, Is There a Benefit to Surgical Staging? *American Journal of Clinical Oncology* 2008; 31:39-42.
30. **Dizon DS**, Perez K, DiSilvestro P, Taneja C, Ilson D. Stage IV small bowel carcinoma mimicking advanced ovarian cancer: case report and review of the literature. *American Surgeon* 2009; 75:864-5.
31. McCourt C, Dessie S, Bradley AM, Schwartz J, Brard L, **Dizon DS**. Is there a taxane-free interval that predicts response to taxanes as a later line treatment of recurrent ovarian or primary peritoneal cancer?? *Int J Gynecol Cancer* 2009; 19:343-7.
32. Schwartz J, Toste B, **Dizon DS**. Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA) > 2m(2). *Gynecol Oncol* 2009; 114:53-6.
33. **Dizon DS**, Blessing JA, McMeekin DS, et al. Ixabepilone as a second-line treatment in advanced endometrial cancer: Phase II Results of Gynecologic Oncology Group Trial 129-P. *J Clin Oncol* 2009; 27:3104-08.
34. Sikov WM, **Dizon DS**, Strenger R, et al. Frequent pathologic complete responses in aggressive stage II-III breast cancers with q4week carboplatin and weekly paclitaxel + trastuzumab: a Brown University Oncology Group study. *J Clin Oncology* 2009; 27:4693-700.

35. **Dizon DS**, Schutzer ME, Politi M, et al. Advance Care Planning Decisions of Women with Cancer: Provider Recognition and Stability of Choices. *J Psychosocial Oncology* 2009; 27:383-95.
36. Penson RT, **Dizon DS**, Cannistra SA, et al. Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab with Maintenance Bevacizumab as First Line Chemotherapy for Advanced Mullerian Tumors. *J Clin Oncol* 2010; 28:154-9.
37. Makhija S, Amler LC, Glenn D, Ueland F, Gold M, **Dizon D**, et al. Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer: Low mRNA expression of the HER2-Coreceptor HER3 May be Predictive of Pertuzumab Activity. *J Clin Oncol* 2010; 28:1215-23.
38. Stuckey A, **Dizon DS**, Legare R, et al. Clinical characteristics and choices regarding prophylactic surgery in BRCA mutation carriers. *Gynecologic and Obstetric Investigation*. 2010; 69:270-73.
39. Kuroki L, Stuckey A, Hirway P, Raker CA, Bandera C, DiSilvestro PA, Granai CO, Legare RD, Sakr BJ, **Dizon DS**. Addressing clinical trials: can the multidisciplinary tumor board improve participation? A study from an academic women's cancers program. *Gynecologic Oncology* 2010; 116:295-300.
40. Politi MC, Clark MA, Ombao H, **Dizon D**, Elwyn G. Communicating uncertainty and its impact on patients' decision satisfaction: A necessary cost off involving patients in shared decision making? *Health Expectations* 2011; 14: 84-91.
41. **Dizon DS**, Sill MW, Gould N, et al. Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a Gynecologic Oncology Group study. *Gyn Oncol* 2011; 123:182-6.
42. Tsiapali E, Schmidt MM, **Dizon DS**, et al. Patterns of cellular distribution with the sentinel node positive for breast cancer. *International J Breast Cancer*, 2011; 2011:873-987.
43. Starikov RS, Goldman R, **Dizon DS**, Kostadinov S, Carr SR. Placental mesenchymal dysplasia as a twin gestation with complete molar pregnancy. *Obstetrics & Gynecology* 2011; 118:445-49.
44. **Dizon DS**, Blessing JA, Penson RT, et al. Evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. *Gyn Oncology* 2012; 125:367-371.
45. Stuckey A, Schutzer M, Rizack T, and **Dizon DS**. Locally advanced vulvar cancer in elderly women: is chemoradiation beneficial? *Am J Clin Oncol* 2012; Epub Ahead of print, April 6, 2012.
46. Horowitz NS, Olawaiye AB, Borger DR, Growdon WB, Krasner CN, Matulonis UA, Liu JF, Lee J, Brard L, and **Dizon D**. Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. *Gyn Oncol* 2012; 127:141-6.
47. **Dizon DS**, Damstrup L, Finkler NJ, et al. Phase II Activity of Belinostat (PXD-101), Carboplatin, and Paclitaxel in Women With Previously Treated Ovarian Cancer. *Inter Journal of Gynecol Cancer* 2012; 22:979-86.
48. Smit WM, Sufliarsky J, Werner TL, **Dizon DS**, et al. A phase II study of patupilone (EPO906) in patients with platinum-resistant or –refractory ovarian cancer. *Clin Ovarian Cancer and Other Gynecologic Cancers* 2012. Online July 15, 2012.
49. Rizack T, Gass JS, Legare RD, Sakr BJ, **Dizon DS**. Is Tumor Board Relevant? *The Breast Journal* 2013; 19:351-3.
50. Rauh-Hain JA, Guseh SH, Esselen KM, Growdon WB, Schorge JO, Horowitz NS, Krasner CN, del Carmen MG, Birrer MJ, **Dizon DS**. Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer. *Int J Gynecol Cancer*. 2013 Sep;23(7):1219-25.
51. MacLaughlan-David S, Salzillo S, Bowe P, Scuncio S, Malit B, Raker C, Gass JS, Granai CO, **Dizon DS**. Randomised controlled trial comparing hypnotherapy versus gabapentin for the treatment of hot flashes in breast cancer survivors: a pilot study. *BMJ Open* 2013; 10:e003138.
52. Wei W, Dizon D, Vathapadiekal V, Birrer MJ. Ovarian cancer: genomic analysis. *Ann Oncol* 2013; 24 Suppl 10 :x7-x15.
53. Roque DR, Cronin B, Robison K, Lopes V, Rizack T, **Dizon DS**. The effects of age on treatment and outcomes in women with stages IB1-IIB cervical cancer. *J Geriatr Oncol* 2013 ; 4 :374-81.
54. Robison KH, Olsen C, Sakr B, Rizack T, Legare R, Stuckey A, Granai CO, **Dizon DS**. Outcomes for women receiving bevacizumab for ovarian cancer treatment compared to other solid tumors at an Academic Oncology Center. *Clinical Ovarian Cancer* 2013. Epub 12/27/2013.

55. Meng X, Yang S, Zhu D, Wang X, Thiel K, Leslie KK, and Dizon D. Strategies for molecularly enhanced chemotherapy to achieve synthetic lethality in endometrial tumors with mutant p53. *Obstet Gynecol Int* 2013; 2013:828165.
56. Politi M, **Dizon DS**, Frosch DL, Kuzemchak MD, Stiggelbout AM. Importance of clarifying patients' desired role in shared decision making to match their level of engagement with their preferences. *Brit Med Journal* 2013 Dec 2; 347:f7066.
57. Rauh-Hain JA, Clemmer J, Clark RM, Bradford LS, Growdon WB, Goodman A, Boruta DM, **Dizon DS**, Schorge JO, del Carmen MG. Management and outcomes for elderly women with vulvar cancer over time. *Br J Obstet Gynecol* 2014; 121:719-27.
58. Robison K, Clark L, Eng W, Wu L, Raker C, Clark M, Tejada-Berges T, and **Dizon DS**. Cervical cancer prevention: Asian American women's knowledge and participation in screening practices. *Women's Health Issues*, 2014; 24:e231-6.
59. Pagan O, Regan MM, Walley BA, et al*. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. *N Engl J Med* 2014; 371:107-18. (*member of the investigative team cited in the appendix of the manuscript)
60. Cronin B, Robison K, Raker C, Moore R, Granai CO, and **Dizon DS**. Pegylated liposomal doxorubicin in recurrent ovarian cancer: Is there a role for maintenance therapy? *Clin Ovarian Cancer* 2014; 6: 17-20.
61. Duska LR, Blessing JA, Rotmensch J, Mannel RS, Hanjani P, Rose PG, and **Dizon DS**. A phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: An NRG Oncology/Gynecologic Oncology Group study. *Gynecol Oncol* 2014; 135: 44-48.
62. Francis PA, Regan MM, Fleming GF, et al*. Adjuvant ovarian suppression in premenopausal breast cancer. *N Engl J Med* 2014; Online first, 12/11/2014. (*member of the investigative team cited in the appendix of the manuscript)
63. **Dizon DS**, Sill MW, Schilder JM, McGonigle KF, Rahman Z, Miller DS, Mutch DG, and Leslie KK. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. *Gynecol Oncol* 2014; 135:441-5.
64. Thakur A, Lum L, Al-Kadhimi Z, Colvin G, Cummings F, Legare R, **Dizon D**, et al. Targeted T cell therapy in stage IV breast cancer: A phase I clinical trial. *Clin Cancer Res* 2015; 21: 2305-14. Epub Feb 16.
65. Joseph N, Clark RM, **Dizon DS**, Lee MS, Goodman A, Boruta D Jr, Schorge JO, Del Carmen MG, Growdon WB. Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer. *Gynecol Oncol* 2015; 137: 401-5. Epub Apr 1.
66. McMeekin DS, **Dizon D**, Barter J, Scambia G, Manzyuk L, Lisayanskaya A, Oaknin A, Ringuette S, Mukhopadhyay P, Rosenberg J. A phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. *Gyn Oncol* 2015; 138:18-23.
67. Foley O, **Dizon D**, Schmeler K, Del Carmen M. Development of a Breast Cancer Advocacy and Access Health Program in Nicaragua. *Breast J.* 2015; 21:570-1.
68. Clark MA, Ott M, Rogers ML, Politi MC, Miller SC, Moynihan L, Robison K, Stuckey A, **Dizon D**. Advance Care Planning (ACP) as a shared endeavor: Completion of ACP documents in a multidisciplinary cancer program. *Psycho-Oncology* 2015. Epub Oct 21.
69. Katz MS, Utengen A, Anderson PF, Thompson MA, Attai DJ, Johnston C, **Dizon DS**. Disease-Specific Hashtags For Online Communication About Cancer Care. *JAMA Oncology*, 2015; Nov 5:1-2.
70. Thaker PH, Salani R, Brady WE, Lankes HA, Cohn DE, Mutch DG, Mannel RS, Bell-McGuinn KM, DiSilvestro PA, Jelovac D, Carter JS, Duan W, Resnick KE, **Dizon DS**, Aghajanian CA, Fracasso PM. A phase I trial of paclitaxel, cisplatin and veliparib in the treatment of recurrence carcinoma of the cervix: An NRG Oncology study (NCT#01281852). *Ann Oncol* 2017 Mar 1;28(3):505-511.
71. McCourt CK, Deng W, **Dizon DS**, Lankes HA, Birrer MJ, Lomme MM, Powell MA, Kendrick JE, Saltzman JN, Warshal D, Tenney ME, Kushner DM, Aghajanian C. A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. *Gynecol Oncol* 2016; 144:101-106.
72. Lax T, **Dizon DS**, Birrer M, Long A, Del Carmen M, Goodman A, Krasner C, Penson RT, Growdon W, Camargo CA Jr, Banerji A. Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer. *J Allergy Clin Immunol Pract.* 2017; 5:177-78.

73. **Dizon DS**, Brady WE, Lankes HA, Jandial DA, Howell SB, Schilder RJ, et al. Results of a phase I pharmacokinetic study of intraperitoneal bortezomib (B) and carboplatin (C) in patients with persistent or recurrent ovarian cancer (OC): An NRG/Gynecologic Oncology Group study. *Gynecol Oncol*, 2017; 145:236-42.
74. Gass JS, Onstad M, Pesek S, Rojas K, Fogarty S, Stuckey A, Raker C, **Dizon DS**. Breast-Specific Sensuality and Sexual Function in Cancer Survivorship: Does Surgical Modality Matter? *Ann Surg Oncol* 2017; 24: 3133-3140.
75. Wo JY, Drapek LC, Niemierko A, Silvia B, Noé BN, Russo AL, Miyamoto DT, Hong TS, Efstathiou JA, Zietman AL, **Dizon DS**. Clinical needs assessment for sexual health among cancer patients receiving pelvic radiation: Implications for development of a radiation oncology sexual health clinic. *Pract Radiat Oncol* 2018; 8:206-12.
76. **DS Dizon**, D Dias-Santagata, A Bregar, L Sullivan, J Filipi, E DiTavi, L Miller, L Ellisen, M Birrer, M DelCarmen. Complete Remission following pembrolizumab in a woman with mismatch repair deficient endometrial cancer and a germline BRCA1 mutation. *The Oncologist* 2018; 23:650-53.
77. Birrer N, Chinchilla C, DelCarmen M, and **Dizon DS**. Is hormone replacement therapy safe in women with a BRCA mutation? A Systematic Review of the Contemporary Literature. *Am J Clin Oncol* 2018; 41:313-15.
78. El-Jawahri A, Fishman SR, Vanderklis J, **Dizon D**, Pensak N, Traeger L, Greer JA, Park E, Markovitz N, Waldman L, Hunnewell C, Saylor M, Driscoll J, Li Z, Spitzer TR, McAfee S, Chen YB, Temel JS. Pilot Study of a Multimodal Intervention to Enhance Sexual Function in Hematopoietic Stem Cell Transplant (HCT) Survivors. *Cancer* 2018; 124:2438-46.
79. de Rooij B, Park ER, Perez-Lougee GK, Rabin J, Quain K, **Dizon DS**, Post K, Chinn G, McDonough AL, Jiminez RB, van de Poll-Franse LK, Peppercorn J. MD. Cluster analysis demonstrates the need to individualize care for cancer survivors. *Oncologist* 2018; 23:1474-1481.
80. Hagan TL, Nauth-Shelley K, Thompson MA, Attai DJ, Katz MS, Graham D, Sparacio D, Lizaso C, Utengen A, and **Dizon DS**. The needs of women treated for ovarian cancer: Results from a #GynCSM Twitter chat. *Am J Participatory Med*, April 2018.
81. Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM; SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. *N Engl J Med*. 2018; 379:122-137.
82. Aghajanian C, Filiaci V, **Dizon DS**, Carlson JW, Powell MA, Secord AA, Tewari KS, Bender DP, O'Malley DM, Stuckey A, Gao J, Dao F, Soslow RA, Lankes HA, Moore K, Levine DA. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. *Gynecol Oncol*. 2018;150:274-281.
83. David SM, Marjon N, English D, Purington N, Han SS, and **Dizon DS**. Palliative total pelvic exenteration (TPE) for gynecologic cancers: a cross-sectional study of current practices and review of the literature. *Int J Gynecol Ca* 2018; 28: 1796-804.
84. B de Rooij, TH Thomas, KE Post, J Flanagan, NPM Ezendam, J Peppercorn, **DS Dizon**. Survivorship care planning in gynecologic oncology – perspectives from patients, caregivers and health care providers. *J Cancer Surv* 2018; 12:762-74.
85. Boardman CH, Brady WE, **Dizon DS**, Kunos CA, Moore KN, Zanotti KM, Matthews C, Cosin JA, Aghajanian C, Fracasso PM. A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study. *Gynecol Oncol* 2018; 151: 202-207.
86. Bandera C, **Dizon DS**. Contemporary approaches to High-risk, Early-Stage Serous Endometrial Cancer: Clinical Equipoise Persists. *Am J Clin Oncol* 2019; 42:107-08.
87. Rafelson W, Bruno J, **Dizon DS**. Protecting patient privacy in narratives: the Lifespan-Brown checklist for appropriate use of patient narratives. *The Oncologist* 2019; 24:285-87.

88. CN Krasner, C Castro, RT Penson, M Roche, D Kendall, UA Matulonis, MA Morgan, C Drescher, DK Armstrong, JK Wolfe, H Lee, J Supko, M Seiden, MJ Birrer, **DS Dizon**. Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. Accepted, *Gyn Oncol*, 2019. 153:223-229.
89. Yerramilli D, Drapek L, Nipp RD, Horick N, Moran SMC, Noé B, D'Arpino SM, Mitra D, Hong TS, Ryan DP, Dizon DS, Wo J. Sexual Function, Quality of Life, and Mood After Radiation Therapy in Patients with Anal Cancer. *J Gastrointest Cancer*. 2019 Epub Apr 13.
90. Katz MS, Anderson PF, Thompson MA, Salmi L, Freeman-Daily J, Utengen A, Dizon DS, Blotner C, Cooke DT, Sparacio D, Staley AC, Fisch MJ, Young C, Attai DJ. Organizing Online Health Content: Developing Hashtag Collections for Healthier Internet-Based People and Communities. *JCO Clin Cancer Informatics* 2019. Accepted for publication.
91. Ciambella CC, Wakeley M, Cabral D, Snow S, Taneja C, Wiggins DL, Emmick CM, Leonard KL, Lopresti ML, Witherby S, Dizon DS, Graves TA. Distress: Characterizing what causes the thermometer to rise in patients with newly diagnosed breast cancer attending a multidisciplinary clinic. *Annals of Surgical Oncology* 2019; Accepted for publication.

INVITED COMMENTARIES

1. **Dizon DS**. Incorporating targeted treatments into standard regimens: whither the role of established doses? *Cancer Investigation* 2004; 6:954.
2. Hachey K and **Dizon DS**. Personalizing chemotherapy through genetic profiling: will pharmacogenomics help improve and extend life for cancer patients? *Personalized Medicine*, 2009; 6:481-4.
3. **Dizon DS** and Gass JS. Perspective: Help or harm: Adjuvant therapies for primary invasive disease and the risk of a second contralateral breast cancer. *Am Journal of Hemat and Oncol* 2009; Available at: <http://www.ajho.com/Help-or-harm-Adjuvant-therapies-for-primary-invasive-disease-and-the-risk-of-a-second-contralateral-breast-cancer/article/141443/>.
4. **Dizon DS**. Where do anti-angiogenic agents belong in the treatment algorithm for ovarian cancer? *American J Clin Oncol*, 2011 May 5.
5. **Dizon DS**. PARP inhibitors for targeted treatment in ovarian cancer. *Lancet* 2017; 390:1929-30.
6. SM Temkin and **D Dizon**. PARP inhibitors for Ovarian Cancer: Who and when, and can we afford it? *First Report Managed Care* 2018; vol 15. <https://www.managedhealthcareconnect.com/article/parp-inhibitors-ovarian-cancer-who-and-when-and-can-we-afford-it>.
7. Carneiro B and **Dizon DS**. Prostate Cancer Social Media: In YouTube We Trust? *European Urology* 2019; 75: 568-69.

TOPIC REVIEWS

1. **Dizon DS** and Sabatini PJ. Management of ovarian cancer: balancing therapy and quality of life. *Oncol Spec Ed*. 2002; 5:1-6.
2. **Dizon DS** and Kemeny N. Intrahepatic arterial infusion of chemotherapy: clinical results. *Sem in Oncol* 2002; 29:126-135.
3. **Dizon DS** and Sabbatini PJ. Management of ovarian cancer: balancing therapy and quality of life. *Oncol Spec Ed*. 2003; 6:11-17.
4. Dupont J, Dizon D, Spriggs D. Management of Ovarian Cancer: Balancing Medical Therapy and Quality of Life. *Oncology Spec Ed*. 2004.
5. **Dizon DS**. Blocking HER dimerization: the clinical development of Pertuzumab in ovarian cancer. *Advances in Ovarian Cancer*, 2005: 3-6.
6. **Dizon DS**. Management of Non-epithelial Ovarian Cancer. <http://images.MD>. Images.MD: the online encyclopedia of medical images. *Current Medicine, LLC*, 2005.
7. **Dizon DS**, Schwartz J, Kemeny N. Regional chemotherapy: a focus on hepatic artery infusion for colorectal cancer liver metastases. *Surg Oncol Clin N Am*, 2008; 17:759-71.
8. Wiggins DL and **Dizon DS**. Dyspareunia and vaginal dryness after breast cancer treatment. *Sexuality, Reproduction, and Menopause*, 2008: 18-22.

9. Kuo A, Wiggins DL, and **Dizon DS**. Sexual dysfunction following breast cancer treatment: common problems, diagnosis, and management. *SRM: Sexuality, Reproduction, and Menopause*, 2008; 6:17-20.
10. **Dizon DS** and Makhija S. HER dimerization inhibitors: Developing pertuzumab as an anti-cancer agent in women's oncology. *Expert Opinion in Drug Discovery*, 2008; 11:1363-69.
11. **Dizon DS**, Duffy CA, Thompson DS, Wiggins DL. The sexuality clinic in the breast center: sex as a survivorship issue. *Breast Cancer Online* 2008; 1:1-3. doi:10.1017/S`47090310800802X
12. Shah N and **Dizon DS**. New generation platinum agents for solid tumors. *Future Medicine* 2009; 5:33-42.
13. **Dizon DS**. Quality of life after breast cancer: survivorship and sexuality. *The Breast Journal*. 2009; 15:500-4.
14. MacLaughlan S and **Dizon DS**. Breast Cancer Follow-Up; Extending the focus beyond survival. *Journal Watch Women's Health*, March 2009; 14:19-20.
15. Kunz MA and **Dizon DS**. Sexuality and intimacy following cancer. *US Obstetrics & Gynecology* 2009; 3:21-23.
16. Perez K, Gadgil M, and **Dizon DS**. Sexual ramifications of medical illness. *Clinics of Obstetrics and Gynecology* 2009; 52:691-701.
17. Kavar N and **Dizon DS**. Ixabepilone as a second-line treatment in advanced endometrial cancer. *Asian-Pacific Journal of Hematology and Oncology* 2010. Epub online 2/2010.
18. Robison K and **Dizon DS**. Moving Beyond Standard of Care: Novel Treatments in Gynecologic Cancer. *Contemporary Oncology* 2010. Published online June 2010.
19. Kilfoyle K and **Dizon DS**. Treating Locally advanced, Recurrent or Metastatic Endometrial Cancer: A Focus on Ixabepilone. *European Journal of Medical Oncology*. 2010; 2:65-70.
20. **Dizon DS**. Treatment options for advanced endometrial cancer. *Gynecologic Oncology* 2010; 117:373-81.
21. Kristjansdottir K and **Dizon DS**. HER-Dimerization Inhibitors: Evaluating pertuzumab in women's cancers. *Expert Opinion on Biologic Therapy*. 2010; 10:243-50.
22. Sakr BJ and **Dizon DS**. Breast cancer: adjuvant modalities. *Clin Obstet Gynecol* 2011; 54:150-6.
23. Roque DR and **Dizon DS**. New advances in the treatment of endometrial cancer. *Clin Invest* 2011; 1:413-422.
24. **Dizon DS**, Lu KH, and Miller DS. Endometrial cancer: Present state and future promise. 2011 Educational Book. American Society of Clinical Oncology.
25. Campos SM and **Dizon DS**. Anti-mitotic inhibitors. *Hematology and Oncology clinics* 2012; 26: 607-628.
26. **Dizon DS**, Graham D, Thompson MA, Johnson L, Johnston C, Fisch M, and Miller R. Practical guidance: The use of social media. *J Oncol Pract* 2012; 8:e114-24.
27. Hill EK and **Dizon DS**. Medical therapy of endometrial cancer: Current status and promising novel treatments. *Drugs* 2012; 26:72:705-13.
28. Stuckey A and **Dizon DS**. Novel antiangiogenic therapies in ovarian cancer. *Womens Health (London Engl)* 2012; 8:447-53.
29. Gao J and **Dizon DS**. Preparing for Survivorship: Quality of Life in Breast Cancer Survivors. *Journal of Sex Medicine* 2013; 10 (Suppl 1):16-20.
30. **Dizon DS**, Politi MA, Back AL. The power of words. *Am Soc Clin Oncol Educ Book*. 2013;2013:442-6. doi: E10.1200/EdBook_AM.2013.33.442.
31. Sabatini ME, **Dizon DS**. Why DOMA is unconstitutional, beyond the traditional views of same sex relationships. *J Assist Reprod Genet* 2013; 30:861.
32. Penson RT, **Dizon DS**, Birrer MJ. Clear cell cancer of the ovary. *Curr Opin Oncol*. 2013 Sep;25(5):553-7.
33. Falk SF and **Dizon DS**. Sexual dysfunction in women with cancer. *Fertility and Sterility* 2013; 100(4):916-920.
34. **Dizon DS**, Ambrosio AJ, Feltmate C, Wright AA, Campos SM, Viswanathan A; Cervical Cancer Special Interest Group of Dana Farber/Harvard Comprehensive Cancer Center Gynecologic Cancer Management Team. Pushing the bar in the treatment of cervical cancer: What can comprehensive cancer centers do on their own? *Gynecol Oncol* 2013; 131:464-6.
35. DeSimone M, Spriggs E, Gass JS, Carson SA, Krychman ML, and **Dizon DS**. Sexual dysfunction in female cancer survivors. *Am J Clin Oncol* 2014; 37:101-6.
36. Reynolds K, Sarangi S, Bardia A, and **Dizon D**. Precision medicine and personalized breast cancer: Combination pertuzumab therapy. *Pharmacogenomics and Personalized Med* 2014; 20:95-105.
37. Duska LR and **Dizon DS**. Improving quality of life in female cancer survivors: Current status and future questions. *Future Med* 2014; 10:1015-26.
38. **Dizon DS** and Birrer MJ. Advances in the diagnosis and treatment of uterine sarcomas. *Discov Med* 2014; 17:339-45.

39. Bregar A, Robison K, **Dizon DS**. Update on the chemotherapeutic management of endometrial cancer. *Clin Adv Hematol Oncol* 2014; 12: 659-65.
40. **Dizon DS**, Mackay H, Thomas G, Werner T, Kohn E, Rose P, and Covens A. State of the science in cervical cancer: Where are we today and where do we need to go. *Cancer* 2014; 120:2282- 2288.
41. **Dizon DS**, Suzin D, and McIlvenna S. Sexual health as a survivorship issue for female cancer survivors. *The Oncologist* 2014; 19:202-10.
42. Pepin K, del Carmen M, Brown A, and **Dizon DS**. CA125 and epithelial ovarian cancer: Role in screening, diagnosis, and surveillance. *American Journal of Hematology and Oncology* 2014. Available online at: <http://www.gotoper.com/publications/ajho/2014/2014Dec/CA-125-and-Epithelial-Ovarian-Cancer-Role-in-Screening-Diagnosis-and-Surveillance>.
43. Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, **Dizon DS**, Fine HA, Kalemkerian GP, Moasser M, Meuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. *J Clin Oncol* 2015; 33:786-809.
44. Boswell E and **Dizon DS**. Breast cancer and sexual function. *Translational Andrology and Urology* 2015; 4:160-68.
45. Amoyal NR, Nisotel L, **Dizon DS**. Sexual recovery after cancer. *Current Sexual Health Reports* 2015; 7:63-69.
46. Strasser-Weippl K, Chavarri-Guerra Y, Villarreal-Garza C, Bychkovsky BL, Debiase M, Liedke PE, Soto-Perez-de-Celis E, **Dizon D**, Cazap E, de Lima Lopes G Jr, Touya D, Nunes JS, Louis JS, Vail C, Bukowski A, Ramos-Elias P, Unger-Saldaña K, Brandao DF, Ferreyra ME, Luciani S, Nogueira-Rodrigues A, de Carvalho Calabrich AF, Del Carmen MG, Rauh-Hain JA, Schmeler K, Sala R, Goss PE. Progress and remaining challenges for cancer control in Latin America and the Caribbean. *Lancet Oncol* 2015; 16:1405-38.
47. Bychkovsky BL, Ferreyra ME, Strasser-Weippl K, Herold CI, de Lima Lopes G Jr, **Dizon DS**, Schmeler KM, Del Carmen M, Randall TC, Nogueira-Rodrigues A, de Carvalho Calabrich AF, St Louis J, Vail CM, Goss PE. Cervical cancer control in Latin America: A call to action. *Cancer*. 2015 Dec 15.
48. Bradford LS, Rauh-Hain JA, Schorge J, Birrer MJ, **Dizon DS**. Advances in the management of recurrent endometrial cancer. *Am J Clin Oncol* 2015; 38:206-12.
49. Katz AN and **Dizon DS**. Sexuality after cancer: A model for male cancer survivors. *J Sex Med* 2016; 13:70-8.
50. **Dizon DS**, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, Hunger S, Krishnamurthy SS, Lassman AB, Markham MJ, Mayer E, Neuss M, Pal SK, Richardson LC, Schilsky R, Schwartz GK, Spriggs DR, Villalona-Calero MA, Villani G, Masters G. Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology 2016; 34: 987-1011.
51. Simone CG, Markham MJ, **Dizon DS**. Chemotherapy in ovarian germ cell tumors: A systematic review. *Gynecol Oncol* 2016; 141:602-07.
52. Attai DJ, Sedrak MS, Katz MS, Thompson MA, Anderson PF, Kesselheim JC, Fisch MJ, Graham DL, Utengen A, Johnston C, Miller RS, **Dizon DS**. Collaboration for Outcomes on Social Media in Oncology (COSMO). Social media in cancer care: highlights, challenges, and opportunities. *Future Oncol* 2016; 12:1549-52.
53. **Dizon DS** and Birrer MJ. Making a Difference: Distinguishing Two Primaries From Metastasis in Synchronous Tumors of the Ovary and Uterus. *JNCI* 2016; 108(6). Pii; djv442.
54. Penson RT, Sales E, Sullivan L, Borger DR, Krasner CN, Goodman AK, Del Carmen MG, Growdon WB, Schorge JO, Boruta DM, Castro CM, **Dizon DS**, Birrer MJ. A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. *Gynecol Oncol* 2016; 141:108-12.
55. Krzystyniak J, Ceppi L, **Dizon DS**, Birrer MJ. Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer. *Ann Oncol* 2016; 27S1:i4-i10.
56. Hall TR and **Dizon DS**. Neoadjuvant chemotherapy for advanced epithelial ovarian cancer. *Clin Adv Hematol Oncol* 2016; 14:262-8.
57. Bychkovsky BL, **Dizon DS**, Sikov WM. Systemic therapies for nonmetastatic breast cancer: the role of neoadjuvant and adjuvant chemotherapy and the use of endocrine therapy. *Clin Obstet Gynecol*. 2016; 59:756-771.
58. **Dizon DS**. Neoadjuvant chemotherapy for newly diagnosed ovarian cancer: It's all about selection. *Gynecol Oncol* 2017; 144: 241-42.

59. Dittrich C, Stiefel F, Kiss A, **Dizon DS**. "Integrating communication as a core skill in the global curriculum for medical oncology" by Horlait et al. *Ann Oncol* 2017; Epub Jan 3.
60. Burstein HJ, Aragon-Ching J, Baxter N, Chiorean EG, Chow WA, de Groot JF, Devine SM, Dubois SG, El-Deiry W, Epstein AS, Heymach JV, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RS, Schuchter LM, Tung NM, Winkfield KM, Wirth LJ, **Dizon DS**. *Clinical Cancer Advances 2017: Annual report on progress against cancer from the American Society of Clinical Oncology*. *J Clin Oncol* 2017; 35:1341-67.
61. Preti EP, Landoni F, Colombo N, **Dizon DS**. How to address sexual problems in female cancer patients. *Oncology (Williston Park)* 2017; 31:258-62, 64.
62. Sedrak MS, **Dizon DS**, Anderson PF, Fisch MJ, Graham DL, Katz MS, Kesselheim JC, Miller RS, Thompson MA, Utengen A, Attai DJ; Collaboration for Outcomes on Social Media in Oncology (COSMO). The emerging role of professional social media use in oncology. *Future Oncol* 2017; 13:1281-85.
63. **Dizon DS**. What's the Harm? *Oncologist* 2017; Epub Jul 24.
64. Attai DJ, Anderson PF, Fisch MJ, Graham DL, Katz MS, Kesselheim J, Markham MJ, Pennell NA, Sedrak MS, Thompson MA, Utengen A, **Dizon DS**; Collaboration for Outcomes on Social Media in Oncology (COSMO). Risks and benefits of Twitter use by hematologists/oncologists in the era of digital medicine. *Semin Hematol*. 2017 Oct;54:198-204.
65. Thompson MA, Ahlstrom J, **Dizon DS**, Gad Y, Matthews G, Luks HJ, Schorr A . Twitter 101 and beyond: introduction to social media platforms available to practicing hematologist/oncologists. *Semin Hematol*. 2017 Oct;54(4):177-183.
66. Lopresti M, Rizack T, **Dizon DS**. Sexuality, fertility and pregnancy following breast cancer treatment. *Gland Surg* 2018; 7: 404-410.
67. Katz MS, Anderson PF, Thompson MA, Salmi L, Freeman-Daily J, Utengen A, **Dizon DS**, Blotner C, Cooke DT, Sparacio D, Staley AC, Fisch MJ, Young C, Attai DJ. Organizing Online Health Content: Developing Hashtag Collections for Healthier Internet-Based People and Communities. Accepted to *JCO Clin Ca Informatics* 2019

TOPIC REVIEWS *Listed below are topics I solicited and/or extensively edited as part of my role as Deputy Editor at UpToDate*

1. Pettaway CA. Pettaway CA. Carcinoma of the penis: Clinical presentation and diagnosis. In: **Dizon DS**, Richie JP, editors. *UpToDate*, January 2012.
2. Sikov WM, Wolff AC. Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options. In: **Dizon DS**, Gralow JR, Hayes DF, editors. *UpToDate*, January 2012.
3. Monk BJ. The role of angiogenesis inhibitors in epithelial carcinoma of the ovary, fallopian tube, or peritoneum. In: **Dizon DS**, Goff B, editors. *UpToDate*, January 2012.
4. Burstein H. Adjuvant medical therapy for HER2-positive breast cancer. In: **Dizon DS**, Hayes DF, editors. *UpToDate*, January 2012.
5. Raghavan D. Management of muscle-invasive urothelial (transitional cell) bladder cancer. In: **Dizon DS**, Kantoff P, Lerner SP, editors. *UpToDate*, February 2012.
6. Coleman RL, Sabbatini P. Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease. In: **Dizon DS**, Goff B, editors. *UpToDate*, February 2012.
7. Pritchard KI. Adjuvant endocrine therapy for non-metastatic, hormone receptor-positive breast cancer. In: **Dizon DS**, Hayes DF, editors. *UpToDate*, February 2012.
8. Ellis M, Naughton MJ, Ma CX. Systemic treatment for advanced or metastatic breast cancer: Endocrine therapy. In: **Dizon DS**, Hayes DF, editors. *UpToDate*, March 2012.
9. Costanza ME and Chen WY. Modifiable risk factors for breast cancer. In: **Dizon DS**, Hayes DF, editors. *UpToDate*, April 2012.
10. Costanza ME and Chen WY. Non-modifiable risk factors for breast cancer. In: **Dizon DS**, Hayes DF, editors. *UpToDate*, April 2012.
11. Hayes DF. Prognostic and predictive factors in invasive breast cancer. In: **Dizon DS**, Hayes DF, editors. *UpToDate*, May 2012.
12. Steele GS, Richie JP. Surgical management of advanced testicular germ cell tumors. In: **Dizon DS**, Kantoff PW, editors. *UpToDate*, June 2012.

13. Shapiro CL. Acute side effects of adjuvant chemotherapy for early stage breast cancer. In: **Dizon DS**, Hayes DF, editors. UpToDate, June 2012.
14. Beard CJ, Vaughn DJ. Approach to the care of long-term testicular cancer survivors. In: **Dizon DS**, Ganz PA, Nekhlyudov L, editors. UpToDate, July 2012.
15. Beard CJ. Treatment of stage I seminoma. In: **Dizon DS**, Oh WK, editors. UpToDate, July 2012.
16. Wright JD. Management of recurrent or metastatic cervical cancer. In: **Dizon DS**, Goff BA, Mundt AJ, editors. UpToDate, July 2012.
17. Ellis M, Naughton MJ, Ma CX. Systemic treatment for metastatic breast cancer: Endocrine therapy. In: **Dizon DS**, Hayes DF, editors. UpToDate, July 2012.
18. MacVicar GR, Bellmunt J. Treatment of metastatic urothelial cancer of the bladder and urinary tract. In: **Dizon DS**, Raghavan D, editors. UpToDate, July 2012.
19. Mohler ER, Mondry TE. Clinical manifestations and diagnosis of lymphedema. In: **Dizon DS**, Hayes DF, editors. UpToDate, July 2012.
20. Steele GS, Richie JP. Active surveillance following orchiectomy for stage I testicular germ cell tumors. In: **Dizon DS**, Oh WK, editors. UpToDate, July 2012.
21. Oh WK, Richie JP. Posttreatment follow-up for men with testicular germ cell tumors. In: **Dizon DS**, Kantoff PW, editors. UpToDate, July 2012.
22. Rosenberg JE, Bellmunt J, Sternberg CN. Adjuvant chemotherapy for urothelial (transitional cell) carcinoma of the bladder. In: **Dizon DS**, Raghavan D, editors. UpToDate, July 2012.
23. Campos SM, Miller DS. Treatment of locally advanced, recurrent, or metastatic endometrial cancer. In: **Dizon DS**, Falk S, Goff BA, editors. UpToDate, August 2012.
24. Gray HJ, Koh W-J. Adjuvant treatment of intermediate-risk endometrial cancers. In: **Dizon DS**, Goff B, editors. UpToDate, August 2012.
25. Plaxe SC, Mundt AJ. Overview of endometrial carcinoma. In: **Dizon DS**, Falk SJ, Goff B, editors. UpToDate, August 2012.
26. Raghavan D. Neoadjuvant treatment of muscle-invasive urothelial (transitional cell) bladder cancer. In: **Dizon DS**, Kantoff PW, Lerner SP, editors. UpToDate, August 2012.
27. Ruddy KJ, Partridge AH. roach to the long-term survivor of breast cancer. In: **Dizon DS**, Nekhlyudov L, Hayes DF, editors. UpToDate, August 2012.
28. Oh WK. Overview of the treatment of testicular germ cell tumors. In: **Dizon DS**, Kantoff PW, editors. UpToDate, August 2012.
29. Burstein H. Adjuvant chemotherapy for HER2-negative breast cancer. In: **Dizon DS**, Hayes DF, editors. UpToDate, August 2012.
30. Sikov WM, Wolff AC. Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options. In: **Dizon DS**, Gralow JR, Chagpar AB, editors. UpToDate, September 2012.
31. Chen WY. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention. In: **Dizon DS**, Hayes DF, editors. UpToDate, September 2012.
32. De Los Santos J, Straughn JM. Management of early stage cervical cancer. In: **Dizon DS**, Falk SJ, Mundt A, Goff B, editors. UpToDate, September 2012.
33. Mawardi HH, Al-Mohaya M, Treister NS. Oral health in cancer survivors. In: **Dizon DS**, Ganz PA, editors. UpToDate, October 2012.
34. Gilligan TD, Kantoff PW. Initial risk-stratified treatment for advanced testicular germ cell tumors. In: **Dizon DS**, Oh WK, editors. UpToDate, October 2012.
35. Hensley ML, Abu-Rustum N. Treatment and prognosis of uterine leiomyosarcoma. In: **Dizon DS**, Falk SJ, Goff B, editors. UpToDate, November 2012.
36. Sikov WM. Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis. In: **Dizon DS**, Gralow JR, Chagpar AB, editors. UpToDate, November 2012.
37. Pettaway CA. Carcinoma of the penis: Clinical presentation and diagnosis. In: **Dizon DS**, Richie JP, editors. UpToDate, November 2012.
38. Pettaway CA. Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis. In: **Dizon DS**, Richie JP, editors. UpToDate, November 2012.
39. Pettaway CA. Carcinoma of the penis: Surgical and medical treatment. In: **Dizon DS**, Richie JP, editors. UpToDate, November 2012.

40. Chen L-M, Berek JS. Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum. In: **Dizon DS**, Falk SJ, Goff B, editors. UpToDate, December 2012.
41. Konstantinopoulos PA, Bristow RE. Neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer. In: **Dizon DS**, Goff B, editors. UpToDate, December 2012.
42. Powell MA, Penson RT. Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma. In: **Dizon DS**, Falk SJ, Goff B, editors. UpToDate, December 2012.
43. Taghian A, El-Ghamry MN, Merajver SD. Overview of the treatment of newly diagnosed, non-metastatic breast cancer. In: **Dizon DS**, Hayes DF, editors. UpToDate, December 2012.
44. De Los Santos J, Straughn JM. Management of locally advanced cervical cancer. In: **Dizon DS**, Falk SJ, Mundt A, Goff B, editors. UpToDate, December 2012.
45. Costanza ME and Chen WY. Factors that modify breast cancer risk in women. In: **Dizon DS**, Hayes DF, editors. UpToDate, January 2013.
46. Esserman L, Joe B. Clinical features, diagnosis, and staging of newly diagnosed breast cancer. In: **Dizon DS**, Duda R, Gralow JR, editors. UpToDate, January 2013.
47. Kimmick G. Treatment of metastatic breast cancer in older women. In: **Dizon DS**, Hayes DF, editors. UpToDate, February 2013.
48. Nekhlyudov L, Snyder C. Overview of cancer survivorship care for primary care and oncology providers. In: **Dizon DS**, Ganz PA, editors. UpToDate, March 2013.
49. Hayes DF. Prognostic molecular profiles of breast cancer. In: **Dizon DS**, Gralow JR, editors. UpToDate, March 2013.
50. Cherny N. Palliative sedation. In: **Dizon DS**, Billings JA, editors. UpToDate, April 2013.
51. Ligibel J, Meyerhardt JA. The roles of diet, physical activity, and body weight in cancer survivorship. In: **Dizon DS**, Ganz PA, editors. UpToDate, April 2013.
52. Lee SI, Duigenan S. Diagnostic approach, differential diagnosis, and treatment of a small renal mass. In: **Dizon DS**, Richie JP, Atkins MB, editors. UpToDate, April 2013.
53. Kimmick G, Seo PH. General principles on the treatment of early stage and locally advanced breast cancer in older women. In: **Dizon DS**, Hayes DF, Schmader KE, editors. UpToDate, April 2013.
54. Moynihan TJ, Bober SL. Sexuality in palliative care. In: **Dizon DS**, Block SD, editors. UpToDate, April 2013.
55. Richie JP, Choueiri TK. Role of surgery in patients with metastatic renal cell carcinoma. In: **Dizon DS**, Atkins MB, editors. UpToDate, April 2013.
56. Duska LR. Overview of the approach to survivors of epithelial ovarian, fallopian tube, or peritoneal carcinomas. In: **Dizon DS**, Nekhlyudov L, Goff B, editors. UpToDate, May 2013.
57. Atkins MB. Overview of the treatment of renal cell carcinoma. In: **Dizon DS**, Richie JP, editors. UpToDate, May 2013.
58. Pritchard KI. Adjuvant endocrine therapy for non-metastatic, hormone receptor-positive breast cancer. In: **Dizon DS**, Hayes DF, editors. UpToDate, May 2013.
59. White DB. Ethics in the intensive care unit: Responding to requests for futile or potentially inappropriate therapies. In: **Dizon DS**, Parsons PE, Arnold RM, editors. UpToDate, May 2013.
60. Choueiri TK. Hereditary kidney cancer syndromes. In: **Dizon DS**, Atkins MB, editors. UpToDate, May 2013.
61. Elkas JC, Berek JS, Russell T. Vulvar cancer: Staging, treatment, and prognosis. In: **Dizon DS**, Falk SJ, Goff B, Mundt AJ, editors. UpToDate, May 2013.
62. White DB. Withholding and withdrawing ventilatory support in the intensive care unit. In: **Dizon DS**, Parsons PE, Arnold RM, editors. UpToDate, May 2013.
63. Richie JP. Definitive surgical management of renal cell carcinoma. In: **Dizon DS**, Atkins MB, editors. UpToDate, July 2013.
64. De Los Santos J, Straughn JM. Management of locally advanced cervical cancer. In: **Dizon DS**, Falk SJ, Mundt A, Goff B, editors. UpToDate, July 2013.
65. Steele GS, Richie JP. Retroperitoneal lymph node dissection for early stage nonseminomatous testicular germ cell tumors. In: **Dizon DS**, Oh WK, editors. UpToDate, July 2013.
66. Skolarus T. Overview of approach to prostate cancer survivors. In: **Dizon DS**, Nekhlyudov L, editors. UpToDate, August 2013.
67. Isaacs M, Curtis JR. Palliative care: Issues in the intensive care unit. **Dizon DS**, Parsons PE, Silveira MJ, Ritchie C, editors. UpToDate August 2013.

68. Winzelberg GS, Hanson LC. Palliative care: Nursing home. In: **Dizon DS**, Billings JA, Schmader KE, editors. UpToDate, September 2013.
69. Campos SM, Cohn DE. Treatment of recurrent or metastatic endometrial cancer. In: **Dizon DS**, Falk S, Goff BA, editors. UpToDate, September 2013.
70. Van Poznak C. Osteoclast inhibitors in the management of bone metastases from breast cancer. In: **Dizon DS**, Gralow JR, editors. UpToDate, September 2013.
71. Atkins MB. Anti-angiogenic and molecularly targeted therapy for advanced or metastatic renal cell carcinoma. In: **Dizon DS**, Richie JP, editors. UpToDate, September 2013.
72. Danis M. Stopping artificial nutrition and hydration at the end of life. In: **Dizon DS**, Arnold RM, editors. UpToDate, September 2013.
73. Mitra AP, Birkhahn M, Penson DF, Cote RJ. Urine biomarkers for the detection of urothelial (transitional cell) carcinoma of the bladder. In: **Dizon DS**, Lerner SP, editors. UpToDate, September 2013.
74. Pierce LJ. Adjuvant radiation therapy for women with newly diagnosed, non-metastatic breast cancer. In: **Dizon DS**, Hayes DF, Wazer DE, editors. UpToDate, September 2013.
75. Pierce LJ. Radiation therapy techniques for newly diagnosed, non-metastatic breast cancer. In: **Dizon DS**, Wazer DE, editors. UpToDate, September 2013.
76. Foukakis T, Bergh J. Prognostic and predictive factors in early, non-metastatic breast cancer. In: **Dizon DS**, Hayes DF, editors. UpToDate, October 2013.
77. Schott AF. Systemic treatment of metastatic breast cancer: Chemotherapy. In: **Dizon DS**, Hayes DF, editors. UpToDate, October 2013.
78. Schott AF. Systemic treatment for HER2-positive metastatic breast cancer. In: **Dizon DS**, Hayes DF, editors. UpToDate, October 2013.
79. Muriel AC. Preparing children for the loss of a loved one. In: **Dizon DS**, Block SD, Brent D, editors. UpToDate, October 2013.
80. Hayes DF. Systemic treatment for metastatic breast cancer: General principles. In: **Dizon DS**, Gralow JR, editors. UpToDate, October 2013.
81. Yamauchi H, Hayes DF. HER2 and predicting response to therapy in breast cancer. In: **Dizon DS**, Gralow JR, editors. UpToDate, October 2013.
82. Chen WY. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention. In: **Dizon DS**, Hayes DF, editors. UpToDate, October 2013.
83. Madeb R, Golijanin D, Messing E, Koontz BF. Urethral cancer in men. In: **Dizon DS**, Richie JP, Lee WR, editors. UpToDate, October 2013.
84. Madeb R, Golijanin D, Messing E, Koontz BF. Urethral cancer in women. In: **Dizon DS**, Richie JP, Lee WR, editors. UpToDate, October 2013.
85. Sikov WM, Wolff AC. Neoadjuvant therapy for breast cancer: Rationale, pretreatment evaluation, and therapeutic options. In: **Dizon DS**, Gralow JR, Chagpar AB, editors. UpToDate, October 2013.
86. Ky B, Kondapalli L, Lenihan DJ. Cancer survivorship: Cardiovascular and respiratory issues. In: **Dizon DS**, Ganz PA, editors. UpToDate, December 2013.
87. Hammond ME. Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy. In: **Dizon DS**, Hayes DF, editors. UpToDate, December 2013.
88. Jimenez JA, Campbell SC. Chemoprevention of bladder cancer. In: **Dizon DS**, Richie JP, Lerner SP, editors. UpToDate, December 2013.
89. Steele GS, Richie JP. Approach to surgery following primary treatment for advanced testicular germ cell tumors. In: **Dizon DS**, Kantoff PW, editors. UpToDate, December 2013.
90. Leitao MM, Zivanovic O. Small cell neuroendocrine carcinoma of the cervix. In: **Dizon DS**, Goff B, editors. UpToDate, January 2014.
91. Duska LR. Overview of approach to endometrial cancer survivors. In: **Dizon DS**, Nekhlyudov L, Goff B, editors. UpToDate, February 2014.
92. Birrer MJ, Monk BJ. The role of angiogenesis inhibitors in epithelial carcinoma of the ovary, fallopian tube, or peritoneum. In: **Dizon DS**, Goff B, editors. UpToDate, February 2014.
93. Haddad RI, Limaye S. Overview of the approach to long-term survivors of head and neck cancer. In: **Dizon DS**, Nekhlyudov L, editors. UpToDate, March 2014.

94. Irwin SA, Hirst JM. Overview of anxiety in palliative care. In: **Dizon DS**, Hermann R, Block SD, editors. UpToDate, March 2014.
95. Detering K, Silveira MJ. Advance care planning and advance directives. In: **Dizon DS**, Arnold RM, editors. UpToDate, April 2014.
96. Lotan Y, Choueiri TK. Clinical presentation, diagnosis, and staging of bladder cancer. In: Dizon DS, Lerner SP, editors. UpToDate, April 2014.
97. Plaxe SC, Mundt AJ. Overview of endometrial carcinoma. In: **Dizon DS**, Falk SJ, Goff B, editors. UpToDate, April 2014.
98. Gilligan TD. Small cell carcinoma of the bladder. In: **Dizon DS**, Raghavan D, editors. UpToDate, April 2014.
99. Coleman RL, Sabbatini P. Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease. In: **Dizon DS**, Goff B, editors. UpToDate, April 2014.
100. Beard CJ, Vaughn DJ. Approach to the care of long-term testicular cancer survivors. In: **Dizon DS**, Ganz PA, Nekhlyudov L, editors. UpToDate, April 2014.
101. Atkins MB. Anti-angiogenic and molecularly targeted therapy for advanced or metastatic renal cell carcinoma. In: **Dizon DS**, Richie JP, editors. UpToDate, April 2014.
102. Emanuel EJ. Legal aspects in palliative and end of life care. In: **Dizon DS**, Arnold RM, Schmader KE, editors. UpToDate, April 2014.
103. Puchalski CM, Ferrell B, Otis-Greene S, Handzo G. Overview of spirituality in palliative care. In: **Dizon DS**, Block SD, editors. UpToDate, May 2014.
104. Karam A. Cervical cancer in pregnancy. In: **Dizon DS**, Barss VA, Ramin SM, Goff B, editors. UpToDate, May 2014.
105. Gershenson DM. Treatment of malignant germ cell tumors of the ovary. In: **Dizon DS**, Falk SJ, Goff B, Pappo AS, editors. UpToDate, May 2014.
106. Steele GS, Richie JP. Retroperitoneal lymph node dissection for early stage nonseminomatous testicular germ cell tumors. In: **Dizon DS**, Oh WK, editors. UpToDate, May 2014.
107. Taplin ME. Testicular sex cord stromal tumors. In: **Dizon DS**, Kantoff PW, editors. UpToDate, May 2014.
108. Richie JP, Choueiri TK. Role of surgery in patients with metastatic renal cell carcinoma. In: Dizon DS, Atkins MB, editors. UpToDate, May 2014.
109. Lerner SP, Raghavan D. Overview of the management of urothelial (transitional cell) bladder cancer. In: **Dizon DS**, Richie JP, editors. UpToDate, May 2014.
110. Twaddle M, McCormick E. Palliative care delivery in the home. In: **Dizon DS**, Ritchie C, Silveira MJ, editors. UpToDate, June 2014.
111. Fromme E, Smith MD. Ethical issues in palliative care. In: **Dizon DS**, Arnold RM, Schmader KE, editors. UpToDate, June 2014.
112. O'Donnell J. Palliative care for homeless persons. In: **Dizon DS**, Ritchie C, Silveira MJ, editors. UpToDate, June 2014.
113. Burstein H. Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer. In: **Dizon DS**, Hayes DF, editors. UpToDate, June 2014.
114. Mohler ER, Mondry TE. Prevention and treatment of lymphedema. In: **Dizon DS**, Gralow JR, Nekhlyudov L, editors. UpToDate, June 2014.
115. Hirst JM, Irwin SA. Overview of insomnia in palliative care. In: **Dizon DS**, Block SD, Benca R, editors. UpToDate, July 2014.
116. Stricker CT. Assuring quality of care for cancer survivors: The survivorship care plan. In: **Dizon DS**, Ganz PA, editors. UpToDate, July 2014.
117. Stubblefield MJ, Sokolof JM, Aghalar MR. Physical rehabilitation for cancer survivors. In: Dizon DS, Ganz PA, Nekhlyudov L, editors. UpToDate, July 2014.
118. Smith A. Communication of prognosis in palliative care. In: **Dizon DS**, Block SD, editors. UpToDate, July 2014.
119. Emanuel EJ. Euthanasia and physician assisted suicide. In: **Dizon DS**, Arnold RM, editors. UpToDate, July 2014.
120. Meadows ME. Cognitive function after cancer and cancer-related treatment. In: **Dizon DS**, Ganz PA, editors. UpToDate, August 2014.

121. Choueiri TK, Pal SK. The treatment approach to non-clear cell renal cell carcinoma. In: **Dizon DS**, Atkins MB, editors. UpToDate, August 2014.
122. Duska LR. Overview of approach to cervical cancer survivors. In: **Dizon DS**, Nekhlyudov L, Goff B, editors. UpToDate, August 2014.
123. Gradishar W. Breast cancer in men. In: **Dizon DS**, Hayes DF, Chagpar AB, editors. UpToDate, August 2014.
124. Stephenson AJ. Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer. In: **Dizon DS**, Lerner SP, editors. UpToDate, September 2014.
125. Sikov WM. Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis. In: **Dizon DS**, Gralow JR, Chagpar AB, editors. UpToDate, September 2014.
126. Oh WK. Overview of the treatment of testicular germ cell tumors. In: **Dizon DS**, Kantoff PW, editors. UpToDate, September 2014.
127. Syrjala KL, Yi JC. Overview of psychosocial issues in the adult cancer survivor. In: **Dizon DS**, Ganz PA, editors. UpToDate, October 2014.
128. Chia ST. Prognostic and predictive factors in metastatic breast cancer. In: **Dizon DS**, Hayes DF, editors. UpToDate, October 2014.
129. Gilligan TD, Kantoff PW. Treatment of relapsed and refractory testicular germ cell tumors. In: **Dizon DS**, Oh WK, editors. UpToDate, October 2014.
130. Kumar S. Palliative care and hospice outside of the United States. In: **Dizon DS**, Arnold RM, editors. UpToDate, November 2014.
131. Okon TR. Overview of comprehensive patient assessment in palliative care. In: **Dizon DS**, Arnold RM, editors. UpToDate, 2014.
132. Gilligan TD, Kantoff PW. Management of stage I nonseminomatous germ cell tumors. In: **Dizon DS**, Oh WK, editors. UpToDate, December 2014.
133. Syrjala KL, Yi JC. Overview of issues in adolescent and young adult cancer survivors. In: **Dizon DS**, Ganz PA, Nekhlyudov L, editors. UpToDate, December 2014.
134. Meier D, McCormick E, Lagman R. Hospice: Philosophy of care and appropriate utilization in the United States. In: **Dizon DS**, Arnold RA, editors. UpToDate, December 2014.
135. Rosenberg JE, Bellmunt J, Sternberg CN. Adjuvant chemotherapy for urothelial (transitional cell) carcinoma of the bladder. In: **Dizon DS**, Raghavan D, editors. UpToDate, December 2014.
136. Anders CK, Carey LA. Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer. In: **Dizon DS**, Hayes DF, editors. UpToDate, December 2014.
137. Karam-Hage M, Minnix J, Cinciripini PM, Gritz E. Alcohol and smoking cessation for cancer survivors. In: **Dizon DS**, Ganz PA, editors. UpToDate, December 2014.
138. Goldstein DP, Berkowitz R, Horowitz N. Hydatidiform mole: Management. In: **Dizon DS**, Falk SF, Goff BA, editors. UpToDate, December 2014.
139. Goldstein DP, Berkowitz R, Horowitz N. Gestational trophoblastic neoplasia: Epidemiology, clinical features, diagnosis, staging, and risk stratification. In: **Dizon DS**, Falk SF, Goff BA, editors. UpToDate, January 2015.
140. Goldstein DP, Berkowitz R, Horowitz N. Initial management of high-risk gestational trophoblastic neoplasia. In: **Dizon DS**, Falk SF, Goff BA, editors. UpToDate, January 2015.
141. Goldstein DP, Berkowitz R, Horowitz N. Initial management of low-risk gestational trophoblastic neoplasia. In: **Dizon DS**, Falk SF, Goff BA, editors. UpToDate, January 2015.
142. Goldstein DP, Berkowitz R, Horowitz N. Management of resistant or recurrent gestational trophoblastic neoplasia. In: **Dizon DS**, Falk SF, Goff BA, editors. UpToDate, January 2015.
143. Bradley KA, McHaffie DR. Treatment-related toxicity from the use of radiation therapy for gynecologic malignancies. **Dizon DS**, Goff BA, editors. UpToDate, January 2015.
144. Tew WP, Moore KN. The approach to ovarian cancer in older women. **Dizon DS**, Goff BA, editors. UpToDate, January 2015.
145. Falk SJ. Overview of sexual dysfunction in female cancer survivors. **Dizon DS**, Ganz PA, editors. UpToDate, January 2015.
146. Karam A, Berek JS. Vaginal cancer. **Dizon DS**, Falk SJ, Goff BA, Mundt AJ, editors. UpToDate, January 2015.

147. Pritchard KI. Adjuvant endocrine therapy for hormone receptor-positive breast cancer. In: Dizon DS, Hayes DF, editors. UpToDate, January 2015.
148. Gilligan TD, Kantoff PW. Management of stage I nonseminomatous germ cell tumors. In: Dizon DS, Oh WK, editors. UpToDate, January 2015.
149. Gilligan TD, Kantoff PW. Classification and management of stage II nonseminomatous germ cell tumors. In: **Dizon DS**, Oh WK, editors. UpToDate, January 2015.
150. Anders CK, Carey LA. Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer. In: **Dizon DS**, Hayes DF, editors. UpToDate, February 2015.
151. Ellis M, Naughton MJ, Ma CX. Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy. In: **Dizon DS**, Hayes DF, editors. UpToDate, March 2015.
152. Hurria A, Come SE. Patterns of relapse and long-term complications of therapy in breast cancer survivors. In: **Dizon DS**, Ganz PA, Nekhlyudov L, editors. UpToDate, April 2015.
153. Harlow SP and Weaver DL. Diagnosis, staging, and the role of sentinel lymph node biopsy in the nodal evaluation of breast cancer. In: **Dizon DS**, Chagpar AB, Hayes DF, Pierce LJ, editors. UpToDate, April 2015.
154. Gaillard S, Secord AA. Classification and treatment of endometrial stromal sarcoma and uterine adenosarcoma. In: **Dizon DS**, Falk SJ, Goff B, editors. UpToDate, June 2015.
155. Chen LM and Berek JS. Borderline ovarian tumors. In: **Dizon DS**, Falk SJ, Goff B, editors. UpToDate, May 2015.
156. Fleming G, DiSilvestro PA. Adjuvant treatment of high-risk endometrial cancers. In: **Dizon DS**, Goff B, editors. UpToDate, May 2015.
157. Straughn JM. Invasive cervical cancer: Patterns of recurrence and posttreatment surveillance. In: **Dizon DS**, Goff B, editors. UpToDate, May 2015.
158. Palefsky JM and Cranston RD. Virology of human papillomavirus infections and the link to cancer. In: Dezube BJ, **Dizon DS**, editors. UpToDate, May 2015.
159. Markman M. Intraperitoneal chemotherapy for treatment of ovarian cancer. In: **Dizon DS**, Goff B, editors. UpToDate, June 2015.
160. Plaxe SC, Mundt AJ. Approach to adjuvant treatment of endometrial cancer. In: **Dizon DS**, Goff B, editors. UpToDate, June 2015.
161. Plaxe SC, Mundt AJ. Treatment of low-risk endometrial cancer. In: **Dizon DS**, Goff B, editors. UpToDate, June 2015.
162. Peshkin B and Isaacs C. Overview of hereditary breast and ovarian cancer syndromes. In: Dizon DS, Chagpar A, Goff B, editors. UpToDate, June 2015.
163. Peshkin B and Isaacs C. Genetic counseling and testing for hereditary breast and ovarian cancer. In: **Dizon DS**, Chagpar A, Goff B, editors. UpToDate, June 2015.
164. **Dizon DS** and Katz A. Overview of sexual dysfunction in male cancer survivors. In: Ganz PA and Vora SR, editors. UpToDate, September 2015.
165. Chen, LM and Berek, JS. Endometrial carcinoma: Epidemiology and risk factors. In: Falk SJ, Goff B, and **Dizon DS**, editors. UpToDate, 2016.
166. Tew WP and Moore KM. The approach to ovarian cancer in older women. In: Vora SR, Goff B, and **Dizon DS**, editors. UpToDate, 2016.
167. Birrer MJ and Fujiwara K. Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease. In: Vora SR and **Dizon DS**, editors. 2016.
168. Herzog TJ, Armstrong DK. First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer. In: Vora SR, Goff B, and **Dizon DS**, eds. UpToDate, 2016.
169. Coleman RL and Sabbatini P. Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease. In: Vora SR and **Dizon DS**, eds. UpToDate, 2016.
170. Duska LR. Overview of the approach to survivors of epithelial ovarian, fallopian tube, or peritoneal carcinoma. In: Nekhlyudov L, Goff B, and **Dizon DS**, eds. UpToDate, 2016.
171. Karam A, Berek JS, and Russo AL. Squamous cell carcinoma of the vulva: Medical therapy and prognosis. In: Vora SR, Falk SJ, Goff B, Mundt AJ, and **Dizon DS**, eds. UpToDate, 2016.
172. Konstantinopoulos PA and Bristow RE. Neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer. Neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer. In: Vora SR, Goff B, and **Dizon DS**, eds. UpToDate, 2016.

173. Berkowitz RS, Goldstein DP, and Horowitz NS. Initial management of low-risk gestational trophoblastic neoplasia. In: Falk SJ, Vora SR, Goff B, and **Dizon DS**, eds. UpToDate, 2016.
174. Karam A, Berek JS, and Russo AL. Squamous cell carcinoma of the vulva: Staging and surgical treatment. In: Vora SR, Falk SJ, Goff B, Mundt AJ, and **Dizon DS**, eds. UpToDate, 2016.
175. Fleming G and DiSilvestro PA. Adjuvant treatment of high-risk endometrial cancers. In: Vora SR, Goff B, and **Dizon DS**, eds. UpToDate, 2016.
176. Chen, LM and Berek, JS Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum. In: Falk SJ, Vora SR, Goff B, and **Dizon DS**, editors. UpToDate, 2016.
177. Gershenson D. Treatment of malignant germ cell tumors of the ovary. In: Falk SJ, Vora SR, Goff B, Pappo AS, and **Dizon DS**, editors. UpToDate, 2016.
178. Steinhoff MM. Endometrial carcinoma: Histopathology and pathogenesis. In: Falk SJ, Goff B, Garcia RL, and **Dizon DS**, editors. UpToDate, 2016.
179. Kesterson JP. Fertility preservation in women with endometrial carcinoma. In: Falk SJ, Vora SR, Goff B, and **Dizon DS**, editors. UpToDate, 2016.
180. Birrer MJ. Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease. In: **Dizon DS**, Goff B, editors. UpToDate, April 2015. *Last Revised*: May 2019.
181. Runyon BA. Malignancy-related ascites. In: Friedman LS, Bruera E, **Dizon DS**, editors. UpToDate, May 2019.
182. Herzog TJ, Armstrong DK. First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer. In: **Dizon DS**, Goff B, editors. UpToDate, January 2012. *Last Revision*: May 2019.
183. Randi MH. Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Histopathology. Goff BA, Garcia RL, **Dizon DS**, editors. UpToDate, May 2019.

BOOK CHAPTERS

1. Srimdkandada S, Fujii T, Wang T, Fu SQ, Yin LH, Guo XYD, Nanakorn T, Peng XY, Wang WL, Zhang L, Canaan A, Anderson M, **Dizon D**, et al. Methods for Chemoprotection and Chemo-sensitization: MDR-1 For Chemoprotection Using Retroviruses to Modify Hematopoietic Cells and Cytosine Deaminase for Chemosensitization Using Adenoviral Vectors. In Gene Therapy of Cancer: Methods and Protocols. Eds. W. Walther, and U. Stein, Humana Press, Totowa, New Jersey, pp. 609-616, 2000.
2. Kemeny N and **Dizon DS**. Adjuvant Chemotherapy After Hepatic Resection for Metastatic Colorectal Carcinoma. In Colorectal Cancer: A Clinical Guide to Therapy. Bleiberg M, Kemeny N, Rougier PH, Wilke HJ, editors. London: Martin Dunitz, 2002:359-366.
3. **Dizon DS** and Kemeny N. Locoregional Chemotherapy for Metastatic Colorectal Cancer to the Liver. In Colorectal Cancer: A Clinical Guide to Therapy. Bleiberg M, Kemeny N, Rougier PH, Wilke HJ, editors. London: Martin Dunitz, 2002:367-374.
4. **Dizon DS**, Poynor E, Hensley ML. Management of Non-Epithelial Ovarian Cancers. In Atlas of Cancer, M Markman, editor. Philadelphia: Lippincott, Williams, & Wilkins, 2002: 100-105.
5. 100 Questions and Answers About Ovarian Cancer. DS Dizon, NA Rustum, A Gibbs Brown (Authors). Sudbury, MA: Jones & Bartlett, 2003.
6. **Dizon DS**, Aghajanian C, Yan XJ, Spriggs D. Targeting NF- κ B to increase the activity of cisplatin in solid tumors. In Cancer Drug Discovery and Development: Combination Cancer Therapy: Modulators and Potentiators. Schwartz, G.K., editor. Totowa, NJ: Humana Press, 2004:197-207.
7. **Dizon DS** and Spriggs DR. Persistent and recurrent ovarian cancer. In Chemotherapy for Gynecologic Neoplasms: Current Therapy and Novel Approaches. Penalver M, Angioli R, Panici PB, Kavanagh J, Pecorelli S, editors. New York: Dekker, 2004: 407-432.
8. Penson RT and **Dizon DS**. Long term quality of life and symptoms management for women with cancer. In: Precis: an Update in Obstetrics and Gynecology. Oncology, 3rd Edition. JS Berek, et al, Eds. Washington, DC: American College of Obstetrics & Gynecology, 2008: 126-138.
9. Krychman M, **Dizon D**, Amsterdam A, Kellogg Spadt S. Ch. 23: Evaluation of the female with sexual dysfunction. In: Cancer and Sexual Health. JP Mulhall, L Incrocci, I Goldstein, R Rosen, Eds. New York: SpringerLink. 2011.

10. **Dizon DS**, Tejada-Berges T, Steinhoff MM, et al. Breast Cancer. In: Principles and Practice of Gynecologic Oncology, Barakat, Markman, and Randall, Eds. Lippincott Williams and Wilkins. 2009. Update in next edition, 2014.
11. **Dizon DS**. Uterine cancers. In Harrison's Manual of Oncology (2nd Edition). Eds: B. Chabner and D. Longo, 2014 (McGraw-Hill).
12. Powell MA, Olawaiye AB, Bermudez A, Bhosale PR, Grigsby PW, Copeland LJ, **Dizon DS**, Erickson BA, Hagemann IS, Portelance L, Prat J, Mutch DG. Chapter 53. Corpus Uteri: Carcinoma and Carcinosarcoma. In: AJCC Cancer Staging Manual, 8th Edition. MB Amin, S Edge, F Greene, DR Byrd, RK Brookland, MK Washington, JE Gershenwald, CC Compton, KR Hess, DC Sullivan, JM Jessup, JD Brierley, LE Gaspar, RL Schilsky, CM Balch, DP Winchester, EA Asare, M Madera, DM Gress, LR Meyer, Eds. In: AJCC Cancer Staging Manual, 8th Edition. New York: Springer, 2017.
13. **Dizon DS**, Olawaiye AB, Bhosale PR, Brookland RK, Erickson BA, Hagemann IS, Oliva E, Powell MA, Prat J, Wolfson AH, Mutch DG. Chapter 54. Corpus Uteri: Leiomyosarcoma and Endometrial Stromal Sarcoma. In: AJCC Cancer Staging Manual, 8th Edition. MB Amin, S Edge, F Greene, DR Byrd, RK Brookland, MK Washington, JE Gershenwald, CC Compton, KR Hess, DC Sullivan, JM Jessup, JD Brierley, LE Gaspar, RL Schilsky, CM Balch, DP Winchester, EA Asare, M Madera, DM Gress, LR Meyer, Eds. New York: Springer, 2017.
14. L-M Chen, Olawaiye AB, Bhosale PR, **Dizon DS**, Erickson BA, Grigsby PW, Hagemann IS, Portelance L, Otis CN, Mutch DG. Chapter 56. Gestational Trophoblastic Neoplasms. In: AJCC Cancer Staging Manual, 8th Edition. MB Amin, S Edge, F Greene, DR Byrd, RK Brookland, MK Washington, JE Gershenwald, CC Compton, KR Hess, DC Sullivan, JM Jessup, JD Brierley, LE Gaspar, RL Schilsky, CM Balch, DP Winchester, EA Asare, M Madera, DM Gress, LR Meyer, Eds. New York: Springer, 2017.
15. Kunos CA, Abdul-Karim FW, **Dizon DS**, Debernardo R. Cervix Uteri. In: Principles and Practice of Gynecologic Oncology, 7th Edition. DS Chi, A Berchuck, DS Dizon, CM Yashar, Eds. Philadelphia, PA: Wolters-Kluwer, 2017: 467-510.
16. Edmonson DA, Rizack T, Steinhoff MM, Sung CJ, Khalil HI, Hepel JT, Pandya SV, Legare RD, **Dizon DS**. In: Principles and Practice of Gynecologic Oncology, 7th Edition. DS Chi, A Berchuck, DS Dizon, CM Yashar, Eds. Philadelphia, PA: Wolters-Kluwer, 2017: 766-803.

CONSENSUS PANEL AND/OR COMMISSIONED RECOMMENDATIONS

1. J Orr, J Kelley, **D Dizon**, P Escobar, E Fleming, M Gemignani, D Hetzel, W Hoskins, J Lapolla, S Lwein, J Lucci, M Markman, B Pothuri, B Powell, T Tejada-Berges, L Kilgore. Breast cancer Task Force SGO Position Paper. Gynecol Oncol 2008; 110:7-12.
2. American Reproductive Health Professionals (ARHP) Interdisciplinary Consensus Panel. Sexual Health Fundamentals for Patient Care Initiative Report of a US Consensus Process. Available at: http://www.arhp.org/uploadDocs/SHF_meetingreport.pdf. Accessed 9/1/2012.
3. Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Whanefried W, **Dizon D**, Friedman DL, Glodman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA. Survivorship: Immunizations and prevention of infections, Version 2.2014. J Natl Compr Canc Netw 2014; 12:1098-1111.
4. Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Whanefried W, **Dizon D**, Friedman DL, Glodman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA. Survivorship: Healthy Lifestyles, Version 2.2014. J Natl Compr Canc Netw 2014; 12:1222-1237.
5. Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Whanefried W, **Dizon D**, Friedman DL, Glodman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA.

- Survivorship: Nutrition and Weight Management, Version 2.2014. *J Natl Compr Canc Netw* 2014; 12:1396-1406.
6. Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Whanefried W, **Dizon D**, Friedman DL, Glodman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Peppercorn J, Raza M, Rodriguez MA, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA. Survivorship: Screening for Cancer and Treatment Effects, Version 2.2014. *J Natl Compr Canc Netw* 2014; 12:1526-1531.
 7. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, **Dizon DS**, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, George S, Han E, Higgins S, Huh WK, Lurain JR 3rd, Mariani A, Mutch D, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Valea FA, Yashar CM, McMillian NR, Scavone JL. Uterine Sarcoma, v 1.2016. *J Natl Compr Canc Netw*. 2015 Nov;13(11):1321-31.
 8. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, **Dizon DS**, Kash JJ, Meyer LA, Moore KN, Olawaiye AB, Oldham J, Salani R, Sparacio D, Tew WP, Vergote I, Edelson MI. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. 2016; 34: 3460-73. Simultaneously published at: *Gynecol Oncol* 2016; 143: 3-15.
 9. Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G; ESMO/ASCO Global Curriculum Working Group. ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016. *Ann Oncol*. 2016 Aug;27(8):1378-81. doi: 10.1093/annonc/mdw239.
 10. Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, **Dizon DS**, Duff J, Duska LR, Eniu A, Ernstoff M, Filip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y. ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016. *ESMO Open* 2016; Epub Sept 29.
 11. Koh WJ, Greer BE, Abu-Rustum NR, Campos SM, Cho KR, Chon HS, Chu C, Cohn D, Crispens MA, **Dizon DS**, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Higgins S, Huh WK, Lurain JR 3rd, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Valea FA, Wyse E, Yashar CM, McMillian N, Scavone J. Vulvar cancer, Version 1.207, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2017; 15:92-120.
 12. DS Dizon, M Sedrak, MA Lewis, E Cook, MJ Fisch, JR Klemp, J Sommers, AM Ciccarella, J Gralow, W Lawton, C Nichols writing for the digital engagement committee. Incorporating digital tools to improve clinical trial infrastructure: A white paper from the digital engagement committee of SWOG. *JCO Clin Cancer Inform*. 2018; 2:1-8.

BOOKS (AUTHORED OR EDITED)

1. 100 Questions and Answers About Ovarian Cancer, Second Edition. **DS Dizon** and NA Rustum (Authors). Sudbury, MA: Jones & Bartlett, 2006.
2. DxRx Cervical Cancer: An approach to preinvasive and invasive malignancies of the cervix. K Robison and **DS Dizon** (Author). Sudbury, MA: Jones and Bartlett, 2007.
3. 100 Questions and Answers about Cervical Cancer. **DS Dizon**, MA Krychman, and PA DiSilvestro (Authors). Sudbury, MA: Jones & Bartlett, 2008.
4. Gynecologic Tumor Board: Clinical Cases in the Diagnosis and Management of Cancer of the Female Reproductive System. **DS Dizon** and NA Rustum, Editors. Sudbury, MA: Jones and Bartlett: 2008.

5. **Dizon DS** and Krychman M. Sexuality. In: Principles & Practice of Cancer Rehabilitation. M Stubblefield, M O'Dell, C Custodio, and T Fitzpatrick, Eds. New York: Demos. 2009.
6. Krychman MA, **Dizon DS**, Amsterdam A, Partridge A. Cancer and Dyspareunia. In: Female Sexual Pain Disorders: Evaluation and Management. Goldstein, Pukall, and Goldstein, Eds. Towson:Blackwell. 2009.
7. Stuckey A and **Dizon DS**. Choosing treatments for recurrent ovarian cancer: the platinum-free interval. The European Society of Gynecologic Oncologists' Handbook for Fellows in Gynecologic Oncology. M. Gultekin, Ed. 2009. Updated in 2011.
8. Questions and Answers about Human Papilloma Virus. **DS Dizon** and MA Krychman (Authors). Sudbury, MA: Jones and Bartlett: 2010.
9. 100 Questions and Answers about Uterine Cancer. **DS Dizon** and LR Duska (Authors). Sudbury, MA: Jones and Bartlett: 2010.
10. DxRx Gynecologic Cancers. SM Campos and **DS Dizon** (Author). Sudbury, MA: Jones and Bartlett, 2010.
11. DxRx Cervical Cancer: An approach to preinvasive and invasive malignancies of the cervix. Second Edition. K Robison and **DS Dizon**. Sudbury, MA: Jones and Bartlett, 2010.
12. Guide to Intimacy and Understanding about intimacy and sexuality. **DS Dizon** (Content Editor). Living Beyond Breast Cancer, 2013.
13. The 2013 ASCO Educational Book. **DS Dizon** (Editor in Chief), N Pennell (Associate Editor). American Society of Clinical Oncology, 2013.
14. The 2014 ASCO Educational Book. **DS Dizon** (Editor in Chief), N Pennell (Associate Editor). American Society of Clinical Oncology, 2014.
15. Principles and Practice of Gynecologic Oncology Handbook. D Levine, **DS Dizon**, CM Yashar, RR Barakat, A Berchuk, M Markman, ME Randall, Editors. Wolters Kluwer, Philadelphia, 2015.
16. The 2015 ASCO Educational Book. **DS Dizon** (Editor in Chief), N Pennell (Associate Editor). American Society of Clinical Oncology, 2015.
17. 100 Questions and Answers About Ovarian Cancer, Third Edition. **DS Dizon** and D Sparacio. Sudbury, MA: Jones and Bartlett, 2015.
18. ASCO Educational Book Collections: Immuno-Oncology. **DS Dizon** and N Pennell, Editors. American Society of Clinical Oncology, 2016.
19. ASCO Educational Book Collections: Surgical Oncology. **DS Dizon** and N Pennell, Editors. American Society of Clinical Oncology, 2016.
20. The 2016 ASCO Educational Book. **DS Dizon** (Editor in Chief), N Pennell (Associate Editor). American Society of Clinical Oncology, 2016.
21. **DS Dizon**, Section Reviewer, Oncology. In: Principles and Practice of Hospital Medicine, Second Edition. SC McKean, JJ Ross, DD Dressler, DB Scheurer (Eds). New York: McGraw Hill, 2017.
22. The 2017 ASCO Educational Book. **DS Dizon** (Editor in Chief), N Pennell and H Rugo (Associate Editors). American Society of Clinical Oncology, 2017.
23. The 2018 ASCO Educational Book. **DS Dizon** (Editor in Chief), N Pennell and H Rugo (Associate Editors). American Society of Clinical Oncology, 2018.
24. Principles and Practice of Gynecologic Oncology, Seventh Edition. D Chi, C Yashar, **DS Dizon**, A Berchuk, Editors. 2017. New York, NY: Wolters Kluwer, 2017. **Recognized as a "Highly Commendable title" at the British Medical Association (BMA) Medical Book Awards, 2018.**
25. The 2019 ASCO Educational Book. **DS Dizon** (Editor in Chief), N Pennell and H Rugo (Associate Editors). American Society of Clinical Oncology, 2019 (In Press).
26. 100 Questions and Answers About Ovarian Cancer, Fourth Edition. **DS Dizon**, D Sparacio, V Broach. Sudbury, MA: Jones and Bartlett, 2019 (In Press).

OTHER NON-PEER REVIEWED PUBLICATIONS

1. Gass J and **Dizon DS**. Continuing the mission for Interdisciplinary Breast Care: the 2007 National Consortium of Breast Centers Annual Meeting. RT Image Magazine, January 2006.
2. Abstracts Presented at The 17th Annual National Interdisciplinary Breast Center Conference: Breast Center Evolution: 2007 and Beyond- Don S. Dizon and Constance A. Roche, Chairpersons, Abstract Committee, NCBC Annual Meeting 2007. Am J Clin Onc, 2007; 30:444-60.

3. Gass JS, Bell J, **Dizon DS**. Breast care in 2011 and beyond: State of Policy, State of Science. *Expert Rev Anticancer Ther* 2011; 6:837-39.
4. **Dizon DS**, Herzog TJ. Advances in the management of ovarian cancer: Highlights from the Gynecologic Oncology Group 86th Semi-Annual Meeting. Educational Concepts Group, 2013.

CORPORATE AUTHORSHIP OR MULTICENTER TRIALS

1. EH Romond, EA Perez, J Bryant, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *New Engl J Med* 2005; 353:1673-84. *I served as Local Responsible Investigator for Women & Infants' Hospital; we actively recruited patients into this trial.*
2. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W. Phase II study of bevacizumab in patients with platinum-resistant ovarian or peritoneal serous cancer. *J Clin Oncol* 2007; 25:5150-2. *I served as Principal Investigator for Women & Infants' Hospital; we actively recruited patients into this trial.*
3. Karlan BY, Oza AM, Richardson GE, Provencher Dm, Hansen VL, Buck M, Chambers SK, Ghatage P, Pippit CH Jr, Brown JV 3rd, Covens A, Nagarkar RV, Davy M, Leath CA 3rd, Nguyen H, Stepan DE, Weinreich DM, Tassoudji M, Sun YN, Vergote IB. Randomized, double-blind placebo controlled phase II study of AMG386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. *J Clin Oncol* 2012; 30:362-71. *I served as Principal Investigator for Women & Infants' Hospital; we actively recruited patients into this trial.*
4. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. *N Engl J Med* 2012; 366:1382. *I served as Principal Investigator for Women & Infants' Hospital; we actively recruited patients into this trial.*

ABSTRACTS (2017-2019)

1. Hayes SM, Petit RG, Balli D, Hong q, Huh W, Brady WE, Dizon D, Powell MA, Leath CA, Landrum LM, Tanner E, Higgins R, Ueda S, McHale M, Aghajanian C, Monk BJ. Baseline serum protein levels associated with survival in Axalimogene Filolisbac (AXAL)-treated metastatic cervical cancer patients: the GOG/NRG-0265 Trial. *Int J Gynecol Cancer* 2017; 27:767-767.
2. Huh W, Brady WE, **Dizon DS**, Powell MA, Landrum LM, Leath CA, Tanner EJ, Higgins RV, Ueda SM, McHale MT, Aghajanian CA. A prospective phase II trial of the listeria-based human papillomavirus immunotherapy axalimogene filolisbac in second- and third-line metastatic cervical cancer: An NRG oncology group trial. Annual Meeting on Women's Cancers 2017, National Harbor, MD.
3. P Konstantinopoulos, JF Liu, W Barry, CN Krasner, **DS Dizon**, MJ Birrer, S Cannistra, M Buss, SM Campos, AA Wright, RT Penson, G Fleming, EH Stover, UA Matulonis. Phase 2, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI) and polymerase epsilon (POLE) mutated recurrent or persistent endometrial cancer (EC). Scientific Plenary, Abstr 49, SGO 2018.
4. DA Levine, **DS Dizon**, JW Carlson, VL Filaci, MA Powell, AA Secord, KS Tewari, DP Bender, DM O'Malley, AR Stuckey, KN Moore, SB Dewdney, J Gao, F Dao, RA Soslow, HA Lankes, CA Aghajanian. Predictive biomarkers of endometrial cancer response: Results from nrg oncology/ Gynecologic Oncology Group study 86P. Scientific Plenary, Abstr 23, SGO 2018.
5. U Matulonis, RT Penson, M Hoffman, CN Krasner, JF Liu, NS Horowitz, SM Campos, EH Stover, S Farooq, Konstantinopoulos P, **Dizon DS**, AA Wright, W Barry, W Luo. Phase II study of pembrolizumab (pembro) and pegylated liposomal doxorubicin (PLD) for recurrent platinum resistant ovarian cancer. Scientific Plenary, Abstr 48, SGO 2018.
6. Avikie E, Dilley S, M Stassenko, W Tew, C Brown, **D Dizon**. Identifying sexual orientation of ovarian cancer patients in the medical record: A first step towards meaningful health care disparities research. Accepted to print, ASCO Annual Meeting, 2018.
7. Ciambella, C, Taneja, C, Dizon, DS, Wiggins, DL, Emmick, CM, Leonard, KL, Lopresti, ML, Witherby, S, Cabral, D, Snow, S, Graves, TA. Distress: Characterizing what causes the thermometer to rise in patients

- with newly diagnosed breast cancer attending a multidisciplinary clinic. Oral presentation, American Society of Breast Surgeons Annual Meeting, 2019.
8. Bare C., Wakeley M., Dube, C., Gass J., Dizon D., and Taneja C. The Impact of Shared Decision Making on Patient Satisfaction Following Breast Reconstruction. Poster Presentation, American Society of Breast Surgeons Annual Meeting, 2019.
 9. Fowler R, Graves T, Taneja C, Wiggins DL, Fenton MA, Lopresti ML, Constantinou M, Strenger R, Dizon DS, Wang Y. The Impact of Recurrence Score versus Sentinel Lymph Node Biopsy on Treatment Decisions in Early Breast Cancer. Poster presentation, National Consortium of Breast Centers Annual Meeting, 2019.
 10. Jermaine Coward, Don S. Dizon, Ganessan Kichenadasse, Paul Harnett, Kathleen Moore, Minal Barve, Daniel Berg, James Garner. Phase I study of intraperitoneal TRX-E-002-1 in patients with persistent or recurrent ovarian cancer, fallopian tube cancer or primary peritoneal cancer: Results of dose-escalation phase. AACR Annual Meeting, 2019.
 11. Saiganesh H, Duffy C, Higel-McGovern C, Lopresti M, Fenton MA, Strenger R, Korber S, Syzmanski T, Dizon DS. After cancer, what's more important: the survivorship care plan or the survivorship care visit? American Society of Clinical Oncology Annual Meeting, 2019.
 12. Lei YY, Quain KM, Dizon DS, Jimenez R, Shin JA, Sepucha K, Perez GK, Peppercorn JM. Desire to address costs at time of treatment decisions among patients with Metastatic Breast Cancer. American Society of Clinical Oncology Annual Meeting, 2019.
 13. Peppercorn JM, Lei YY, Horrick N, Quain KM, Dizon DS, Jimenez R, Shin JA, Sepucha K, Perez GK. The Individualized Goals of Care Discussion Guide: A Simple Tool to Empower Patients with Metastatic Breast Cancer. American Society of Clinical Oncology Annual Meeting, 2019.

SCHOLARLY WORK PUBLISHED IN OTHER MEDIA: NON-PEER REVIEWED

Blogs and podcasts

1. Interdisciplinary care of cancer. American Society of Clinical Oncology (ASCO) Connection. July 19, 2011. <http://connection.asco.org/Commentary/Article/id/2991/Interdisciplinary-Care-of-Cancer.aspx>
2. Female sexual health and survivorship. ASCO Connection. August 14, 2011. <http://connection.asco.org/Commentary/Article/id/3008/Female-Sexual-Health-and-Survivorship.aspx>
3. Dignity, hope and loss: Lessons from oncology. September 11, 2011. <http://connection.asco.org/Commentary/Article/id/3025/Dignity-Hope-and-Loss-Lessons-from-Oncology.aspx>
4. Cancer management in the 21st century. ASCO Connection. September 24, 2011. <http://connection.asco.org/Commentary/Article/id/3042/Cancer-Management-in-the-21st-Century.aspx>
5. A public thank you to Steve Jobs. ASCO Connection. October 6, 2011. <http://connection.asco.org/Commentary/Article/id/3050/A-public-thank-you-to-Steve-Jobs.aspx>
6. When celebrities get cancer. ASCO Connection. October 22, 2011. <http://connection.asco.org/Commentary/Article/id/3060/When-Celebrities-Get-Cancer.aspx>
7. On IVF and ovarian malignancies. ASCO Connection. October 29, 2011. <http://connection.asco.org/Commentary/Article/id/3065/On-IVF-and-ovarian-malignancies.aspx>
8. Learning something new. ASCO Connection. December 6, 2011. <http://connection.asco.org/Commentary/Article/id/3088/Learning-Something-New.aspx>
9. Auld Lang Syne. ASCO Connection. December 27, 2011. <http://connection.asco.org/Commentary/Article/id/3119/Auld-Lang-Syne.aspx>. Reposted on kevinMD.com on January 29, 2012: <http://www.kevinmd.com/blog/2012/01/sense-loss-extends-death-patient.html>
10. Deals with fate. ASCO Connection. January 10, 2012. <http://connection.asco.org/Commentary/Article/id/3125/Deals-with-Fate.aspx>. Reposted on kevinMD.com on January 18, 2012: <http://www.kevinmd.com/blog/2012/01/oncologists-deal-fate.html>
11. Oncologist as optimist. ASCO Connection. January 24, 2012. <http://connection.asco.org/Commentary/Article/id/3134/Oncologist-as-Optimist.aspx>
12. Clinical trials endpoints and an electronic age. ASCO Connection. February 4, 2012. <http://connection.asco.org/Commentary/Article/id/3137/Clinical-trials-endpoints-and-an-electronic-age.aspx>
13. Controversies. ASCO Connection. February 11, 2012. <http://connection.asco.org/Commentary/Article/id/3143/Controversies.aspx>
14. Beating the odds. ASCO Connection. March 10, 2012. <http://connection.asco.org/Commentary/Article/id/3166/Beating-the-Odds.aspx>

15. Perceptions. ASCO Connection. March 22, 2012.
<http://connection.asco.org/Commentary/Article/id/3173/Perceptions.aspx>. Reposted on kevinMD.com on May 9, 2012: <http://www.kevinmd.com/blog/2012/05/hollywood-treatment-oncologists.html>.
16. Rebirth. ASCO Connection. April 4, 2012.
<http://connection.asco.org/Commentary/Article/id/3182/Rebirth.aspx>.
17. When do we stop being someone's oncologist? ASCO Connection. April 4, 2012.
<http://connection.asco.org/Commentary/Article/id/3182/Rebirth.aspx>. Reposted on kevinMD.com on April 26, 2012: <http://www.kevinmd.com/blog/2012/04/stop-someones-oncologist.html>.
18. Get busy living. ASCO Connection. May 1, 2012. <http://www.kevinmd.com/blog/2012/04/stop-someones-oncologist.html>.
19. Moving forward. ASCO Connection. May 12, 2012.
<http://connection.asco.org/Commentary/Article/id/3216/Moving-Forward.aspx>. Reposted on kevinMD.com on June 13, 2012: <http://www.kevinmd.com/blog/2012/06/remember-doctor.html>.
20. The power of words. ASCO Connection. May 19, 2012.
<http://connection.asco.org/Commentary/Article/id/3219/The-Power-of-Words.aspx>. Reposted on kevinMD.com on May 30, 2012: <http://www.kevinmd.com/blog/2012/05/power-words-cancer-care.html>.
21. Redesigning studies: Pushing the envelope. ASCO Connection. June 3, 2012.
<http://connection.asco.org/Commentary/Article/id/3232/Redesigning-Studies-Pushing-the-Envelope.aspx>.
22. Everything must change. ASCO Connection. June 21, 2012.
<http://connection.asco.org/Commentary/Article/id/3245/Everything-Must-Change.aspx>. Reposted on kevinMD.com on July 3, 2012: <http://www.kevinmd.com/blog/2012/07/patients-doctors-remain-connected-distance.html>.
23. Remembering to laugh. ASCO Connection. July 4, 2012.
<http://connection.asco.org/Commentary/Article/id/3270/Remembering-to-Laugh.aspx>.
24. You've got a friend. ASCO Connection. July 19, 2012.
<http://connection.asco.org/Commentary/Article/ID/3276/Youve-Got-a-Friend.aspx>. Reposted on kevinMD.com on July 29, 2012: <http://www.kevinmd.com/blog/2012/07/circle-support-critical-moments-cancer-journey.html>.
25. Is cancer an adjective? ASCO Connection. August 7, 2012.
<http://connection.asco.org/Commentary/Article/id/3285/Is-Cancer-an-Adjective.aspx>. Reposted on kevinMD.com on August 30, 2012: <http://www.kevinmd.com/blog/2012/08/unsspoken-sentiment-patients-advanced-cancer.html>.
26. Autonomy. ASCO Connection. August 23, 2012.
<http://connection.asco.org/Commentary/Article/id/3289/Autonomy.aspx>. Reposted by the Center for Advancing Health on September 17, 2012: <http://www.cfah.org/blog/2012/guest-blog-stilettos-and-chemotherapy-an-oncologist-reflects-on-patient-autonomy>. It was also reposted by kevinMD.com on September 19, 2012. <http://www.kevinmd.com/blog/2012/09/evidence-oncologists-dictate-treatment.html>.
27. Help from an online community. ASCO Connection. September 13, 2012.
<http://connection.asco.org/Commentary/Article/id/3317/Help-from-an-Online-Community.aspx>. Reposted on kevinMD.com on October 15, 2012: <http://www.kevinmd.com/blog/2012/10/doctors-twitter-battle-emotional-fatigue.html>.
28. Cancer survivors. ASCO Connection. October 4, 2012.
<http://connection.asco.org/Commentary/Article/id/3328/Cancer-Survivors.aspx>. Reposted on kevinMD.com on November 9, 2012: <http://www.kevinmd.com/blog/2012/11/cancer-survivors-cancer.html>.
29. Volunteering at ASCO. ASCO Connection. October 11, 2012.
<http://connection.asco.org/Commentary/Article/id/3332/Volunteering-at-ASCO-.aspx>.
30. My father's final lesson. ASCO Connection. October 24, 2012.
<http://connection.asco.org/Commentary/Article/id/3340/My-Fathers-Final-Lesson-.aspx>. Reposted on kevinMD.com on 11/21/2012: <http://www.kevinmd.com/blog/2012/11/cancer-realize-gift-time.html>.
31. On cancer prevention, risk reduction, and cure. ASCO Connection. November 8, 2012.
<http://connection.asco.org/Commentary/Article/id/3368/On-Cancer-Prevention-Risk-Reduction-and-Cure.aspx>.
32. A physician, a patient, and a lack of data. ASCO Connection. November 18, 2012.
<http://connection.asco.org/Commentary/Article/id/3372/A-Physician-a-Patient-and-a-Lack-of-Data.aspx>. Reposted on kevinMD.com on December 30, 2012: <http://www.kevinmd.com/blog/2012/12/plea-oncologists-confront-treatment-rare-diseases.html>.
33. Reacting to a national tragedy. ASCO Connection. December 18, 2012.
<http://connection.asco.org/Commentary/Article/id/3383/Reacting-to-a-National-Tragedy.aspx>. Reposted on

- kevinMD.com on December 19, 2012: <http://www.kevinmd.com/blog/2012/12/oncologist-thought-words-console-survivors.html>.
34. Reflections on time at the end of the year. ASCO Connection. December 30, 2012. <http://connection.asco.org/Commentary/Article/id/3414/Reflections-on-Time-at-the-End-of-the-Year.aspx>.
 35. Miller RS, Thompson M, **Dizon DS**, Johnston C. Roundtable: The Use of Social Media in Oncology Practice [podcast]. Journal of Oncology Practice, 2013. Available at: <http://jop.ascopubs.org/site/podcasts/audio/2013/jop-podcast-3-26-2013.mp3>. Accessed 4/2/2013.
 36. Katz A and **Dizon DS**. Is there sex for women after cancer. Coping magazine, Jan/Feb 2013; 16.
 37. **Dizon DS**, Back A, Politi M. Editor's podcast: Power of Words In Oncology Care. ASCO University, 2013. Available at ASCO University on iTunes U. Accessed 8/3/2013.
 38. **Dizon DS**, Sparano JA, Turner N, Perez-Garcia J. ASCO University course: Ed Book Essentials. Treatment of the newly diagnosed patient with early breast cancer: Bridging technological advances with best clinical practice. Available at: <https://registrar.asco.org/Users/selectUserCertType.aspx?productid=3730>. Accessed 9/2/2013.
 39. Blogging safely: The value of feedback. ASCO Connection. January 9, 2013. <http://connection.asco.org/Commentary/Article/id/3420/Blogging-Safely-The-Value-of-Feedback.aspx>.
 40. What to do when a patient wants you to make decisions for them. ASCO Connection. January 26, 2013. <http://connection.asco.org/Commentary/Article/id/3424/What-to-Do-When-a-Patient-Wants-You-to-Make-Decisions-for-Them.aspx>. Reposted on kevinMD.com on February 25, 2013: <http://www.kevinmd.com/blog/2013/02/physicians-improve-experience-communication.html>.
 41. Goodbyes. ASCO Connection. February 13, 2013. <http://connection.asco.org/Commentary/Article/id/3434/Goodbyes.aspx>. Reposted on kevinMD.com on March 14, 2013: <http://www.kevinmd.com/blog/2013/03/importance-goodbye-life.html>.
 42. Cancer and sex. ASCO Connection. March 5, 2013. <http://connection.asco.org/Commentary/Article/id/3477/Cancer-and-Sex.aspx>. Reposted on kevinMD.com on April 4, 2013: <http://www.kevinmd.com/blog/2013/04/sexual-health-women-treated-cancer.html>.
 43. On doctor-patient connections. ASCO Connection. March 20, 2013. <http://connection.asco.org/Commentary/Article/id/3480/On-DoctorPatient-Connections.aspx>. Reposted on kevinMD.com on April 17, 2013. <http://www.kevinmd.com/blog/2013/04/medicine-compel-treat.html>.
 44. In memorium. ASCO Connection. March 26, 2013. <http://connection.asco.org/Commentary/Article/id/3486/In-Memorial.aspx>.
 45. Continuity of care and the role of nonphysician providers. ASCO Connection. April 15, 2013. <http://connection.asco.org/Commentary/Article/id/3496/Continuity-of-Care-and-the-Role-of-Nonphysician-Providers-.aspx>. Reposted on kevinMD.com on May 29, 2013: <http://www.kevinmd.com/blog/2013/05/rely-nonphysician-providers.html>.
 46. A New York state of mind. ASCO Connection. April 25, 2013. <http://connection.asco.org/Commentary/Article/id/3523/A-New-York-State-of-Mind.aspx>. Reposted on kevinMD.com on May 3, 2013: <http://www.kevinmd.com/blog/2013/05/boston-marathon-reflection-york.html>.
 47. Laughing at cancer. ASCO Connection. May 13, 2013. <http://connection.asco.org/Commentary/Article/id/3530/Laughing-at-Cancer.aspx>. Reposted on kevinMD.com on June 6, 2013: <http://www.kevinmd.com/blog/2013/06/cancer-laughter-humor-humanize.html>.
 48. The ASCO Educational Book: A labor of love and a work in progress. ASCO Connection. May 21, 2013. <http://connection.asco.org/Commentary/Article/id/3540/The-ASCO-Educational-Book-a-Labor-of-Love-and-a-Work-in-Progress.aspx>.
 49. Cervical cancer: Building bridges, making progress. ASCO Connection. June 2, 2013. <http://connection.asco.org/Commentary/Article/id/3548/Cervical-Cancer-Building-Bridges-Making-Progress.aspx>.
 50. What I've learned about family meetings. ASCO Connection. June 19, 2013. <http://connection.asco.org/Commentary/Article/id/3559/What-Ive-Learned-about-Family-Meetings.aspx>. Reposted on kevinMD.com on July 29, 2013: <http://www.kevinmd.com/blog/2013/07/lessons-learned-family-meeting.html>.
 51. Optimism. ASCO Connection. July 3, 2013. <http://connection.asco.org/Commentary/Article/id/3591/Optimism.aspx>. Reposted on kevinMD.com on August 20, 2013: <http://www.kevinmd.com/blog/2013/08/complicated-existential-dilemma-living-cancer.html>.
 52. Cultivating a new generation of oncologists. ASCO Connection. July 24, 2013. <http://connection.asco.org/Commentary/Article/id/3608/Cultivating-a-New-Generation-of-Oncologists.aspx>. Reposted on kevinMD.com on August 13, 2013: <http://www.kevinmd.com/blog/2013/08/inspiring-generation-oncologists.html>.

53. Time after time. ASCO Connection. August 8, 2013.
<http://connection.asco.org/Commentary/Article/id/3618/Time-After-Time.aspx>. Reposted on kevinMD.com on August 23, 2013: <http://www.kevinmd.com/blog/2013/08/immortal-patients.html>.
54. A tale of two women, HER2-Positive breast cancer, and clinical trials. ASCO Connection. August 29, 2013.
<http://connection.asco.org/Commentary/Article/id/3644/A-Tale-of-Two-Women-HER2Positive-Breast-Cancer-and-Clinical-Trials.aspx>. Reposted on kevinMD.com on September 10, 2013:
<http://www.kevinmd.com/blog/2013/09/people-participate-clinical-trials-trailblazers.html>.
55. Live tweeting #BCS13. ASCO Connection. September 9, 2013.
<http://connection.asco.org/Commentary/Article/id/3649/LiveTweeting-BCS13.aspx>.
56. The lingering effects of end-of-life decisions after one's life has ended. ASCO Connection. September 24, 2013. <http://connection.asco.org/Commentary/Article/id/3659/The-Lingering-Effects-of-EndofLife-Decisions-after-Ones-Life-Has-Ended.aspx>. Reposted on kevinMD.com on October 4, 2013:
<http://www.kevinmd.com/blog/2013/10/hope-life.html>.
57. Pragmatism, Realism, and Optimism. ASCO Connection. October 7, 2013.
<http://connection.asco.org/Commentary/Article/id/3669/Pragmatism-Realism-and-Optimism.aspx>.
58. International outreach and thoughts of home. ASCO Connection. October 23, 2013.
<http://connection.asco.org/Commentary/Article/id/3678/International-Outreach-and-Thoughts-of-Home.aspx>.
59. Living for today. ASCO Connection. November 6, 2013.
<http://connection.asco.org/Commentary/Article/id/3704/Living-for-Today.aspx>. Reposted on kevinMD.com on November 13, 2013: <http://www.kevinmd.com/blog/2013/11/valuable-lessons-learned-oncologist-patients.html>.
60. Thanksgiving. ASCO Connection. November 28, 2013.
<http://connection.asco.org/Commentary/Article/id/3712/Thanksgiving.aspx>.
61. Parenthood and cancer. ASCO Connection. December 12, 2013.
<http://connection.asco.org/Commentary/Article/id/3722/Parenthood-and-Cancer.aspx>. Reposted on kevinMD.com on December 30, 2013: <http://www.kevinmd.com/blog/2013/12/desire-baby-face-metastatic-cancer.html>.
62. A very worthy program: Cancer.net's patientACCESS. ASCO Connection. December 26, 2013.
<http://connection.asco.org/Commentary/Article/id/3753/A-Very-Worthy-Program-CancerNets-patientACCESS.aspx>.
63. On endings and beginnings. ASCO Connection. December 31, 2013.
<http://connection.asco.org/Commentary/Article/id/3754/On-Endings-and-Beginnings.aspx>.
64. **Dizon DS**. Guilt and the burden on oncology providers. *The Oncologist* 2014; 19:441-2.
65. **Dizon DS**. Narratives in Oncology. *The Oncologist* 2014; 19:789.
66. **Dizon DS**. My father's final lesson. *The Oncologist* 2014; 19:1110-1.
67. Twitter responds: Reactions to patients tweeting about their cancer. ASCO Connection. January 14, 2014.
<http://connection.asco.org/Commentary/Article/id/3758/Twitter-Responds-Reactions-to-Patients-Tweeting-about-Their-Cancer.aspx>. Reposted on kevinMD.com on January 21, 2014:
<http://www.kevinmd.com/blog/2014/01/twitter-cancer-patients-outrage.html>.
68. The awakening of the ePatient: Are we prepared to engage? ASCO Connection. February 5, 2014.
<http://connection.asco.org/Commentary/Article/id/3776/The-Awakening-of-the-ePatient-Are-We-Prepared-to-Engage.aspx>. This was picked up on kevinMD on February 21, 2014:
<http://www.kevinmd.com/blog/2014/02/physicians-ready-epatient-movement.html>.
69. One patient's transformation leads to new mission: Crowdfunding for research. ASCO Connection. February 20, 2014. <http://connection.asco.org/Commentary/Article/id/3786/One-Patients-Transformation-Leads-to-a-New-MissionCrowdfunding-for-Research.aspx>.
70. Beliefs, attitudes, and evidence. ASCO Connection. March 7, 2014.
<http://connection.asco.org/Commentary/Article/id/3786/One-Patients-Transformation-Leads-to-a-New-MissionCrowdfunding-for-Research.aspx>. Reposted on kevinMD.com on March 13, 2014:
<http://www.kevinmd.com/blog/2014/03/patients-ignore-evidence-understand-values.html>. It was also reposted on the Center for Advancing Health on April 7, 2014. <http://www.cfah.org/blog/2014/shared-decision-making-blending-beliefs-and-attitudes-with-evidence>.
71. Narrative medicine: Where empathy meets quality. ASCO Connection. March 27, 2014.
<http://connection.asco.org/Commentary/Article/id/3835/Narrative-Medicine-Where-Empathy-Meets-Quality.aspx>. Reposted on kevinMD.com on April 7, 2014. <http://www.kevinmd.com/blog/2014/04/narrative-medicine-inform-quality-care.html>.
72. At what price? Discussing cost of care with patients. ASCO Connection. April 10, 2014.
<http://connection.asco.org/Commentary/Article/id/3843/At-What-Price-Discussing-Cost-of-Care-with->

- Patients.aspx. Reposted on kevinMD.com on April 24, 2014. <http://www.kevinmd.com/blog/2014/04/treating-cancer-paved-patients-financial-despair.html>.
73. Empowering patients is more than engagement. ASCO Connection. April 24, 2014. <http://connection.asco.org/Commentary/Article/id/3860/Empowering-Patients-Is-More-Than-Engagement.aspx>.
 74. Goals and preferences: An international experience. ASCO Connection. May 15, 2014. <http://connection.asco.org/Commentary/Article/id/3886/Goals-and-Preferences-An-International-Experience.aspx>. Reposted on kevinMD.com on May 28, 2014. <http://www.kevinmd.com/blog/2014/05/cancer-care-international-patients.html>.
 75. Seeking answers: Preventive care for patients with metastatic cancer. ASCO Connection. June 2, 2014. <http://connection.asco.org/Commentary/Article/id/3896/Seeking-Answers-Preventive-Care-for-Patients-with-Metastatic-Cancer.aspx>. Reposted on kevinMD.com on June 18, 2014. <http://www.kevinmd.com/blog/2014/06/cancer-screening-metastatic-disease.html>.
 76. An IDEA experience. ASCO Connection. June 23, 2014. <http://connection.asco.org/Commentary/Article/id/3920/An-IDEA-Experience.aspx>.
 77. Delivering bad news cannot be someone else's job. ASCO Connection. July 10, 2014. <http://connection.asco.org/Commentary/Article/ID/3943/Delivering-Bad-News-Cannot-Be-Someone-Else-Job.aspx>. Reposted on kevinMD.com on August 22, 2014. <http://www.kevinmd.com/blog/2014/08/delivering-bad-news-dont-pass-buck.html>.
 78. Can addressing survivorship issues also provide solace to the oncologist? ASCO Connection. July 31, 2014. <http://connection.asco.org/Commentary/Article/id/3964/Can-Addressing-Survivorship-Issues-Also-Provide-Solace-to-the-Oncologist.aspx>.
 79. Is chemotherapy ever palliative? ASCO Connection. August 28, 2014. <http://connection.asco.org/Commentary/Article/id/3998/Is-Chemotherapy-Ever-Palliative.aspx>.
 80. I did it my way. ASCO Connection. September 11, 2014. <http://connection.asco.org/Commentary/Article/ID/4007/I-Did-It-My-Way.aspx>. Reposted on kevinMD.com on September 19, 2014: <http://www.kevinmd.com/blog/2014/09/two-women-two-cancers-two-different-pathways.html>.
 81. When is it time to stop? ASCO Connection. September 26, 2014. <http://connection.asco.org/Commentary/Article/ID/4016/When-Is-It-Time-to-Stop.aspx>. Reposted on kevinMD.com on October 7, 2014: <http://www.kevinmd.com/blog/2014/10/public-perception-oncologists-really-true.html>.
 82. Why do Twitter? Because Twitter counts. ASCO Connection. October 9, 2014. <http://connection.asco.org/Commentary/Article/ID/4023/Why-Do-Twitter-Because-Twitter-Counts.aspx>. Reposted on kevinMD.com on October 24, 2014: <http://www.kevinmd.com/blog/2014/10/twitter-counts-doctor-read.html>.
 83. It's not about us: The time of 'doc as deity' has long passed. ASCO Connection. October 23, 2014. Reposted on kevinMD.com on November 12, 2014: <http://www.kevinmd.com/blog/2014/11/patients-seek-second-opinion.html>.
 84. A good death. ASCO Connection. November 6, 2014. <http://connection.asco.org/Commentary/Article/id/4067/A-Good-Death.aspx>. Reposted on kevinMD.com on November 19, 2014: <http://www.kevinmd.com/blog/2014/11/good-death-mean.html>.
 85. Does cancer ever stop taking? ASCO Connection. November 30, 2014. <http://connection.asco.org/Commentary/Article/id/4078/Does-Cancer-Ever-Stop-Taking.aspx>. Reposted on kevinMD.com on November 30, 2014: <http://www.kevinmd.com/blog/2014/11/trivializing-significance-losing-ones-hair-cancer-treatment.html>.
 86. What about intimacy? ASCO Connection. December 5, 2014. <http://connection.asco.org/Commentary/Article/id/4086/What-About-Intimacy.aspx>. Reposted on kevinMD.com on December 16, 2014: <http://www.kevinmd.com/blog/2014/12/prostate-cancer-treatment-intimacy-men.html>.
 87. Being grateful. ASCO Connection. December 16, 2014. <http://connection.asco.org/Commentary/Article/id/4099/Being-Grateful.aspx>.
 88. **Dizon DS**. Toward eubiosia: Bridging oncology and palliative care. *The Oncologist* 201; 20:5-6.
 89. All we have is here and now. ASCO Connection. January 5, 2015. <http://connection.asco.org/Commentary/Article/id/4127/All-We-Have-Is-the-Here-and-Now.aspx>. Reposted on kevinMD.com on February 2, 2015: <http://www.kevinmd.com/blog/2015/02/patient-reminds-doctor-unpredictable-life.html>.

90. Word associations: breaking the bonds between “palliative care” and “hospice”. ASCO Connection. January 22, 2015. Reposted on kevinMD.com on February 21, 2015: <http://www.kevinmd.com/blog/2015/02/lets-break-association-palliative-care-hospice.html>. Reposted on Living Beyond Breast Cancer’s blog on March 13, 2015: <https://livingbeyondbc.wordpress.com/2015/03/13/word-associations-breaking-the-bonds-between-palliative-care-and-hospice/> and on Fighter Coming Through’s blog on March 14, 2015: <https://fightercomingthrough.wordpress.com/2015/03/14/word-associations-breaking-the-bonds-between-palliative-care-and-hospice/>.
91. What does it mean? ASCO Connection. February 12, 2015. <http://connection.asco.org/Commentary/Article/id/4160/What-Does-It-Mean.aspx>. Reposted at kevinMD.com, Oct 26, 2016. <http://www.kevinmd.com/blog/2016/10/whats-one-word-cancer-patients-never-want-hear.html>.
92. When even the best advice isn’t good enough. Guest post for the National Coalition for Cancer Survivorship. February 20, 2015. <http://www.canceradvocacy.org/news/guest-post-by-dr-don-dizon-when-even-the-best-advice-isnt-good-enough/>. Reposted on ASCO Connection on February 25, 2015: <http://connection.asco.org/Commentary/Article/id/4179/When-Even-the-Best-Advice-Isnt-Good-Enough.aspx>. Also reposted on kevinMD.com on March 11, 2015: <http://www.kevinmd.com/blog/2015/03/cant-let-guard-cancer-constant-threat.html>.
93. The tribulations about trials. ASCO Connection. March 13, 2015. <http://connection.asco.org/Commentary/Article/id/4189/The-Tribulations-about-Trials.aspx>.
94. Through the eyes of a child. ASCO Connection. March 25, 2015. <http://connection.asco.org/commentary/through-eyes-child>
95. Why did this happen to me? ASCO Connection. April 9, 2015. <http://connection.asco.org/commentary/%E2%80%9Cwhy-did-happen-me%E2%80%9D>. Reposted on kevinMD.com on August 31, 2015. <http://www.kevinmd.com/blog/2015/08/dont-blame-yourself-after-a-cancer-diagnosis.html>.
96. Not everyone follows the literature... and on rare occasions that works. April 23, 2015. <http://connection.asco.org/commentary/not-everyone-follows-literature-and-rare-occasions-works>. Reposted on kevinMD.com on May 1, 2015: <http://www.kevinmd.com/blog/2015/05/a-patient-this-oncologist-cant-forget.html>.
97. The vaccine debate: bad science is bad for everyone. May 1, 2015. <http://connection.asco.org/commentary/vaccine-debate-bad-science-bad-everyone>. Reposted on kevinMD.com on May 17, 2015: <http://www.kevinmd.com/blog/2015/05/there-should-not-be-a-body-count-to-disprove-bad-science.html>.
98. Birthdays, May 21, 2015. <http://dondizon.blogspot.com/2015/05/welcome.html>. Reposted at ASCO Connection on May 26, 2015: <https://connection.asco.org/commentary/birthdays>. Also reposted at kevinMD.com on June 9, 2015: <http://www.kevinmd.com/blog/2015/06/a-poignant-facebook-birthday-for-this-physician.html>.
99. The obligation- and the opportunity- of the poster presenter. May 30, 2015. <https://connection.asco.org/commentary/obligation-and-opportunity-poster-presenter>.
100. Mentor and Mentee, June 15, 2015 (Co-written with A. Hurria). http://dondizon.blogspot.com/2015/06/mentor-and-mentee_15.html.
101. Sometimes, there is a time and a place for alternative therapies, July 2, 2015. <https://connection.asco.org/commentary/sometimes-there-time-and-place-alternative-therapies>. Reposted at kevinMD.com on August 9, 2015: <http://www.kevinmd.com/blog/2015/08/is-there-a-place-for-alternative-therapy-in-cancer-treatment.html>.
102. When chemotherapy doesn’t palliate, July 23, 2015 (Co-written with E. Bruera). <http://dondizon.blogspot.com/2015/07/when-chemotherapy-doesnt-palliate.html>. Reposted at ASCO Connection on July 27, 2015: <https://connection.asco.org/commentary/when-chemotherapy-doesn%E2%80%99t-palliate>.
103. Precision Therapy and a new kind of disappointment (Co-written with L. Sequist). August 5, 2015. <http://dondizon.blogspot.com/2015/08/precision-therapy-and-new-kind-of.html>. Reposted at ASCO Connection on August 31, 2015. <http://connection.asco.org/commentary/precision-therapy-and-new-kind-disappointment>.
104. Sex in the face of metastatic disease, August 13, 2015 (Co-written with E. Doroff). <https://connection.asco.org/commentary/sex-face-metastatic-disease>.
105. The importance of because. September 9, 2015. <http://connection.asco.org/commentary/importance-%E2%80%9Cbecause%E2%80%9D>.

106. Survivor's Guilt. September 24, 2015. <http://dondizon.blogspot.com/2015/09/survivors-guilt.html>. Reposted at ASCO Connection on September 29, 2015: <https://connection.asco.org/commentary/survivors%E2%80%99-guilt-dealing-anxiety-and-questions-years-after-successful-cancer-treatment#sthash.vuT2yrxD.dpuf>.
107. Providing Resources to New Mothers with Cancer: Before, During, and After Treatment. October 5, 2015. <https://connection.asco.org/commentary/providing-resources-new-mothers-cancer-during-and-after-treatment#sthash.716DWylh.dpuf>. Reposted at kevinMD.com on October 18, 2015: <http://www.kevinmd.com/blog/2015/10/moms-after-cancer-are-a-new-demographic.html>.
108. International outreach is in the eye of the beholder. October 14, 2015 (Co-written with B. Chabner). http://dondizon.blogspot.com/2015/10/international-outreach-is-in-eye-of_14.html. Reposted at ASCO Connection on Nov 9, 2015: <https://connection.asco.org/commentary/%E2%80%9Cinternational%E2%80%9D-outreach-eye-beholder>.
109. On conversations and connections. October 29, 2015. <https://connection.asco.org/commentary/conversations-and-connections>.
110. Don Dizon, MD, on sexual health after a cancer diagnosis, and the disappointments of precision medicine. *Oncology (Williston Park)* 2015; 29: Epub November 15.
111. Hope (Co-written with M. Sabbatini). November 16, 2015. <https://connection.asco.org/commentary/hope-0>.
112. On Opportunities and Obligations: Perspectives on Work-Life Balance. <http://theoncologist.alphamedpress.org/site/blog/>. Reposted on ASCO Connection, December 31, 2015: <https://connection.asco.org/commentary/opportunities-and-obligations-perspectives-work-life-balance>.
113. Honesty and Clarity. December 10, 2015. <https://connection.asco.org/commentary/honesty-and-clarity>.
114. Hospital for the Holidays. December 23, 2015. <http://theoncologist.alphamedpress.org/site/blog/>.
115. "Just Do What I Tell You": Authority and Shared Decision-Making. Jan 15, 2016. <https://connection.asco.org/commentary/just-do-what-i-tell-you-authority-and-shared-decision-making>. Reposted on kevinMD.com on February 2, 2016: <http://www.kevinmd.com/blog/2016/02/key-shared-decision-making-patients.html>.
116. Happy New Year. January 28, 2016. <http://dondizon.blogspot.com/2016/01/happy-new-year.html>. Reposted on ASCO Connection, Feb 01, 2016: <https://connection.asco.org/commentary/happy-new-year>.
117. "I don't know". February 11, 2016. <https://connection.asco.org/commentary/i-dont-know>. Reposted at kevinMD on July 23, 2016. <http://www.kevinmd.com/blog/2016/07/reminder-no-guarantees-cancer.html>.
118. Sexual health in women following cancer: there is no "I" in team. February 25, 2016 (Co-written with A. Katz). <http://dondizon.blogspot.com/2016/02/sexual-health-in-women-following-cancer.html>.
119. Running to cover: patient-centered care as an inpatient rounder. March 21, 2016. <https://connection.asco.org/commentary/running-cover-patient-centered-care-inpatient-rounder>.
120. The kindness of oncologists. April 7, 2016. <http://dondizon.blogspot.com/2016/04/the-kindness-of-oncologists.html>. Reposted on kevinMD, April 10, 2016: <http://www.kevinmd.com/blog/2016/04/compassion-inpatient-oncology-service.html>. Reposted on ASCO Connection, April 11, 2016. <https://connection.asco.org/commentary/kindness-oncologists>.
121. Adolescents- and parents- and cancer. April 19, 2016. <https://connection.asco.org/commentary/adolescents-and-parents-and-cancer>. Reposted on kevinMD.com on May 23, 2016: <http://www.kevinmd.com/blog/2016/05/a-story-that-showed-me-how-cancer-is-a-social-disease.html>.
122. Learning to Pause, May 10, 2016. <http://dondizon.blogspot.com/2016/05/learning-to-pause.html>. Reposted at ASCO Connection, May 12, 2016: <https://connection.asco.org/blogs/cost-cure-when-cancer-treatment-and-patient-well-being-diverge>. Reposted on kevinMD.com on June 6, 2016. <http://www.kevinmd.com/blog/2016/06/cured-result-unacceptable.html>.
123. Reclaiming your sexuality after cancer diagnosis: worth fighting for. May 23, 2016. <https://connection.asco.org/blogs/reclaiming-your-sexuality-after-cancer-diagnosis-worth-fighting>. Reposted on kevinMD.com on June 14, 2016: <http://www.kevinmd.com/blog/2016/06/cancers-toll-romance-sensuality.html>.
124. In praise of technology. June 8, 2016. <https://connection.asco.org/blogs/asco16-praise-technology>.
125. Medicine is a calling, not a profession. <http://dondizon.blogspot.com/2016/06/medicine-is-calling-not-profession.html>. Reposted at ASCO Connection, Jul 6, 2016. <https://connection.asco.org/blogs/medicine-calling-not-profession>.
126. A young mother with cancer, choosing to go it alone. Jul 14, 2016. <https://connection.asco.org/blogs/young-mother-cancer-choosing-go-it-alone>.
127. She's not on my schedule is not acceptable. Jul 29, 2016. <http://dondizon.blogspot.com/2016/07/not-on-my-schedule.html>. Reposted at ASCO Connection on Aug 4, 2016. <https://connection.asco.org/blogs/shes-not-my-schedule-not-acceptable>.

128. When a patient becomes a friend, how do you say goodbye. Aug 23, 2016. <https://connection.asco.org/blogs/when-patient-becomes-friend-how-do-you-say-goodbye>. Reposted at kevinMD.com on Nov 15, 2016. <http://www.kevinmd.com/blog/2016/11/saying-goodbye-patient-whos-friend.html>.
129. Evidence should inform guidelines, not mandate care. Sept 22, 2016. <http://dondizon.blogspot.com/2016/09/evidence-should-inform-guidelines-not.html>. Reposted at ASCO Connection, Sep 27, 2016. <https://connection.asco.org/blogs/evidence-should-inform-guidelines-not-be-used-mandate>. Reposted at kevinMD.com on Oct 5, 2016. <http://www.kevinmd.com/blog/2016/10/evidence-not-used-enforce-mandates.html>.
130. "I'm just not ready": Helping a patient and her family find common ground regarding hospice. <https://connection.asco.org/blogs/im-just-not-ready-helping-patient-and-her-family-find-common-ground-regarding-hospice>. Reposted at kevinMD.com on Nov 8, 2016. <http://www.kevinmd.com/blog/2016/11/doctor-thinks-patient-prepared-death-hes-wrong.html>.
131. Doing what's right. Nov 7, 2016. <http://dondizon.blogspot.com/2016/11/doing-whats-right.html>. Reposted at ASCO Connection, Nov 11, 2016. <https://connection.asco.org/blogs/doing-what%E2%80%99s-right-respecting-patient-preferences-end-life-0>. Reposted at kevinMD.com on Dec 14, 2016. <http://www.kevinmd.com/blog/2016/12/not-patients-share-views-end-life.html>.
132. Don't let an election change you. Nov 22, 2016. <https://connection.asco.org/blogs/dont-let-election-change-you>.
133. When being wrong feels so right. Dec 8, 2016. <http://dondizon.blogspot.com/2016/12/when-being-wrong-feels-so-right.html>. Reposted at ASCO Connection, Dec 14, 2016. <https://connection.asco.org/blogs/when-being-wrong-feels-so-right-joy-seeing-patient-defy-odds>. Reposted at kevinMD.com on Dec 27, 2016. <http://www.kevinmd.com/blog/2016/12/oncologist-experiences-joy-wrong.html>.
134. Even in sadness, being an oncologist is a privilege and a gift. Dec 27, 2016. <https://connection.asco.org/blogs/even-sadness-being-oncologist-privilege-and-gift>. Reposted at kevinMD.com on Jan 27, 2017. <http://www.kevinmd.com/blog/2017/01/oncologist-privilege-even-sad.html>.
135. What's the harm? January 31, 2017. <http://dondizon.blogspot.com/2017/01/whats-harm.html>. Reposted at ASCO Connection, Feb 02, 2017. <https://connection.asco.org/blogs/whats-harm-alternative-therapies-and-supplements-can-impede-cancer-care>. Reposted at kevinMD, Mar 06, 2017. <http://www.kevinmd.com/blog/2017/03/please-dont-mix-herbal-supplements-cancer-treatments.html>.
136. On immigration, and bans, and my responsibility to my patients. ASCO Connection, Feb 23, 2017. <https://connection.asco.org/blogs/immigration-and-bans-and-my-responsibility-my-patients>.
137. What's in a Word? March 14, 2017. <http://dondizon.blogspot.com/2017/03/whats-in-word.html>. Reposted at ASCO Connection, Mar 16, 2017. <https://connection.asco.org/blogs/when-remission-isnt-enough>. Reposted at kevinMD, Aug 09, 2017. <http://www.kevinmd.com/blog/2017/08/cancer-patients-incredible-response-treatment.html>.
138. Cancer Care Ethics: Torn Between What You Should Do and What She Wants. ASCO Connection, Mar 31, 2017. <https://connection.asco.org/blogs/cancer-care-ethics-torn-between-what-you-should-do-and-what-she-wants>. Reposted at kevinMD, Jul 24, 2017. <http://www.kevinmd.com/blog/2017/07/end-life-decisions-doctors-patients.html>.
139. Being Human. April 25, 2017. <http://dondizon.blogspot.com/2017/04/being-human.html>. Reposted at ASCO Connection, Apr 27, 2017. <https://connection.asco.org/blogs/being-human-practicing-medicine-means-serving-my-patients-not-my-ego>.
140. Priorities: As a Doctor and a Dad, Family Comes First. ASCO Connection, May 09, 2017. <https://connection.asco.org/blogs/priorities-doctor-and-dad-family-comes-first>.
141. Cancer as a Chronic Disease. May 25, 2017. <http://dondizon.blogspot.com/2017/05/cancer-as-chronic-disease.html>. Reposted at ASCO Connection, May 30, 2017. <https://connection.asco.org/blogs/thinking-about-cancer-chronic-disease>. Reposted at kevinMD, June 8, 2017. <http://www.kevinmd.com/blog/2017/06/lets-stop-calling-cancer-war.html>.
142. #ASCO17: Patient Engagement Improves Survival Outcomes. ASCO Connection, Jun 8, 2017. <https://connection.asco.org/blogs/asco17-patient-engagement-improves-survival-outcomes>.
143. When Cure Isn't What It's Supposed to Look Like. June 15, 2017. <http://dondizon.blogspot.com/2017/06/when-cure-isnt-what-its-supposed-to.html>. Reposted at ASCO Connection, Jun 20, 2017. <https://connection.asco.org/blogs/isnt-what-cure-supposed-look-like>.
144. "At Least": Helping Our Patients Live Life on Their Terms. Jul 25, 2017. <http://dondizon.blogspot.com/2017/07/at-least-helping-our-patients-live-life.html>. Reposted at ASCO Connection, Aug 01, 2017. <https://connection.asco.org/blogs/at-least-helping-our-patients-live-life-their-terms>.

145. Feeling Valued in Academic Oncology. ASCO Connection, Aug 29, 2017. <https://connection.asco.org/blogs/feeling-valued-academic-oncology>.
146. #Sharethepurplelove: Our patients need more clinical trial options. Sept 6, 2017. <http://dondizon.blogspot.com/2017/09/sharethepurplelove.html>. Reposted at ASCO Connection, Sep 12, 2017. <https://connection.asco.org/blogs/sharethepurplelove-our-patients-need-more-clinical-trial-options>.
147. Living in my memory. Sept 26, 2017. <https://connection.asco.org/blogs/living-my-memory>.
148. Goals and preferences. Oct 13, 2017. <http://dondizon.blogspot.com/2017/10/goals-and-preferences.html>.
149. Am I a survivor? ASCO Connection, Oct 31, 2017. <https://connection.asco.org/blogs/am-i-survivor>.
150. Mourning and Oncology. Nov 16, 2017. <http://dondizon.blogspot.com/2017/11/mourning-and-oncology.html>. Reposted at ASCO Connection, Nov 21, 2017. <https://connection.asco.org/blogs/mourning-and-oncology>.
151. For some, family is about wanting to, not having to. ASCO Connection, Dec 5, 2017. <https://connection.asco.org/blogs/some-family-about-wanting-not-having>. Reposted at KevinMD on Dec 18, 2017. <https://www.kevinmd.com/blog/2017/12/power-family-end-life.html>.
152. Holidays in Cancer Land. ASCO Connection, Dec 20, 2017. <http://dondizon.blogspot.com/2017/12/holidays-in-cancer-land.html>. Reposted at ASCO Connection, Dec 28, 2017. <https://connection.asco.org/blogs/holidays-cancer-land>.
153. What makes a good doctor? The Oncologist, Jan 19, 2018. <http://dondizon.blogspot.com/2018/01/what-makes-good-doctor.html>. Reposted at ASCO Connection, Jan 17, 2018. <https://connection.asco.org/blogs/what-makes-good-doctor>. Reposted at KevinMD, Jan 18, 2018. <https://www.kevinmd.com/blog/2018/01/makes-great-doctor-physician-reflects.html>.
154. "What happens if...": Navigating decisions with the curious patient. ASCO Connection, Jan 30, 2018. <https://connection.asco.org/blogs/what-happens-if-navigating-decisions-curious-patient>.
155. "Why should I stop?" The Oncologist, Feb 20, 2018. <http://dondizon.blogspot.com/2018/02/why-should-i-stop.html>. Reposted at ASCO Connection, Mar 01, 2018. <https://connection.asco.org/blogs/why-should-stop>. Reposted at KevinMD.com, Mar 14, 2018. <https://www.kevinmd.com/blog/2018/03/challenge-oncology-balancing-hope-reality.html>.
156. "February break." The Oncologist, Mar 14, 2018. <http://dondizon.blogspot.com/2018/03/february-break.html>. Reposted at ASCO Connection, March 20, 2018. <https://connection.asco.org/blogs/february-break-working-vacation-isnt-work-life-balance>.
157. "Do we need another trial?" ASCO Connection, March 22, 2018. <https://connection.asco.org/blogs/do-we-need-another-trial>.
158. "On patient care and equipoise as SWOG meets in San Francisco". The Oncologist, April 12, 2018. <http://dondizon.blogspot.com/2018/04/on-patient-care-and-equipoise-as-swog.html>. Reposted at ASCO Connection, April 17, 2018. <https://connection.asco.org/blogs/who-enters-trial-patient-care-and-equipoise>.
159. "Yes, patients with cancer can live with metastatic disease". ASCO Connection, April 24, 2018. <https://connection.asco.org/blogs/yes-patients-cancer-can-live-metastatic-disease>. Reposted at kevinMD as "Patients can live with metastatic cancer". KevinMD.com, May 3, 2018. <https://www.kevinmd.com/blog/2018/05/patients-can-live-with-metastatic-cancer.html>.
160. "Saying the things unsaid, even when we aren't their doctors. The Oncologist, May 16, 2018. <http://dondizon.blogspot.com/2018/05/saying-things-unsaid-even-when-we-arent.html>. Reposted as "Breaking the collusion of science". ASCO Connection, May 22, 2018. <https://connection.asco.org/blogs/breaking-collusion-silence>. Reposted at kevinMD as "Cross-coverage has made me aware of the art in medicine. KevinMD.com, May 28, 2018. <https://www.kevinmd.com/blog/2018/05/cross-coverage-has-made-me-aware-of-the-art-in-medicine.html>.
161. "Becoming a Fellow of ASCO". ASCO Connection, June 7, 2018. <https://connection.asco.org/blogs/becoming-fellow-asco>.
162. "Treatment in the dark". The Oncologist, June 7, 2018. <http://dondizon.blogspot.com/2018/06/treatment-in-dark.html>. Reposted at ASCO Connection, June 19, 2018. <https://connection.asco.org/blogs/treatment-dark>.
163. "Time Ran Out". The Oncologist, July 24, 2018. <http://dondizon.blogspot.com/2018/07/time-ran-out.html>. Reposted at ASCO Connection, July 31, 2018. <https://connection.asco.org/blogs/time-ran-out>.
164. "Caught Off Guard". The Oncologist, September 6, 2018. <http://dondizon.blogspot.com/2018/09/caught-off-guard.html>. Reposted at ASCO Connection, Sept 11, 2018. <https://connection.asco.org/blogs/caught-guard>.
165. "The Good Doctor. ASCO Connection, Sept 25, 2018. <https://connection.asco.org/blogs/good-doctor>.
166. "It Takes a Village". The Oncologist, October 25, 2018. <http://dondizon.blogspot.com/2018/10/it-takes-village.html>.
167. The Language of Clinical Trials. ASCO Connection, October 30, 2018. <https://connection.asco.org/blogs/language-clinical-trials>.

168. No Words. The Oncologist, November 15, 2018. <http://dondizon.blogspot.com/2018/11/no-words.html>.
Reposted as ASCO Connection, November 20, 2018. <https://connection.asco.org/blogs/no-words-grieving-dr-karen-meneses-and-dr-arti-hurria>.
169. Teachable moment? Or one to be ignored. The Oncologist, December 7, 2018.
<http://dondizon.blogspot.com/2018/12/teachable-moment-or-one-to-be-ignored.html>. Reposted at ASCO Connection, December 11, 2018. <https://connection.asco.org/blogs/teachable-moment-or-one-be-ignored>.
170. When we can't cure, we can alleviate fear and suffering. ASCO Connection, December 20, 2018.
<https://connection.asco.org/blogs/when-we-cant-cure-we-can-alleviate-fear-and-suffering>.
171. It was supposed to work. The Oncologist, January 24, 2019. <http://dondizon.blogspot.com/2019/01/it-was-supposed-to-work.html>. Reposted at ASCO Connection, January 29, 2019.
<https://connection.asco.org/blogs/it-was-supposed-work-managing-disappointment-when-promising-treatments-fail>.
172. Is it a recommendation or a suggestion. The Oncologist, February 19, 2019.
<http://dondizon.blogspot.com/2019/02/is-it-recommendation-or-suggestion.html>. Reposted at ASCO Connection, February 21, 2019. <https://connection.asco.org/blogs/recommendation-or-suggestion-discussing-treatment-options-requires-precision>.
173. Parenting after cancer: Hope lives on. The Oncologist, March 22, 2019.
http://theoncologist.alphamedpress.org/site/blog/parenting_after_cancer.html. Reposted at ASCO Connection, March 28, 2019: <https://connection.asco.org/blogs/parenting-after-cancer-hope-lives>.
174. Is the patient difficult? Or are you not listening? The Oncologist, April 18, 2019.
http://theoncologist.alphamedpress.org/site/blog/is_the_patient_difficult.html. Reposted at ASCO Connection, April 23, 2019: <https://connection.asco.org/blogs/patient-difficult-or-are-you-not-listening>.
175. Letting Go, Not Giving Up: Accepting the Reality of a Cancer Diagnosis. ASCO Connection, May 16, 2019.
<https://connection.asco.org/blogs/letting-go-not-giving-accepting-reality-cancer-diagnosis>. Reposted at The Oncologist, May 21, 2019. http://theoncologist.alphamedpress.org/site/blog/letting_go.html.

INVITED PRESENTATIONS

REGIONAL

1. Gestational Trophoblastic Disease. Women and Cancer: Issues and Answers Conference, Memorial Sloan-Kettering Cancer Center, New York City, 2003.
2. Intraperitoneal Treatment of Ovarian Cancer. MGH, Boston, Medical Oncology Conference, 2004.
3. A Disease States Model of Ovarian Cancer: Where we are and where we're going/ Grand Rounds, Women & Infants' Hospital, Providence, 2004.
4. Gynecologic Oncology Group Review of the Winter Meeting, Women & Infants' Hospital, Providence, RI, 2005.
5. Update on Metastatic Breast Cancer. Rhode Island Oncology Nursing Society, Providence, RI, 2005.
6. Progress in Ovarian Cancer: Prevention, Diagnosis, and Treatment/ Grand Rounds, St. Luke's Hospital, New Bedford, MA 2005.
7. An Update in the Management of Ovarian Cancer/ Hematology/Oncology Grand Rounds, Rhode Island Hospital, Providence, RI, 2005.
8. An Update in the Management of Metastatic Breast Cancer: Controversies and New Treatment Options/ Hematology/Oncology Grand Rounds, St. Elizabeth's Hospital, Boston, MA, 2005.
9. Recent Advances in Ovarian Cancer: Screening, Diagnosis, and Treatment/ Department of Obstetrics/Gynecology Grand Rounds, University of Vermont . Burlington, VT, 2006.
10. Intraperitoneal treatment for ovarian cancer/ Department of Obstetrics/Gynecology Grand Rounds, Women & Infants' Hospital, Providence, RI, 2007.
11. What you say, what we do: Interdisciplinary collaboration in breast cancer treatment. Rhode Island Society of Pathologists Meeting, Providence, RI, 2007.
12. Sexuality and the Cancer Patient, Women & Infants' Hospital, Providence, RI, 2007.
13. Confronting Disparities: The Program in Women's Oncology/ Presentation and Panel discussion, The Partnership to Reduce Cancer in Rhode Island, Warwick, RI, 2007.
14. Endometrial Cancer: A Multi-Disciplinary Approach/ Department of Obstetrics/Gynecology Grand Rounds, Women & Infants' Hospital, Providence, 2007.
15. Strength and Resilience: Important Issues in Cancer Survivorship. Redwood Library, Newport, RI, 2007.
16. An Evidence Based Approach to Endometrial Cancer/ Department of Obstetrics & Gynecology Grand Rounds, St. Luke's Hospital, New Bedford, MA, 2007.

17. Controversies in adjuvant chemotherapy: to treat or not to treat. Breast Center Multi-disciplinary Rounds, Massachusetts General Hospital, Boston, 2007.
18. An Evidence Based Approach to Endometrial Cancer/ Grand Rounds, Falmouth Hospital, Falmouth, MA, 2008.
19. Ovarian cancer: State of the Art and Current Controversies/ Medical Grand Rounds, Roger Williams Medical Center, Providence, RI, 2008.
20. Sexuality and Intimacy in Female Cancer Survivors. Rhode Island Partnership to Reduce Cancer Coalition Cancer Summit, Warwick, RI 2009.
21. You've Lost that Loving Feeling: Sexual Health and Breast Cancer Survivors. Breast Cancer Survivors' Day, Greenfield, MA, 2009.
22. Ovarian Cancer: Novel Treatments and Current Paradigms/ Cancer Center Grand Rounds, Rhode Island Hospital, Providence, RI 2010.
23. Documentation in Research. Women & Infants Hospital Research Administration, Providence, RI, 2010.
24. Sex and Intimacy in the female cancer survivor/ Hematology/Oncology Grand Rounds, Rhode Island Hospital, Providence, RI, 2010.
25. Anti-Angiogenesis Agents in Ovarian Cancer: Where are we going?/Cancer Center Rounds, Falmouth Hospital, Falmouth, MA 2011.
26. Dignity, Hope, and Loss: Lessons From Oncology/ Department of Obstetrics-Gynecology Grand Rounds, Women & Infants Hospital, Providence, RI, 2011.
27. Sexuality and Cancer. Gynecologic Cancer Survivors' Course, Foundation for Women's Cancers, Boston, MA, 2012.
28. One Physician's Journey to Academic Success and Participation in ASCO on a National Level/Cancer Center Grand Rounds, Rhode Island Hospital, Providence, RI, 2012.
29. Quality of life issues in ovarian cancer survivors, Ovations for the Cure Event, Boston, MA, 2012.
30. You've lost that loving feeling: Sexual health in female cancer survivors, Massachusetts General Hospital, Radiation Oncology Conference, Boston, MA, 2012.
31. Oncology sexual health. Patient and Family Advisory Council, MGH Cancer Center, Boston, MA, 2013.
32. Update on clinical trials. Gynecologic Cancer Survivors' Course, Foundation for Women's Cancers, Boston, MA, 2013.
33. Women's Health Issues: An emphasis on sexual health. Cancer Survivorship Conference, The Warren Alpert Medical School of Brown University, Providence, RI, 2013.
34. Social medicine in clinical practice: You, your reputation, your institution, Social Media in Medicine Conference, Massachusetts Medical Society, 2013.
35. Sexual health after breast cancer. Breast Center Multidisciplinary Rounds, Massachusetts General Hospital Cancer Center, Boston, MA, 2014.
36. Survivorship 2.0. Massachusetts General Hospital Cancer Center, Boston, MA, 2014.
37. After Cancer (Or, On being an oncologist) (Keynote Speaker). Massachusetts General Hospital Cancer Survivors' conference, Boston, MA, 2014.
38. Through each other's eyes: sharing what we've learned from living with cancer. Massachusetts General Hospital Cancer Survivors' conference, Boston, MA, 2014.
39. Living after cancer: pragmatism, realism, and optimism. Gynecologic Cancer Survivors Conference, Foundation for Women's Cancers. Boston, MA, 2014.
40. The Oncology Sexual Health Clinic, Cancer Center Noontime Conference, MGH North Shore Cancer Center, Danvers, MA, 2014.
41. Novel treatments for uterine cancer. Foundation for Women's Cancers Gynecologic Cancer Survivors' Course, Foundation for Women's Cancers, Boston, MA, 2014.
42. After Cancer: The Oncology Sexual Health Clinic. National Med-Peds Residents' Association Northeast Regional Conference, Providence, RI, 2015.
43. After Cancer: A Focus on Sexual Health & Intimacy. Exeter Hospital Grand Rounds, Exeter, NH, 2015.
44. Sexual Health in Breast Cancer Survivors. MGH Breast Center Rounds, Boston, MA, 2015.
45. Shared Concerns, Shared Objectives: Towards the Concept of Community after the Cancer Experience. The 2015 MGH Cancer Center Survivorship Conference: Sustaining a Cancer Community in the Era of Personalized Medicine, Boston, MA, 2015.
46. Sexual health and Cancer. MGH Urogynecology Conference, Boston, MA, 2015.
47. Sexual health in Palliative Care, MGH Palliative Care Grand Rounds, Boston, MA, 2016.
48. Precision in Endometrial Cancer. Molecular and Precision Therapy Tumor Board, MGH Cancer Center, Boston, MA, 2016.

49. (Im)precision therapy for ovarian cancer. Rhode Island Hospital Cancer Center Grand Rounds, Providence, RI, 2016.
50. Sexuality and intimacy after cancer. Midlife Women's Health 2017: A Multidisciplinary Approach to Care. Boston, MA, 2017.
51. After cancer: Sexual health and intimacy. Newton-Wellesley Hospital Cancer Survivorship Conference, Newton, MA, 2017.
52. Remembering Jessica. RI Ovarian Cancer Walk for Life. September 2017.
53. Second Opinion: New and Emerging Treatment Strategies in the Management of Recurrent Ovarian Cancer. Research to Practice Grand Rounds in Ovarian Cancer. Falmouth, MA, September 2017.
54. Unique Survivorship Issues of Patients with Advanced or Chronic Cancer. Cancer Survivorship: Optimizing Care and Outcomes. Dana Farber Cancer Institute, Boston, MA, October 2017.
55. Ovarian cancer: Common questions and answers. BankRI Women's Event, Cranston, RI. May 2018.
56. Recent advances in Gynecologic Cancers. Rose B. David Memorial Lecture, Newport Hospital, Newport, RI, May 2018.
57. Fertility preservation in oncology: Updates from an Oncologist. Rhode Island Hospital Department of Medicine Grand Rounds, Providence, RI, June 2018.
58. Oncology PER Oncology Best Practice: Expert perspectives to incorporate evidence on PARP inhibitors into practice and optimize the medical management of ovarian cancer. Al Forno Restaurant, Providence, RI, June 2018.
59. Sexual Health: A Primer. University of Massachusetts Medical Center Hematology/ Oncology Grand Rounds, Worcester, MA, September 2018.
60. Sexual health after cancer. Avenues of Healing, Warwick, RI, October 2018.
61. Sexuality and Intimacy after cancer: A Primer. Hematology-Oncology Grand Rounds, Lifespan Cancer Institute, Providence, RI, January 2019.
62. Barbosa F and Dizon DS (Moderators). The Power of Our Humanity: A Call for Preserverence. Schwartz Center Rounds at Rhode Island Hospital, February 2019.
63. Gynecologic Oncology Research. Translational Research Disease Group- Gynecologic Oncology. April 2019.
64. Engagement in Social Media: Why you should care, what you should know. Dana Farber Cancer Institute, GU Oncology Seminar, May 2019.
65. Sex and Intimacy: How it changes after cancer. Survivor Journeys, June 2019.

NATIONAL

1. New Normal: On Living with and after cancer. The Young Women with Cancer Workshop, University of Alabama at Birmingham, April 2019.
2. Panelist, Digital Clinical Trials Workshop: Creating a Vision for the Future (Co-sponsored by NHLBI/NSF), Bethesda, MD, April 2019.
3. Imaging and Treatment Options in Suspected Metastatic Breast Cancer. National Consortium of Breast Centers Annual Meeting, Las Vegas, NV, 2006.
4. The Interdisciplinary Case Conference (Panelist). National Consortium of Breast Centers Annual Meeting. Las Vegas, NV, 2006.
5. Chemotherapy Treatment Landscape for Patients with Metastatic Breast Cancer. Regimens in Bevacizumab in Breast Oncology (RIBBON) Investigators' Meeting. Genentech, New York City, NY, 2006.
6. Innovative Therapies for Breast Cancer. Topics in Oncology, San Jose, CA, 2006.
7. Innovative Therapies for Breast Cancer. Topics in Oncology, San Francisco, CA, 2006.
8. The importance of clinical trials in oncology (Keynote). Fearless Caregivers Conference, Branford, CT, 2006.
9. Sexual Function in Women: In Health and In Sickness. The Haunted Histories of the Female Body: Gynecology, Obstetrics and Women's Health. Symposium of the School of Literature, Communication and Culture, Georgia Technological Institute, Atlanta, GA 2006.
10. Chemotherapy Treatment Landscape in Metastatic Breast Cancer: An Emphasis on Second Line Therapy. Regimens in Bevacizumab in Breast Oncology (RIBBON2) Investigators' Meeting. Genentech, San Diego, CA 2007.
11. Medical Therapy in Advanced Breast Cancer with Discussion of Case Studies, National Consortium of Breast Centers Annual Meeting, Las Vegas, NV 2007.
12. Health or Harm: The Impact of Hormone Replacement Therapy (Plenary Presentation). National Consortium of Breast Centers Annual Meeting, Las Vegas, NV 2007.

13. The Interdisciplinary Case Conference (Panelist). National Consortium of Breast Centers Annual Meeting, Las Vegas, NV 2007.
14. Toxicity of a modified outpatient regimen of intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in women with newly diagnosed ovarian cancer (Focused Plenary Discussant). Society of Gynecologic Oncologists 38th Annual Meeting. San Diego, CA, 2007.
15. Innovative Therapies for Breast Cancer. Topics in Oncology, Columbia, MD, 2007.
16. Hormone Replacement Therapy: Health or Harm? Lessons from the Women's Health Initiative. The 2007 Breast Cancer Symposium. The Research and Education Institute for Texas Health Resources. Dallas, TX, 2007.
17. You've Lost that Loving Feeling: Sexual Health After Breast Cancer. The 2007 Breast Cancer Symposium. The Research and Education Institute for Texas Health Resources. Dallas, TX, 2007.
18. Health or Harm: Lessons learned from the Women's Health Initiative (Grand Rounds). Riverside Memorial Hospital. Columbus, OH, 2007.
19. Sexuality and Survivorship After Breast Cancer. University of Florida, College at Jacksonville's 13th Annual Multidisciplinary Symposium on Breast Disease. Amelia Island, FL, 2008.
20. The Time is Now: Development of a Sexuality and Fertility Clinic for Cancer Patients (Panel Discussion). The Symposium on Sexuality and Fertility After Breast Cancer. National Consortium of Breast Centers, Las Vegas, NV, 2008.
21. Families and Breast Cancer: Advance care planning and primary support. 18th Annual Interdisciplinary Conference of the National Consortium of Breast Centers. Las Vegas, NV, 2008.
22. Practice Patterns on the use of intraperitoneal chemotherapy in women with ovarian cancer (Focused Plenary Discussant). Society of Gynecologic Oncologists 39th Annual Meeting. Tampa, FL, 2008.
23. Challenges in Survivorship (Session Chairman). Breast Cancer Symposium. Washington, DC, 2008.
24. You've Lost that Loving Feeling: Sexual Health after Breast Cancer (Keynote Lecture). The 2008 Breast Cancer Conference. McKinney, TX, 2008.
25. The Women's Health Initiative: Answers and Even More Questions. The Breast Cancer Conference. McKinney, TX, 2008.
26. Recurrent Endometrial Cancer: Chemotherapy. Society of Gynecologic Oncologists 2008 State of the Art Conference: Endometrial Cancer- New Insights in Treatment: Radiation, Chemotherapy, or Targeted Therapy: Passé or Je ne sais quoi? Chicago, IL, 2008.
27. Targeted Therapies: An Update. Society of Gynecologic Oncologists 2008 State of the Art Conference: Endometrial Cancer- New Insights in Treatment: Radiation, Chemotherapy, or Targeted Therapy: Passe or Je ne sais quoi? Chicago, IL, 2008.
28. Controversies in Breast Cancer Management. National Consortium of Breast Centers, 19th Annual Interdisciplinary Breast Conference, Las Vegas, NV, 2009.
29. Bevacizumab should not be continued indefinitely and utilized with every drug regimen for recurrence. Gynecologic Oncology Group Summer Symposium, Baltimore, MD, 2009.
30. Moving Beyond Standard of Care: Novel Treatments in Gynecologic Malignancies. Chemotherapy Foundation Symposium, New York City, NY, 2009.
31. Challenges in Survivorship (Co-Chair). The Breast Cancer Symposium, San Francisco, CA, 2009.
32. Current Strategies in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer. Clinical Advances in Gynecologic Malignancies. Society of Gynecologic Oncologists Annual Meeting, San Francisco, CA, 2010.
33. Golden Girls: The Approach to Breast Health in Women over 70. National Consortium of Breast Centers Annual Meeting, Las Vegas, NV 2010.
34. Approaching Metastatic Breast Cancer (Panel member). National Consortium of Breast Centers Annual Meeting, Las Vegas, NV 2010.
35. New Strategies in the clinical treatment of endometrial cancer. The Chemotherapy Foundation Symposium XXVII, New York City, NY 2010.
36. Screening Mammography in Women Aged 40-49/ (Session moderator). National Consortium of Breast Centers Annual Meeting, Las Vegas, NV 2011.
37. Medical Oncology Basics. National Consortium of Breast Centers Annual Meeting, Las Vegas, NV, 2011.
38. Options in the Treatment of relapsed endometrial cancer: beyond first-line therapy. Annual Meeting of the American Society of Clinical Oncology, Chicago, IL 2011.
39. Endometrial Cancer: Present State and Future Promise (Session Chair). Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, 2011.
40. Cervical Cancer: Screening and Prevention. Sixth Annual Oncology Congress, San Francisco, CA, 2011.
41. Sexuality and Fertility: talking with your male and female patients about their options. Sixth Annual Oncology Congress, San Francisco, CA, 2011.

42. Preparing for survivorship: Quality of life of breast cancer survivors. Assessments and Interventions. International Society for Sexuality and Medicine Symposium, Washington, DC. 2011.
43. Fertility and Sexuality. Core Curriculum Seminar, Vanderbilt University School of Medicine, Nashville, TN, 2012.
44. Intimacy and Sexuality. Living Beyond Breast Cancer Conference, Philadelphia, PA, 2012.
45. Complementary methods for managing symptoms and side effects. Living Beyond Breast Cancer Conference, Philadelphia, PA, 2012.
46. Can we personalize cervical cancer therapy (Clinical Science Symposium Discussant). American Society of Clinical Oncology Annual Meeting, Chicago, IL, 2012.
47. Gynecologic Oncology Oral Abstract Session (Co-Chair). American Society of Clinical Oncology Annual Meeting, Chicago, IL, 2012.
48. Advancing medicine in clinical trials. Ovarian Cancer Patients: Clinical Practice Patterns, Evolving Data, and Clinical Trial Awareness. San Diego, CA, 2013.
49. Improving Management Strategies. Ovarian Cancer Patients: Clinical Practice Patterns, Evolving Data, and Clinical Trial Awareness, San Diego, CA, 2013.
50. Living with metastatic breast cancer: Pragmatism, Realism, Optimism, and Legacies. Annual meeting of the Metastatic Breast Cancer Network, Houston, TX, 2013.
51. Intimacy and Sexuality. Annual meeting of the Metastatic Breast Cancer Network, Houston, TX, 2013.
52. Sexual Health Fundamentals. National Consortium of Breast Centers Pre-Conference, Las Vegas, NV, 2013.
53. Tumor Board Panel Presentation (Member). National Consortium of Breast Centers Annual Meeting, Las Vegas, NV, 2013.
54. Communicating Cancer. National Consortium of Breast Centers Annual Meeting, Las Vegas, NV, 2013.
55. Communicating Cancer: The Power of Words. Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, 2013.
56. State of the Science in Cervical Cancer: Where are we today and Where do We Need to Go (Co-Chair). Gynecologic Oncology Group Semi-Annual Meeting, San Antonio, TX, 2013.
57. Patient Perspectives and Survivorship (Poster Discussion). Breast Cancer Symposium, San Francisco, CA, 2013.
58. Best of ASCO: Gynecologic Oncology. Association of Physician Assistants in Oncology Annual Meeting, Philadelphia, PA, 2013.
59. Running a survivorship clinic for women. Sexual Medicine Society of North America Fall Scientific Meeting, New Orleans, LA, 2013.
60. The advanced practitioner and social media. JADPRO Live, St. Petersburg, FL, 2014.
61. Treating breast cancer survivors- bone health, fitness, mental and sexual health. Holy Cross/MGH Winter Oncology Symposium, Fort Lauderdale, FL, 2014.
62. The power of words: Communicating with our patients. The Foundation of Women's Cancer Gynecologic Cancer Survivors Course, Anchorage, AK, 2014.
63. Innovative new therapies for Gynecologic Cancers. Gynecologic Cancer Survivor's Course, Foundation for Women's Cancers, Anchorage, AK, 2014.
64. Data and Perspectives: Clinical Investigators Review Key Research Developments and Current Cases in Gynecologic Oncology. Research to Practice, Tampa, FL.
65. Sexual health in older female cancer survivors. 45th Annual Meeting on Women's Cancer (Society of Gynecologic Oncologists), Tampa, FL, 2014.
66. Results of GOG 229K: A phase II trial of BIBF-1120 for women with advanced, recurrent, or metastatic endometrial cancer (Focused Plenary). 45th Annual Meeting on Women's Cancer (Society of Gynecologic Oncologists), Tampa, FL, 2014.
67. Etiology of sexual complaints (Sexuality Pre-Conference). National Consortium of Breast Centers Annual Meeting, Las Vegas, NV, 2014.
68. Case Studies, Communication Techniques, and Small Groups (Sexuality Pre-Conference). National Consortium of Breast Centers Annual Meeting, Las Vegas, NV, 2014.
69. Long term considerations post medical and radiological intervention (Survivorship Pre-Conference). National Consortium of Breast Centers Annual Meeting, Las Vegas, NV, 2014.
70. The Power of Words: How to communicate cancer in a breast center (Plenary). National Consortium of Breast Centers Annual Meeting, Las Vegas, NV, 2014.
71. Navigating the annual meeting. Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, 2014.
72. There is no blue pill for this: Sexual health after gynecologic cancer. Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, 2014.

73. Communicating Cancer: Hope and Truth. Seventh Annual University of Illinois College of Medicine at Peoria Breast Cancer Symposium, Peoria, IL, 2014.
74. Grand Rounds in Ovarian Cancer (Co-presented with J. Gahres, PA at Memorial Sloan-Kettering Cancer Center). JADPRO Live at the Advanced Practitioner Society in Hematology and Oncology Meeting, Orlando, FL, 2014.
75. Innovative therapies in gynecologic malignancies (Wayne Day). Wayne State University School of Medicine, Detroit, MI, 2014.
76. Patient engagement: Social media, health professionals, and advocacy. Global Advocacy Leadership Academy, Chicago, IL, 2014.
77. Tumor Board on issues of sexuality: who says what when? (Co-presentation with Drs. Jennifer S. Gass and Michael Krychman). National Consortium of Breast Centers Annual Meeting, Las Vegas, NV, 2015.
78. Words in cancer care: What you say, what our patients hear. National Consortium of Breast Centers Annual Meeting, Las Vegas, NV, 2015.
79. Surviving cancer: Engagement to Empowerment. National Consortium of Breast Centers Annual Meeting, Las Vegas, NV, 2015.
80. Here's what it sounds like: Mini case studies and role plays in sexual medicine (Co-presentation with Drs. Anne Katz and Michael Krychman). National Consortium of Breast Centers Annual Meeting, Las Vegas, NV, 2015.
81. Difficult relationship issues when a family faces cancer – sexuality and intimacy with and after cancer: What your patients won't ask. Lee Memorial Health Systems Oncology Conference for Clinicians, Fort Myers, Florida, 2015.
82. Navigating the Annual Meeting. American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, 2015.
83. Gynecologic Oncology Track: Added Value or Splitting Hairs: Adding Targeted Therapy to the Mix (Oral Abstract session). American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, 2015.
84. Best of ASCO: Gynecologic Oncology. American Physicians Assistants in Oncology Annual Meeting, Alexandria, VA, 2015.
85. Sexual health after gynecologic cancers. Johns Hopkins Gynecologic Cancer Survivors Course, Baltimore, MD, 2015.
86. Breast cancer research: Where are we and where do we need to go? (Panel Discussion with Drs. Susan Love and Banu Arun). The Young Survivors Coalition (YSC) Summit, Houston, TX, 2015.
87. The Oncologist in You (Case studies panel alongside Drs. Susan Love and Banu Arun). The Young Survivors Coalition (YSC) Summit, Houston, TX, 2015.
88. Sexual Health and Intimacy (for women only). The Young Survivors Coalition (YSC) Summit, Houston, TX, 2015.
89. Managing side effects in the setting of metastatic breast cancer. Living Beyond Breast Cancer Meeting for Women with Metastatic Breast Cancer, Philadelphia, PA, 2015.
90. Sexuality and intimacy of cancer patients and survivors. Lee Memorial Health Systems Community event for cancer survivors. Fort Myers, FL, 2015.
91. What I've learned about living, I've learned from my patients. National Cancer Survivors Day, Lee Memorial Health System. Fort Myers, FL. 2015.
92. Surviving cancer and Health Literacy: Engagement to Empowerment. The 8th Annual Breast Cancer Conference. University of Illinois, Peoria/OSF Health Systems, Peoria, IL, 2015.
93. Models of Sexual Health. National Consortium of Breast Centers Annual Meeting, Las Vegas, NV, 2016.
94. Case studies in sexual health. National Consortium of Breast Centers Annual Meeting, Las Vegas, NV, 2016.
95. Engagement to Empowerment (Plenary Presentation). National Consortium of Breast Centers Annual Meeting, Las Vegas, NV, 2016.
96. Managing long term toxicities after breast cancer. National Consortium of Breast Centers Annual Meeting, Las Vegas, NV, 2016.
97. Navigating the Annual Meeting. American Society of Clinical Oncology Annual Meeting, Chicago, IL, 2016.
98. Sexual health after cancer: Therapeutics. Annual Meeting of the American Society of Radiation Oncology (ASTRO), Boston, MA, 2016.
99. Sexual health after breast cancer. The 9th Breast Cancer Symposium, The University of Illinois at Peoria, Peoria, IL, 2016.
100. (Im)Precision therapy for Gynecologic cancers. NYU Langone Cancer Center Grand Rounds, New York, NY, 2016.
101. Social networks and survival. Metastatic cancer task force testimony and operations meeting, Mclean, Virginia, 2016.

102. Social Media in Oncology (Visiting Professor). Inova Fairfax Hospital, Fairfax, VA, 2017.
103. Sexual Health after Cancer. Holy Cross/MGH Winter Oncology Symposium, Fort Lauderdale, FL, 2017.
104. Sexual Health After Cancer: An Overview On Therapeutics. SGO Annual Meeting on Women's Cancers, National Harbor, MD, 2017.
105. Case studies in Sexual Health. SGO Annual Meeting on Women's Cancers, National Harbor, MD, 2017.
106. Sexuality and Intimacy After Cancer. 5th Annual Young Breast Cancer Survivors Workshop, UAB School of Nursing, Birmingham, AB, 2017.
107. Second Opinion: Challenging Clinical Questions and Controversies in the Treatment of Ovarian Cancer. Research to Practice Grand Rounds, Phoenix, AZ, 2017.
108. Sexual Dysfunction in Women with Cancer: Navigating Intimacy and Intercourse between Women and their Partners. Annual Scientific Program of the Sexual Medicine Society of North America, Boston, MA, 2017.
109. Navigating the Annual Meeting, ASCO Annual Meeting, Chicago, IL, 2017.
110. Second Opinion: Challenging Clinical Questions and Controversies in the Treatment of Ovarian Cancer. Research to Practice Grand Rounds, Morristown Medical Center, Summit, NJ, 2017.
111. Sexuality and Intimacy. Bladder Cancer Action Network Think Tank, Charlotte, NC, 2017.
112. Second Opinion: Challenging Clinical Questions and Controversies in the Treatment of Ovarian Cancer. Research to Practice Grand Rounds, Mayo Clinic, Jacksonville, FL, 2017.
113. Second Opinion: Challenging Clinical Questions and Controversies in the Treatment of Ovarian Cancer. Research to Practice Grand Rounds, White Plains Cancer Center, White Plains, NY, 2017.
114. Social Media and Breast Cancer Engagement. Puerto Rico Breast Cancer Conference, San Juan, PR, 2017.
115. Sexual health after breast cancer. Puerto Rico Breast Cancer Conference, San Juan, PR, 2017.
116. Second Opinion: Challenging Clinical Questions and Controversies in the Treatment of Ovarian Cancer. Research to Practice Grand Rounds, Lenox Hill Hospital Hematology-Oncology Conference, New York, NY, 2017.
117. Second Opinion: New and Emerging Treatment Strategies in the Management of Recurrent Ovarian Cancer. Research to Practice Grand Rounds in Ovarian Cancer. Lenox Hill Hospital, New York, NY, October 2017.
118. Second Opinion: New and Emerging Treatment Strategies in the Management of Recurrent Ovarian Cancer. Research to Practice Grand Rounds in Ovarian Cancer. SUNY Downstate Health Sciences Center, Brooklyn, NY, October 2017.
119. How I Treat High-grade Early stage Endometrial Cancer. Chemotherapy Foundation Symposium, New York, NY, November 2017.
120. Second Opinion: New and Emerging Treatment Strategies in the Management of Recurrent Ovarian Cancer. Research to Practice Grand Rounds in Ovarian Cancer. Watson Cancer Research Center, Lakeland, FL, January 2018.
121. Second Opinion: New and Emerging Treatment Strategies in the Management of Recurrent Ovarian Cancer. Research to Practice Grand Rounds in Ovarian Cancer. Watson Cancer Research Center, Mesa, AZ, January 2018.
122. Practical guidance: Social media for health care professionals. The water's just fine. Gynecologic Cancer Course, Anchorage, AK. February 2018.
123. Female sexual health and breast cancer: A Framework. 28th Annual Meeting of the National Consortium of Breast Centers, March 2018.
124. Interventions for sexual dysfunction. 28th Annual Meeting of the National Consortium of Breast Centers, March 2018.
125. Patient- and Disease-Specific Considerations in the Management of Platinum-Resistant Recurrent Ovarian Cancer. Cases from the Community: Clinical Investigators Provide Their Perspectives on Emerging Research and Actual Patients with Ovarian Cancer. Research To Practice, March 2018.
126. Answering global questions locally: The power and limitations of the retrospective study utilizing institutional data. SGO Educational Forum, SGO Annual Meeting, March 2018.
127. Cancer Care and Social Media: What can we learn from engagement? Cancer Control and Population Sciences Meeting, University of Alabama Cancer Center, April 2018.
128. **Keynote Lecture:** Moving beyond breast cancer: Perspectives, Problems, and promises. Young Breast Cancer Survivors Network Annual Meeting, SurviveAL. Birmingham, AL, April 2018.
129. **Keynote Panel:** Ask the Experts: Managing Symptoms and Side Effects. Living Beyond Breast Cancer 2018 Annual Conference of Metastatic Breast Cancer. Philadelphia, PA, April 2018.
130. Sex, Intimacy, and Metastatic Breast Cancer. Living Beyond Breast Cancer 2018 Annual Conference of Metastatic Breast Cancer. Philadelphia, PA, April 2018.

131. Moving beyond breast cancer: Perspectives, Problems, and promises (**Keynote Lecture**). Sidney Kimmell Comprehensive Cancer Center 4th Annual Breast Cancer Survivorship Day, Baltimore, MD, April 2018.
132. Novel treatment strategies in Ovarian Cancer: The role of PARP inhibitors. 2018 Spring Managed Care Forum. Orlando, FL. April 2018.
133. Utilizing Social Media: On Dual Passports and data mining. Alliance Semi-Annual Meeting, Chicago IL, June 2018.
134. New approaches for less studied tumors. Gynecologic Oncology Poster Discussion session. 2018 ASCO Annual Meeting, Chicago, IL, June 1, 2018.
135. Navigating the Annual Meeting. 2018 ASCO Annual Meeting, Chicago, IL, June 1, 2018.
136. Clinicians on Social Media: A Call for Engagement. NCI Clinical trials and social media workshop. Bethesda, MD, June 2018.
137. Social media beyond borders: The Collaboration for Social Media in Oncology. University of Miami Sylvester Cancer Center Global Health Rounds. June 2018.
138. Social Media and Cancer Professionals: The Collaboration for Social Media in Oncology. City of Hope Medical Rounds, Duarte, CA, July 2018.
139. Social Media and the Research Enterprise: On Applications and Practical Utilization. Jeri and Noboru Oishi Symposium, SWOG Cancer Research Network Semi-Annual Meeting, Chicago, IL, October 2018.
140. Ovarian Cancer. Year in Review: A Multitumor Regional Symposia Series Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers, Orlando, FL, October 2018.
141. Survivorship. San Antonio Breast Cancer Symposium Official Review. Cleveland Clinic, Fort Lauderdale, FL, January 2019.
142. Addressing Libido and Sexual Health after Cancer. Foundation for Women's Cancer Gynecologic Cancer Survivors' Course, West Palm Beach, FL. February 2019.
143. Old standards and new tricks for Ovarian Cancer. Gynecologic Oncology Oral Abstract Discussion Session, American Society of Clinical Oncology 2019 Annual Meeting.

INTERNATIONAL

1. Management of Ovarian Cancer, South American Cancer Conference, Quito, Ecuador, 2002.
2. Management of Cervical Cancer, South American Cancer Conference, Quito, Ecuador, 2002.
3. Ovarian Cancer: Diagnosis to Treatment/ Ovarian Cancer Conference, Guam Medical Association, Tumon, Guam, 2003.
4. Blocking HER Dimerization: Preclinical and Early Clinical Evaluation of Pertuzumab. The Fifth International Congress on Monoclonal Antibodies in Cancer, Quebec City, Canada, 2005.
5. From Bench to Bedside: The Clinical Development of Pertuzumab in Women's Cancers. International Conference on Drug Discovery and Delivery, Dubai, UAE, 2008.
6. Interactive Tumor Board: Breast Cancer (Panelist). International Gynecologic Cancer Society Meeting (IGCS-12). Bangkok, Thailand, 2008.
7. Breast Cancer (Session Chair- Oral Poster Presentations). International Gynecologic Cancer Society Meeting (IGCS-12). Bangkok, Thailand, 2008.
8. Results from a phase II trial of ixabepilone for women with advanced endometrial cancer (GOG-129P). International Gynecologic Cancer Society Meeting (IGCS-12). Bangkok, Thailand, 2008.
9. Current options in chemoprevention. Progress in hormonal and chemotherapy agents. Ville Marie Oncology Center 15th Anniversary Breast Cancer Conference, Montreal, Quebec, 2009.
10. You've lost that loving feeling: Sexual health and the breast cancer survivor. Ville Marie Oncology Center 15th Anniversary Breast Cancer Conference, Montreal, Quebec, 2009.
11. Intravenous chemotherapy should be the first choice for adjuvant treatment for epithelial ovarian cancer. Controversies in Obstetrics, Gynecology, and Infertility, Paris, France, 2011.
12. Bevacizumab and other biologics for the treatment of epithelial ovarian cancer. Controversies in Obstetrics, Gynecology, and Infertility, Paris, France, 2011.
13. Ovarian Cancer (Co-chair, Opening Plenary). International Gynecologic Cancer Society Biennial Meeting, Vancouver, BC, 2012.
14. Optimizing hormonal and chemotherapy. Ville Marie Medical 20th Anniversary Breast Cancer Conference: Progress in Prevention, Detection, Management and Survivorship, Montreal, BC, 2014.
15. Current status of chemoprevention. Ville Marie Medical 20th Anniversary Breast Cancer Conference: Progress in Prevention, Detection, Management and Survivorship, Montreal, BC, 2014.

16. Progress in hormonal therapy. Ville Marie Medical 20th Anniversary Breast Cancer Conference: Progress in Prevention, Detection, Management and Survivorship, Montreal, BC, 2014.
17. Monitoring, Supporting, and Survivorship. Ville Marie Medical 20th Anniversary Breast Cancer Conference: Progress in Prevention, Detection, Management and Survivorship, Montreal, BC, 2014.
18. Coordination of Care: The Survivorship Care Plan. The 1st Breast Cancer Survivorship Symposium (Sponsored by the Emirates Association for Cancer Support and Tawam Hospital), Al Ain, Abu-Dhabi, UAE, 2015.
19. Follow-up: What tests are warranted, what tests are not. The 1st Breast Cancer Survivorship Symposium (Sponsored by the Emirates Association for Cancer Support and Tawam Hospital), Al Ain, Abu-Dhabi, UAE, 2015.
20. Psychosocial issues in the breast cancer survivor. The 1st Breast Cancer Survivorship Symposium (Sponsored by the Emirates Association for Cancer Support and Tawam Hospital), Al Ain, Abu-Dhabi, UAE, 2015.
21. Endocrinologic issues after breast cancer. The 1st Breast Cancer Survivorship Symposium (Sponsored by the Emirates Association for Cancer Support and Tawam Hospital), Al Ain, Abu-Dhabi, UAE, 2015.
22. Bone and cardiovascular health in the breast cancer survivor. The 1st Breast Cancer Survivorship Symposium (Sponsored by the Emirates Association for Cancer Support and Tawam Hospital), Al Ain, Abu-Dhabi, UAE, 2015.
23. Exercise and physical activity after breast cancer. The 1st Breast Cancer Survivorship Symposium (Sponsored by the Emirates Association for Cancer Support and Tawam Hospital), Al Ain, Abu-Dhabi, UAE, 2015.
24. A couple's guide to intimacy after breast cancer. The 1st Breast Cancer Survivorship Symposium (Sponsored by the Emirates Association for Cancer Support and Tawam Hospital), Al Ain, Abu-Dhabi, UAE, 2015.
25. Experiences with survivorship plans: The Brown University and MGH experience. The 1st Breast Cancer Survivorship Symposium (Sponsored by the Emirates Association for Cancer Support and Tawam Hospital), Al Ain, Abu-Dhabi, UAE, 2015.
26. Adjuvant therapy for breast and cervical cancers: Best Practices. Guam Cancer Conference, Guam Comprehensive Cancer Control Program, 2015.
27. After Cancer: Long term considerations. The 4th National Breast Cancer Conference, Hamad Medical Corporation, Doha, Qatar, 2015.
28. The Survivorship Symposium lecture series: Survivorship care plans: The Basics; Follow-Up after breast cancer: What tests are warranted? What tests are not?; Psychosocial issues in breast cancer survivors; Gynecologic issues after breast cancer; Issues after breast cancer: Bone health; Issues after breast cancer: Cardiovascular health; Genetic Evaluation of breast cancer survivors; After breast cancer: Healthy Lifestyles. The 4th National Breast Cancer Conference, Hamad Medical Corporation, Doha, Qatar, 2015.
29. Words in cancer care: What we say, What they hear. Guam Cancer Conference, Tumon Bay, Guam, 2016.
30. Breast cancer screening and prevention: It's Time (A Guam Cancer Coalition event), Tumon Bay, Guam.
31. Surviving cancer and Health Literacy: Engagement to Empowerment. Guam Cancer Conference, Tumon Bay, Guam, 2016.
32. Globalization of communication in oncology in Europe and the United States. The Italian Association of Medical Oncology (AIOM) 2nd Course for Communication in Medical Oncology. Reggio Emilia, Italy, 2016.
33. Sexuality and Intimacy after Cancer. Breast Cancer in Young Women 3rd Meeting (BCY3), Lugano, Switzerland, 2016.
34. Sexual Health after cancer. Icelandic Medical Association Annual Meeting, Reykjavik, Iceland, 2017.
35. Gynecologic cancer: State of the Art (or the Imprecision therapy in Gynecologic Oncologic). Icelandic Medical Association Annual Meeting, Reykjavik, Iceland, 2017.
36. Cervical cancer: Making sense of the guidelines. Cervical cancer awareness program, Tumon Bay, Guam, 2017.
37. Female sexual health after cancer. Cervical cancer awareness program, Tumon Bay, Guam, 2017.
38. Transforming the oncofertility patient experience through team-based care and compassion (Co-presented with Marie-Madeleine Dolmans of the Catholic University of Louvain, Belgium). BeConnected Conference, Teva Pharmaceuticals, Barcelona, Spain, 2017.
39. Humanizing medicine through social media: practical guidance for using social media in the oncology practice. BeConnected Conference, Teva Pharmaceuticals, Barcelona, Spain, 2017.
40. Novelty in the systemic treatment of locally advanced and metastatic endometrial tumors. The 7th International Gynecologic Cancer Conference, Sao Paulo, Brazil, 2017.
41. Multimodal treatment of locally advanced disease: what is the gold standard? The 7th International Gynecologic Cancer Conference, Sao Paulo, Brazil, 2017.

42. State of the art and new agents in the systemic treatment of metastatic or recurrent cancer. The 7th International Gynecologic Cancer Conference, Sao Paulo, Brazil, 2017.
43. Postoperative systemic treatment of early ovarian cancer: who is not benefited? The 7th International Gynecologic Cancer Conference, Sao Paulo, Brazil, 2017.
44. Incorporation of bevacizumab in the first-line treatment of advanced ovarian cancer: results and indications. The 7th International Gynecologic Cancer Conference, Sao Paulo, Brazil, 2017.
45. Cancer as a chronic disease. Unmasking Breast Cancer Conference, Guam, 2017.
46. Ten things to understand about breast cancer. University of Guam, Guam, 2017.
47. Living Past Cancer: A Focus on Survivorship. Emirates Oncology Conference, Abu-Dhabi, UAE, 2017.
48. Social media for the sexual medicine practitioner 2.0. World Meeting on Sexual Medicine, Lisbon, Portugal, March 2018.
49. Survivorship after ovarian cancer. International Gynecologic Cancer Society Meeting, Kyoto, Japan, September 2018.
50. Joint Symposium 3 ASCO/ECCO/JSCO Joint Symposium, Multidisciplinary Case Discussion Session: Endometrial Cancer. Japanese Society of Clinical Oncology Annual Meeting, Yokohama, Japan, October 2018.

DIGITAL

1. Medicine and the iPad: Lessons from an Early Adapter (Webinar). Oncology Net Guide, 2010.
2. Newly Diagnosed: Using Complementary Therapies to Manage Side Effects (Webinar). Living Beyond Breast Cancer, 2013.
3. Communicating Cancer: Hope and Truth (Webinar). SHARE Support Group for women with breast or ovarian cancer, 2013.
4. #gynscm. A monthly Tweetchat on Gynecologic Cancers (Moderator), 2013. Guest on survivorship (2016).
5. #treatdiarieschat. Tweetchat on Treatment Diaries. Guest host on: Women's cancers (2013), Sexual Health (2013), Ovarian cancer (2013), Cervical cancer (2014).
6. #hcldr. Tweetchat for healthcare leaders. Sexual health guest host (2013).
7. #bcsm. Tweetchat on breast cancer. Guest on research studies (2013), sexual health (2014).
8. Healthcare provider Twitter Chat Training (Webinar). Living Beyond Breast Cancer, 2014.
9. Social Media in Oncology (Webinar). American Society of Clinical Oncology, 2014.
10. Palliative Care Specialty: A New Section in UpToDate (Webinar). UpToDate, 2014.
11. Living after cancer: Pragmatism, Realism, and Optimism (Teleconference). Sharsheret Embrace support group, 2014.
12. News from ASCO 2014: What is relevant for those living with metastatic breast cancer (Webinar). SHARE Support Group for women with breast or ovarian cancer, 2014.
13. Living beyond the pink-colored glasses of October (Webinar). Co-Sponsored by the Metastatic Breast Cancer Network (MBCN) and SHARE Support Group, 2014.
14. Advances in the treatment of metastatic breast cancer: An ASCO 2015 update (Webinar). SHARE Cancer Support Group, 2015.
15. Clinical Trials and breast cancer (Google Hangout). Co-sponsored event by Young Survivors Coalition, Cancer Fight Club, and Sharsheret, 2015.
16. #lbbc. Tweetchat of the Living Beyond Breast Cancer group. Guest on menopause topic (2016).
17. Sexuality and Intimacy after Cancer. European Society of Medical Oncology webinar (2017).
18. Sexuality and Intimacy after breast cancer. Webinar for the Inflammatory Breast Cancer Research Foundation (2017).
19. Ovarian cancer 101. SHARE Network, May 2018.
20. Sexual Health after Gynecologic Cancer. A Society of Gynecologic Oncologists Webinar. August 2018.
21. Sexual health after breast cancer: A primer for clinicians. Living Beyond Breast Cancer, September 2018.
22. A Deeper Look into PARP Inhibitors in the Management of Ovarian, Breast and Prostate Cancers: Individualizing Treatment for Improved Clinical and Economic Outcomes. National Association of Managed Care Physicians Webinar, January 2019.
23. Information Technology and Cancer Care. Lilly Webinar. June 2019.

GRANTS**Active**

1. An intimacy intervention for couples completing breast or prostate cancer treatment (PI, Dizon). Funding source: Clinical Research on Families (PI, Don S Dizon). Total: 20,000. 7/2019-7/2020.
This is a new line of research evaluating the quality of life of couples after the completion of curative intent treatment for breast or prostate cancer.
2. Randomized trial of a multimodal sexual dysfunction intervention for hematopoietic stem cell transplant survivors (PI, Areej El-Jawarhi, MGH Cancer Center). Funding source: American Cancer Society. Role: Co-Investigator. Total: 122,896. 1/1/2019-12/31/2022.
This will be the first sexual health intervention trial in patients who underwent a bone marrow transplant. I will serve as co-Investigator on this project, responsible for training staff on this project and assessment during the course of the trial.
3. NCT02903771: Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. Role: **US Lead PI**. Funding: Kazia Pharmaceuticals.
This is an International phase I dose-expansion study of a novel intraperitoneally delivered agent, Cantrixil, being evaluated for use in recurrent ovarian cancer. I am the FDA lead for the company and serve as the United States overall PI of the trial.
4. SIMPRO Research Center: Integration of PROs for Symptom Management in Oncology Practice: NIH/National Cancer Institute (UM1CA233080, PIs: Schrag, Osarogiagbon, Wong). Role: Site Principal Investigator Total: 1,127,000. 9/25/2018-8/31/2023.
This project's goal is to develop, implement, and evaluate a multi-component ePRO reporting and management system to improve symptom control for patients recovering from cancer surgery or patients receiving palliative chemotherapy in smaller, rural, and community cancer centers. This is a cluster randomized stepped wedge study conducted in a collaboration between a multi-disciplinary team of clinicians and researchers at Lifespan/Brown University, West Virginia University, The Baptist Health System, Dartmouth Hitchcock Medical Center, Maine Medical Center, Dana Farber Cancer Institute and national thought leaders in ePROS and cancer care delivery. This project is part of the NCI's IMPACT consortium and the award is through the Biden Moonshot program.
5. SWOG Network for Clinical Trials. Funding Source: National Cancer Institute (5U10CA180888-04). Role: Chair, Digital Engagement (3610.00/year), 2016-present.
SWOG is one of five federally sponsored cooperative groups for oncology clinical trials that comprise the National Clinical Trials Network (NCTN). I serve as the inaugural chair of the Digital Engagement committee, an administrative committee empowered to provide guidance and direction on the evaluation and utilization of digital tools to support SWOG and the process of clinical trials.
6. Gynecologic Cancer Center of Excellence. Funding Source: Henry M. Jackson Foundation. Role: Social Media Manager (20,000/year), 2017-
The Gynecologic Cancer Center of Excellence is designated by the Department Of Defense, and is located at Inova Health in Fairfax, VA. I agreed to join as the Social Media Manager for the COE's Ovarian Cancer Registry. My charge is to lead the committee that will develop and sustain a community of women with ovarian cancer through social media outreach.
7. BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extrarenal Clear Cell Carcinomas. Funding source: Bristol Myers Squibb. Role: Principal Investigator (461,225). 2018-present.
This is the first trial being performed specifically in clear cell cancers arising outside of the kidney. It will test two immunotherapy strategies in women with recurrent ovarian cancer (cohort 1) and those with extra-renal clear cell cancers.
8. BrUOG 355: A Pilot Feasibility study incorporating Nivolumab to tailored radiation therapy with concomitant cisplatin in the treatment of patients with cervical cancer. Funding Source: Bristol-Myers Squibb. Role: Principal Investigator (224,944). 2018-present.
This is an Investigator Initiated Trial being run through Brown University Oncology Group. I am the PI of this trial

which seeks to incorporate the immune checkpoint inhibitor, nivolumab, in to definitive chemoradiation for cervical cancer.

9. DF/HCC 16-263: A Phase I/II study of nivolumab, bevacizumab, and rucaparib for the treatment of recurrent platinum-resistant or sensitive (within 12 months of last platinum) epithelial ovarian, fallopian tube or peritoneal cancer. (PI, Joyce Liu, DF/HCC. Funding: Bristol Myers Squibb. Role: Co-Principal Investigator. *This is a phase 2 trial I helped write and ran as co-PI while at DF/HCC. We are planning to participate at Lifespan, and my role has continued.*

Completed

1. Cancer Chemotherapy Training Program. NIH Training Grant, NIH 5-T32-CA09207-24. 2000-2001.
2. NF-kB mediated resistance in ovarian cancer. MSKCC Byrne Institutional Grant, PI (150,000), 2002-2003.
3. Essiac in the management of women's cancers. Alpert Medical School of Brown University, Department of OB/GYN Seed Grant, PI (9,000), 2004-2005.
4. Modifying platinum resistance in ovarian cancer by manipulating the NF-kB pathway. American Society of Clinical Oncology Career Development Award, PI (150,000), 2002-2006.
5. A Phase II trial of Bortezomib and Irinotecan for women with advanced or metastatic cervical, vulvar or vaginal cancer. Millennium Pharmaceuticals, PI (10,000), 2004-2006.
6. A phase II randomized, placebo-controlled, double-blind study to evaluate the efficacy of pertuzumab (rhuMAb 2C4) in combination with gemcitabine and the effect of tumor-based HER2 activation in subjects with platinum-resistant ovarian, primary peritoneal cancer, or fallopian tube cancer. Genentech, Local PI (820,915), 2005-2007.
7. A phase I safety, pharmacodynamic, and pharmacokinetic study of intravenously administered PXD101 in combination with carboplatin or paclitaxel or both in patients with advanced solid tumors. Curagen Pharmaceuticals, National PI (89,942), 2005-2008.
8. A phase II evaluation of carboplatin, paclitaxel, and bevacizumab as first line chemotherapy for advanced ovarian cancer. Genentech, Local PI (52,000), 2005-2009.
9. A Phase II trial of Ixabepilone (BMS-247550 [NCI Supplied Agent #710428]) in the Treatment of Recurrent or Persistent Endometrial Carcinoma (GOG 129P). National PI, Gynecologic Oncology Group Trial, National Cancer Institute, NCI Grant/Contract U10-CA27469, 2005-2009.
10. A Phase II trial of Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin (GOG 126-T). National PI, Gynecologic Oncology Group Trial, National Cancer Institute, NCI Grant/Contract U10-CA27469, 2005-2009.
11. Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer (GOG-9921). National PI, Gynecologic Oncology Group Trial, National Cancer Institute, NCI Grant/Contract U10-CA27469, 2005-2009.
12. Prolonging the second remission in women with ovarian cancer using immunotherapy: A Phase I/II Evaluation of OKT3 x Herceptin Armed Activated T Cells with Low Dose IL-2 and GM-CSF. Rhode Island Medical Foundation, PI (\$10,000), 2006-2007.
13. EPO2203e: An open-label Phase I/II dose escalation study evaluating the safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer. Novartis. Local PI (168,458), 2006-2008.
14. AVF3693g: A multicenter phase III, randomized placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously treated metastatic breast cancer. Genentech, Local PI (536,550), 2006-2009.
15. AVF3694g: A multicenter phase III, randomized, placebo-controlled trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy regimens in subjects with previously untreated metastatic breast cancer. Genentech, Local PI (541,774), 2006-2009.
16. The Integrative Care Program at Women & Infants' Hospital. Rhode Island Foundation, PI (90,000), 2007-2008.
17. AVF3991: An observational study of Avastin® (bevacizumab) in combination with chemotherapy for treatment of metastatic or locally advanced and unresectable colorectal cancer, locally advanced or metastatic non-small cell lung (excluding predominant squamous histology), or locally recurrent or metastatic breast cancer. Genentech, Local PI (79,500), 2007-2009.
18. AVF4173s-BrUOG BR-213: A phase II study of adjuvant gemcitabine/capecitabine/ Avastin for patients treated neoadjuvantly for early stage breast cancer with high risk of relapse. Genentech, Local PI (183,000), 2007-2012.
19. A phase II trial of erlotinib (Tarceva) in women with vulvar squamous cell carcinoma. Massachusetts General Hospital, Local PI (25,000), 2007-2010.

20. AVF4095g: A phase II, multicenter, randomized, blinded, placebo-controlled trial of carboplatin and gemcitabine plus bevacizumab in patients with platinum-sensitive recurrent ovary, primary peritoneal, or fallopian tube carcinoma. Genentech, Local PI (203,000), 2007-2011.
21. A phase II, randomized, double-blind, multicentre study to assess efficacy of AZD2881 in the treatment of patients with platinum sensitive ovarian cancer following treatment with two or more platinum containing regimens. Astra-Zeneca, Local PI (150,000), 2008-2012
22. A Phase II Trial of BIBF-1120 in Recurrent or Advanced Endometrial Cancer (GOG 229K). National PI, National Cancer Institute, NCI Grant/Contract U10-CA27469, 2008-2014.
23. Exercise and relaxation intervention for young adult cancer survivors. American Cancer Society/ Grant # MRS-09-091-01 CPPB. PI, Carolyn Rabin (134,943). (Co-Investigator Role), 2009-2013
24. T-cell gene therapy to eradicate disseminated breast cancers. Department of Defense/ Grant 00461063. PI: Richard Junghans (5,910,691). (Co-Investigator) 2009-2014
25. Social Networks and Care Planning in Women with Cancer. National Institutes of Health/ Grant R21CA137290-01A2. Co-PI (with Dr. Melissa Clark at Brown) Amount: \$250,000, 2010-2011.
26. A phase III randomized study of carboplatin, paclitaxel, and BIBF-1120 versus placebo as first-line therapy of ovarian cancer. Boehringer-Ingelheim, PI (250,000), 2010-2012.
27. A Phase I Trial of Intraperitoneal Bortezomib and Carboplatin in Recurrent Ovarian Cancer (GOG 9924). National PI, National Cancer Institute, NCI Grant/Contract U10-CA27469, 2006-2015
28. Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer (GOG 86-P). PI, Carol Aghajanian. National Cancer Institute, NCI Grant/Contract U10-CA27469 (National Co-PI), 2005-present.
29. A multimodal intervention to address sexual dysfunction in female hematopoietic stem cell transplant survivors. Patty Brisben Foundation. PI; Areej El-Jawahri (100,000 over two years) (Collaborator) 2015-2017.
30. A multimodal intervention to address sexual dysfunction in female hematopoietic stem cell transplant survivors. National Comprehensive Cancer Center Network, PI: Areej El-Jawahri (100,000 over two years) (Collaborator), 2015-2017.
31. Empowering patients to achieve individualized care for advanced breast cancer. National Comprehensive Cancer Center Network, PI: Jeffrey Peppercorn (245,004.00) (Co-Investigator), 2015-2017.

UNIVERSITY TEACHING ROLES

Lecturer, Genomics and Personalized Health Module, Personalized Medicine in Breast Oncology. Brown University School of Public Health, 2009. Students: 10.

Core Field Experience and Field Project Supervisor, Community Medicine Clerkship. Warren Alpert Medical School of Brown University. 2005-2011. One per clerkship.

Course Director, Bio498: The Care of Patients with Women's Cancers. Warren Alpert Medical School of Brown University. 2006-2011. Students: One per 4-week elective.

Doctoring Course preceptor. Warren Alpert Medical School of Brown University. 2006-2011. Students: one per clerkship.

Course Co-Director, MED525m.3: Medical Care of the Gynecologic Oncology Patient, Harvard Medical School, 2012-2017.

HOSPITAL TEACHING ROLES

Director, Chemotherapy Review Meeting, Program in Women's Oncology, Women & Infants' Hospital, 2005-2010

Medical Oncology/Chemotherapy Program, Women & Infants' Hospital/Alpert Medical School of Brown University, 2005-2012

Second site clinic, Internal Medicine Residency, Warren Alpert Medical School of Brown University. 2007-2009

Second site clinic preceptor, Hematology-Oncology Fellowship, Warren Alpert Medical School of Brown University. 2010-2012

Co-Director, Chemotherapy Review Conference, Gynecologic Oncology Program, MGH Cancer Center, 2014-2017

Co-Leader, Gynecologic Oncology Tumor Board, Gynecologic Oncology Program, MGH Cancer Center, 2014-2017

MENTORSHIP

Undergraduate students

1. Hillary Magruder, 2006.
Project: Clinical outcomes in women with tubular carcinomas of the breast. (Presented at the 2007 National Consortium of Breast Centers Annual Meeting)
2. Matthew Young, 2006
Project: Is there a taxane-free interval in women with heavily treated recurrent ovarian cancer? (Presented at the 2007 Society of Gynecologic Oncologists Annual Meeting; Published in Gynecologic Oncology)
3. Kaitlyn Lew, 2019.
Project: Cancer Survivorship.

Medical students

Alpert Medical School

1. Adam Rojan, 2004-2006
Project: Clinical outcomes in women with ovarian cancer (Published in Gynecologic Oncology 2006)
Project: Clinical outcomes in HER-2/neu positive breast cancers stratified by hormone receptor status. (Presented at the 2007 American Society of Breast Surgeons Annual Meeting)
2. Daniel Kelly, 2005
Project: Demographic patterns of stage at diagnosis and survival for ovarian cancer: Analysis of Rhode Island women utilizing gynecologic oncology services (Oral presentation at the 134th Annual American Public Health Association Annual Meeting, 2006)
Project: Clinical Significance of Borderline Amplification, Amplified Clones of HER-2/neu Gene and Polysomy 17 in Breast Cancer Patients (Presented at the 2006 San Antonio Breast Cancer Symposium)
3. Tamara Chang, 2006.
Project: Concordance between preoperative assessment of T1 cancers and pathologic results: considerations for ablative therapy (Presented at the 2008 Society of Gynecologic Oncologists Annual Meeting)
4. Terrissa Martin-Hanley, 2006.
Project: Adjuvant therapy for endometrial cancer: "sandwich therapy" of carboplatin and paclitaxel with radiation therapy (Published in Cancer Therapy, 2007)
5. Beth Toste, 2007.
Project: Evaluating the effect of chemotherapy dosing in obese women treated for gynecologic malignancies (Presented at the 2008 American Society of Clinical Oncology Annual Meeting and published in Gynecologic Oncology 2009)

6. Mari Tokita, 2007
Project: Characteristics and Outcomes of Women with Endometriosis Associated Ovarian and Extra-Ovarian Cancers.
7. Sybil Dessie, 2007.
Project: Platinum-free, Taxane-free, or Treatment-free: Which interval predicts response to paclitaxel as a later-line therapy in ovarian cancer? (Presented at the 2008 Society of Gynecologic Oncologists Annual Meeting; Published, International J Gyn Cancer 2009)
8. Neel Shah, 2008
Project: New generation platinum therapies for solid tumors. (Published, Future Medicine 2009)
9. Lindsay Kuroki, 2008.
Project: The influence of Tumor Board presentation on medical decision making (Poster presentation at the 2008 New England Association of Gynecologists Annual Meeting; published in Gynecologic Oncology 2010)
10. Lindsay Clark, 2008.
Project: The Laotian Cervical Cancer Screening Project: Assessing Barriers to Prevention (Presented, 2008 New England Association of Gynecologists Annual Meeting)
11. Ann Kuo, 2008
Summer Project: Breast Tumor Board: A prospective evaluation on the impact of tumor board presentations on the management of women with breast cancer; sexual health of breast cancer survivors (Published in OB-Gyn Management)
12. Lily Wu, 2009.
Project: Incidence of proliferative breast lesions in women undergoing cosmetic breast surgery. (Presented, 2009 Breast Cancer Symposium)
13. Courtney Olson, 2009
Project: Clinical experience with bevacizumab treatment for women's cancers. (Presented, Society of Gynecologic Oncologists Annual Meeting, March 2010)
14. Katy Tsai, 2009
Project: Reconstruction outcomes in women with breast cancer. (Presented at Society of Surgical Oncology, 2011)
15. Matthew Schutzer, 2009
Project: The management of vulvar cancers in elderly women: what is the risk/benefit profile? (Presented at IGCS 2010; Published, Am J Clin Oncol 2012)
16. Jessica Zarrillo, 2010
Project: Cervical Cancer Screening in Asian Communities: What are the barriers to prevention.
17. Bridget Malit. 2010
Project: Provider and Patient Perceptions on Integrative Care Modalities. (Presented at the New England Association of Gynecologic Oncologists Annual Meeting, 2010)
18. Brian Nguyen, 2010
Project: Sexual Ramifications in Oncology: Colorectal, Bladder, Vaginal, and Hematologic malignancies. On-line publication: <http://sexmed.org>.
19. Jennifer Gao, 2010
Project: Breast cancer: To Screen or Not To Screen. (Poster presentation at the 2011 Annual Interdisciplinary Conference of the National Consortium of Breast Centers)

20. Sarah Fleisig, 2011
Project: A Pilot study to optimize emergency contacts of unpartnered women with cancer.
21. Elizabeth Rodriguez, 2011
Project: Case series on vulvar melanoma: the Women & Infants Hospital experience.
22. Jamie Odzer, 2019
Project: Understanding the needs of caregivers at the end of curative intent cancer therapy (Brown Summer Research Assistantship)

Harvard Medical School

1. Kimberly E. Kopecky, 2013
Project: Role of PET/CT in the preoperative evaluation of women with Type II endometrial cancer. (Presented at the 2013 New England Association of Gynecologic Oncologists Annual Meeting)
2. Vineeta Agarwal, 2014
Project: Are there subtypes of serous ovarian carcinoma?
3. Sandy Truong, 2015
Harvard School of Medicine
Project: Alternative therapies and bleeding risk
4. Alexander Bagley, 2015
Harvard School of Medicine
Project: RECIST criteria and beyond

Other institutions

1. Megan Kunz, 2008
Albany Medical School
Project: Proportion of patients undergoing breast reconstruction who complete to nipple tattooing: Effect on body image and quality of life.
2. Kimberly Kilfoyle, 2009
University of Medicine and Dentistry, New Jersey, Robert Wood Johnson Medical School
Project: Treatment Options in Endometrial Cancer. (Published, European Journal of Clinical Oncology 2009)
3. Shanna Levine, 2009
State University of New York at Stony Brook
Summer Project: Nodal retrieval in endometrial cancer. Does the number of nodes predict recurrent free survival?
4. Randi Goldman, 2010
Albany Medical College
Project: The differential diagnosis of an elevated hCG and placental abnormalities in pregnancy: beyond Gestational trophoblastic neoplasia. (Published, Am Journal of Obstetrics-Gynecology, 2010)
5. Bronwyn Kenny, 2010
Saint Louis University School Of Medicine
Project: Vulvar manifestation of chemotherapy toxicity due to pegylated liposomal doxorubicin.
6. Elizabeth Liveright, 2010
Wayne State University School of Medicine
Project: Correlation between preoperative T1 breast tumors and final pathology

7. Amrita Roy, 2011
Royal College of Surgeons, Dublin, Ireland.
Project: Advance Directives: A Quality Assurance Project.
8. Christine (Jeehey) Song. 2013
Visiting medical student from South Korea.
Project: An Update on Cancer of Unknown Primary. Blog publication: "Cultivating a new generation of oncologists. Available at: <http://connection.asco.org/Commentary/Article/id/3608/Cultivating-a-New-Generation-of-Oncologists.aspx>. Accessed July 28, 2013.
9. Stephanie Leiva Espinosa. 2013
Visiting medical student from Dominican Republic.
Project: Intimacy as an aspect of sexual health in women diagnosed with cancer. (Published on the Cancer Knowledge Network. Available at: <https://cancerkn.com/intimacy-as-an-aspect-of-sexual-health-in-women-diagnosed-with-cancer/>. Accessed December 26, 2013)
10. Daniel Przybysz, 2013
Visiting medical student from Universidade Federal do Paraná (Brazil).
Project: Sexual intimacy in cancer survivors (Poster presented at the Cancer Survivorship symposium, 2013, Boston, MA)
11. Joylyn Kurian, 2013
Visiting medical student from Siddhartha Medical College (India)
Project: Cancers beyond breast and ovarian primaries occurring in women with a germline BRCA-mutation.
12. Kuan (Justin) Chen Yen, 2014
Visiting medical student from Taiwan.
Project: BRCA1 and BRCA2 mutations: Update on management.
13. Javier Velasquez, 2014
Visiting medical student from Nicaragua
Project: Infertility after gynecologic cancer
14. Katherine Hicks-Courant, 2014
University of Massachusetts
Project: Opportunistic Salpingectomy
15. Ashleigh Long, 2014
University of Kentucky
Project: Coital Cephalgia
16. Carolina Chinchilla, 2014
Universidad Francisco Marroquin, Guatemala City
Project: Hormone replacement therapy in women with BRCA mutations (Published in the American Journal of Clinical Oncology)
17. Zoulikha Outaggarts, 2015
Eberhard-Karls University, Tubingen, Germany
Project: Port-site metastases
18. Tere Campa, 2015
Instituto Tecnológico de Estudios Superiores De Monterrey
19. Ritika Abrol, 2015
Visiting Student from India
Project: CA125 in the follow-up of women with ovarian cancer

20. Azza Abdalla, 2015
Medical University of South Carolina
Project: Prevention of chemotherapy-induced alopecia
21. Minxiang Lee, 2015
Zhong Shan Medical College, China
Project: Medical treatment of Low grade endometrial cancer
22. Da Young Lee, 2016
Chonbuk National University College of Medicine, South Korea
Immunotherapy for ovarian cancer
23. Patricia Mighiu, 2016
University of London, Imperial College School of Medicine
Project: Fertility after ovarian cancer
24. Katherine Wang, 2016
University of Vermont
Project: Endocrine therapy for endometrial cancer (Published in Cancer Therapy Advisor. Available at: [http://www.cancertherapyadvisor.com/gynecologic-cancer/aromatase-inhibitors-endometrial-cancer-higher-risk/article/579684/2/.](http://www.cancertherapyadvisor.com/gynecologic-cancer/aromatase-inhibitors-endometrial-cancer-higher-risk/article/579684/2/))
25. Lauren Kendall, 2016
University of Central Florida
Project: Immunotherapy toxicities in gynecologic malignancies
26. Aditi Arvind Tyagi, 2017
DR DY Patil Medical College, India
Project: Placental Site Trophoblastic Tumors: A Review

Internal medicine residents

1. Elise McCormack, 2006
Program: Roger Williams Medical Center Department of Medicine
Project: Clinicopathologic analysis of tubular carcinoma of the breast. (Presented at the 17th Annual Interdisciplinary Breast Conference of the National Consortium of Breast Centers)
2. Furha Cossor, 2006
Program: Brown University Internal Medicine Residency Program
Project: Infection or Malignancy by PET/CT: A Cautionary Case Report. (Podium Presentation, RI American College of Physicians Meeting, 2007)
3. Reve Purisima, 2007
Project: In patients with a terminal illness, does having a family meeting predict the place of death? (Published abstract, ASCO 2009 Annual Meeting)
4. Kim Perez, 2007
Project 1: Clinical outcomes in women with Stage IV bowel adenocarcinomas presenting as a pelvic mass. (Published Am Surgeon, 2009)
Project 2: Sexual ramifications of medical illness. (Published Clin Obstet and Gynecol 2009)
5. Tina Rizack, 2008
Project: Is the Tumor Board relevant? (Presented at the 2011 Interdisciplinary Conference of the National Consortium of Breast Centers, March 2011. Las Vegas, NV; Published in The Breast Journal, 2012)
6. Harish Saiganesh, 2018
Program: Brown University Internal Medicine Program

Project: Survivorship Care Planning at the Lifespan Cancer Institute (Project presented at the 2019 ASCO Annual Meeting)

7. Kristina Fanucci, 2018
Program: Brown University Internal Medicine Program
Project: Primary care prevention in patients with chronic and/or advanced cancer

Obstetrics-Gynecology residents, Women & Infants' Hospital

1. Roxanne Vrees, 2007
Resident Thesis: Characteristics and Outcomes of Women with Endometriosis Associated Ovarian and Extra-Ovarian Cancers.
2. Cara Mathews, 2008
Thesis: Correlation of preoperative and postoperative pathological diagnosis in low grade endometrial cancer. (Presented at the 2008 Meeting of the Society of Gynecologic Oncologists)
3. Beth Cronin, 2009-2011
Resident Thesis: Characteristics and Outcomes of Women receiving long-term Pegylated Liposomal Doxorubicin (PLD) therapy (Department of Ob/Gyn Resident Research Prize, 2009, Presented at the 2009 European Society of Gynecologic Oncology Meeting, Published in Am J Clin Oncol 2010)
Project: The role of radiofrequency ablation in women's cancer. (Presented at the New England Association of Gynecologic Oncologists Annual Meeting. June 2011.)
4. Dario Roque, 2011
Resident Thesis: The effect of age on toxicity in the treatment for cervical cancer. (Poster presentation, ASCO Annual Meeting, 2012; Published J Geriatric Oncology, 2013)

General Surgery residents

1. Chelsey Ciambella, 2018.
Project: Characterizing distress among women seen in a multidisciplinary breast health clinic. (Project presented at the 2019 American Society of Breast Surgeons; accepted for publication in Annals of Surgical Oncology)
2. Rachel Fowler, 2018.
Project: Does axillary node status aide treatment decision making among women with clinically node-negative early breast cancer following Oncotype DX testing? (project presented at the 2019 Interdisciplinary Meeting of the National Consortium of Breast Surgeons).
3. Michelle Wakeley, 2018.
Needs of women undergoing mastectomy without reconstruction: Understanding the needs of women in the "Go Flat" movement. (Project presented at the 2019 American Society of Breast Surgeons Annual Meeting)

Fellows in Gynecologic Oncology

Program in Women's Oncology, Women & Infants' Hospital

1. Antonella Restivo, 2007
Project: For women receiving chemotherapy for Clinically apparent Early Ovarian Cancer, is there a benefit to Surgical Staging? (Oral Presentation, International Gynecologic Cancer Society Meeting, October 2008, Published, American J Clin Oncol. 2008)
2. Carolyn McCourt, 2008.
Project: Is there a taxane-free interval that predicts response to taxanes as a later line treatment of recurrent ovarian or primary peritoneal cancer? (Poster Presentation, Society of Gynecologic Oncologists' Annual Meeting 2008; Published, Int J Gynecol Cancer 2009)

3. Shannon MacLaughlan, 2008
Fellow Thesis: A Prospective randomized pilot study comparing hypnotherapy and gabapentin for hot flashes in breast cancer survivors. (Presented at the New England Association of Gynecologic Oncologists Annual Meeting, June 2011; Presented at 2011 Breast Cancer Symposium, Published BMJ Open, 2013)
4. Ashley Stuckey, 2008.
Project: A prospective evaluation of multidisciplinary tumor board presentation and ultimate care of the female patient with cancer. (Presented, International Gynecologic Cancer Society Meeting, 2008; Published, Gyn Oncol 2010)
5. Katrin Kristjandottir, 2009
Project: Gemcitabine and docetaxel for uterine leiomyosarcoma: dose rate of administration affect response? (Presented, New England Association of Gynecologic Oncologists Annual Meeting, June 2009, Portsmouth, NH)
6. Nada Kavar, 2010-2012
Project: Beta-III tubulin expression in uterine cancers: does it predict taxane resistance? (Presented at 2011 American Society of Breast Diseases and Society for Surgical Oncology Annual Meetings)
7. Emily Hill, 2012.
Project: A Prospective Evaluation of Quality of Life, Sexual Function, and Depression in Women Self-referred to a Sexuality Clinic for Female Cancer Survivors. Society of Gynecologic Oncologists Annual Meeting. (Presented at 2012 Society for Gynecologic Oncologists Annual Meeting and 2012 Annual Meeting of the American Society of Breast Diseases)

Massachusetts General Hospital

1. J. Alejandro Rauh, 2013
Project: Patterns of recurrence after bevacizumab in ovarian cancer. (Published in International J of Gynecologic Cancer, 2013)

Second Mentor, R25T Transdisciplinary Cancer Research Training Grant (CA87972), Department of Psychology, Brown University

1. Mary Politi, PhD, 2008-2010
Project: Communicating uncertainty and its impact on patients' decision satisfaction: A necessary cost off involving patients in shared decision making? (Published, Health Expectations 2011)

Women's Reproductive Health Research Fellowship Mentor

1. Katina Robison, 2008
Project: The Southeast Cervical Cancer Screening Project: Assessing Barriers to prevention. The Epidemiology of HPV Infection among Southeast Asian women.

Breast Surgery Fellows, Program in Women's Oncology, Women & Infants' Hospital

1. Nicole Figueredo, 2009
Project: Accuracy of office-based ultrasound fine needle aspiration for women with breast disease (Presented, New England Association of Gynecologic Oncologists Annual Meeting, June 2009; Presented, San Antonio Breast Conference, 2009)
2. Marcia Schmidt, 2012
Project: An analysis of breast cancer detected through the Women's Cancers Screening Program of Rhode Island: The experience at Women & Infants' Hospital. (Presented at the New England Association of Gynecologic Oncologists Annual Meeting, June 2011)

Research Mentor, MPH Program, Brown University

1. Kimmy Dickinson, 2010-2012
Project: Erythropoietin-stimulating agents (ESA) and the treatment of anemia in oncology patients. (Poster presentation, ASCO Annual Meeting 2012)

American Society of Clinical Oncology International Development and Education Award (IDEA) Mentor

1. Iryna Muryzina, MD. 2014.
Assistant Professor, Kharkov National Medical University, Ukraine
2. Tania Echeveste, MD. 2016
Hospital de general de Mexico

SWOG Cancer Research Network

1. Mina Sedrak, 2017-2019 Charles A. Coltman Fellowship. Understanding the barriers to social media use for clinical trials among cancer professionals.

Medical Oncology Fellows, Hospital Beneficência Portuguesa de São Paulo, Brazil

1. Larissa Gomes, MD. 2018